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1.1 Antibody-mediated immunity 
1.1.1 The immune system at a glance 
The immune system is an amazingly elaborate and dynamic system, equipped to protect the 
body against myriad infectious agents and to eliminate abnormal host cells, without causing 
undue injury to normal tissues.1 It is composed of many different organs (e.g. skin, thymus, 
spleen), tissues (e.g. mucosal membranes, blood and lymphatic vessels, lymph nodes), cell 
types (e.g. phagocytes, lymphocytes), serum proteins (e.g. complement, antibodies), and 
signal transduction molecules (e.g. cytokines, receptors, enzymes, transcription factors). 
While each component has its specific role, all are entangled in a complex network of 
interactions necessary to orchestrate adequate immune responses.1  
The immune system is broadly divided in an innate and adaptive arm (Figure 1).1 Innate 
immunity (also called natural immunity) forms the body’s first line of defense against 
microbes. When epithelial barriers are breached, immune responses are immediately 
initiated within minutes to hours after invasion (Figure 1).1 To meet these requirements, 
components of the innate immune system are mature at birth and are able to recognize a 
broad range of pathogens in a nonspecific manner.1 The innate immune response is also 
important for inducing and directing the adaptive immune response.1 In contrast to innate 
immunity, adaptive or acquired immunity has an exquisite specificity for distinct microbial 
substances termed antigens.1 The disadvantage is that cells of the adaptive immune system 
need several days to further differentiate and proliferate before reaching a full response 
(Figure 1).1 However, after initial exposure to an antigen, the adaptive immune system will 
have acquired immunological memory providing long-term protection.1 Upon re-exposure to 
the same antigen, adaptive immunity will mount a more rapid and potent response enhancing 
pathogen clearance.1 Adaptive immune responses are mainly executed by B and T 
lymphocytes (Figure 1).1 Of note, B lymphocytes (or B cells) predominantly develop in the 
bone marrow whereas T lymphocytes (or T cells) complete their development in the thymus. 
During an adaptive immune response, B cells differentiate to produce antigen-specific 
antibodies, as outlined in the following section (1.1.2).1 T cells, on the other hand, 
differentiate into diverse effector cells that perform different functions.1 CD4+ T helper (Th) 
cells consist of several subpopulations that either help the activity of other immune cells, 
such as B cells and phagocytes, or help regulate immune responses.1 CD8+ cytotoxic T cells 




Figure 1. Innate and adaptive immunity. Schematic representation of the main components and 
kinetics of the innate and adaptive immune responses. ILCs: innate lymphoid cells, NK: natural killer. 
Adapted from Abbas AK, Lichtman AH and Pillai S. Cellular and Molecular Immunology. 8th ed. 
Philadelphia: Elsevier Saunders; 2014. 
 
In general, immune responses mediated by molecules in extracellular body fluids (called 
“humors” by the ancient Greeks) are designated as humoral immunity (e.g. complement, 
secreted antibodies). Analogously, cellular components of the immune system provide cell-
mediated immunity (e.g. phagocytes, T cells).1 In practice, however, the terminology 
“humoral immune response” is most often used to refer to the activation of B cells and their 
differentiation into antibody-secreting factories, and “cell-mediated immunity” is usually 
ascribed to the actions of T cells. 
 
1.1.2 B cell development and antibody production 
1.1.2.1 Introduction 
As mentioned above, antibodies, also known as immunoglobulins, are produced by cells 
of the B lymphocyte lineage.1 Immunoglobulins are composed of two heavy chains and two 
light chains that together recognize specific antigens.1,2 They are first expressed on the cell 
membrane as a B cell antigen receptor (BCR).1,2 Upon antigen-specific stimulation and 
differentiation, immunoglobulins are secreted as soluble proteins in blood and mucosal 
secretions (Figure 1).1,2 During B cell development and differentiation, immunoglobulins 
undergo several steps of diversification via somatic rearrangements and point mutations in 
their germline encoded genes. These diversification steps greatly expand the antibody 
repertoire and allow the immune system to recognize virtually any antigen.2,3 To ensure the 
production of functional non-self-reactive antibodies, B cells progress through a series of 
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1.1.2.2 Antigen-independent B cell development 
B cells originate from hematopoietic stem cells, in the liver during fetal life and in the bone 
marrow after birth (Figure 2).2 During early B cell development, a primary repertoire of 
antibody specificities is acquired by somatic recombination of immunoglobulin heavy chain 
and light chain gene segments.1,2 These recombinations occur randomly and independent of 
antigen contact.1,2 Pro-B cells first rearrange gene segments of the heavy chain locus 
(Figure 2).1,2 The recombined region together with the constant µ and δ gene segments 
constitutes the primary transcript. Via alternative splicing of this transcript, cells can produce 
both µ and δ heavy chain proteins. However, expression of δ-chain containing IgD seems to 
occur predominantly after completion of the early developmental and maturation steps 
(Figure 2).2 In the bone marrow, the µ heavy chain and a surrogate light chain form the pre-
BCR expressed by the pre-B cell (Figure 2).1,2 Surface expression of the pre-BCR stops 
further rearrangements of the heavy chain loci, assuring that the developing B cell produces 
only one antigenic specificity.2,4  
 
 
Figure 2. Antigen-independent B cell development. During early B cell development in the bone 
marrow, precursor B cells only proceed to the next stage after productive rearrangement of the heavy 
chain (pro- to pre-B cell) and light chain (pre- to immature B cell) immunoglobulin gene segments. The 
subsequent maturation steps take place in the bone marrow and/or spleen. Mature naive B cells enter 
the peripheral blood whereas marginal zone B cells reside in the spleen. BCR: B cell receptor, HSC: 
hematopoietic stem cell, Ig: immunoglobulin. Adapted from Siebenlist U et al. Nat Rev Immunol. 
2005;5(6):435-45. 
 
Of interest, Bruton tyrosine kinase (BTK) is an important signaling molecule downstream of 
the pre-BCR and, later, the mature BCR.2 Mutations in the BTK gene, which is located on the 
X chromosome, cause an early B cell developmental block that results in X-linked 
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agammaglobulinemia (XLA), a disease first described by Colonel Bruton in 1952 (see section 
1.2.1.1).2,5 
 
Following heavy chain recombination, pre-B cells recombine gene segments of the κ or 
λ light chain locus.1,2 The light chain associates with the previously synthesized µ heavy 
chain, forming an IgM BCR on the surface of immature B cells (Figure 2).1,2 Note that large 
numbers of precursor B cells go into apoptosis when somatic recombination does not result 
in a functional heavy or light chain protein.4 IgM-expressing immature B cells develop over 
transitional B cells into mature naive B cells expressing high levels of both IgM and IgD 
(Figure 2).4,6 These maturation steps occur simultaneously in the bone marrow and spleen. A 
selection of transitional B cells becomes marginal zone B cells that reside in the spleen 
(Figure 2). Mature naive B cells recirculate between the blood and lymphoid organs. 
 
1.1.2.3  Antigen-dependent T cell-dependent B cell development 
Typically, mature naive B cells recirculate through peripheral lymphoid organs until they 
encounter their specific antigen (Figure 3).2,7 Binding of antigen to its specific BCR triggers B 
cell activation.1 The antigen is then internalized, processed and presented on the B cell 
surface via major histocompatibility complex class II (MHC II) molecules, where it can be 
recognized by cognate T cells.1 Cognate naive CD4+ Th cells are first activated upon 
recognition of the same protein antigen presented by dendritic cells (DCs) via MHC II 
(Figure 3).1 Next, initial cognate interactions between activated B cells and Th cells take 
place at the border between B cell follicles and T cell zones (Figure 3).7,8 After these initial 
interactions, activated B cells can migrate to the extrafollicular areas of peripheral lymphoid 
organs where they proliferate and terminally differentiate into short-lived plasma cells (Figure 
3).7,8 Alternatively, activated B cells can move into B cell follicles and engage in what is 





Figure 3. T cell-dependent antibody responses in peripheral lymphoid organs. Upon encounter 
of a protein antigen presented by dendritic cells in peripheral lymphoid tissues, B cells are activated 
with help of T cells. After the initial T-B interaction, B cells can move to extrafollicular areas and 
differentiate into short-lived plasma cells with limited affinity maturation and class switching. 
Alternatively, B cells can migrate into B cell follicles and engage in a germinal center reaction with 
affinity maturation, class switching and terminal differentiation into memory B cells and long-lived 
plasma cells. Adapted from Abbas AK, Lichtman AH and Pillai S. Cellular and Molecular Immunology. 
8th ed. Philadelphia: Elsevier Saunders; 2014. 
 
The formation of GCs requires intense reciprocal interactions between cognate B cells and 
follicular Th (Tfh) cells, of which the most important are shown in Figure 4.2,7,8 These 
interactions provide B cells with the necessary helper signals for proliferation and 
differentiation, and also enhance the effector functions of Tfh cells.2,7,8  
 
 
Figure 4. Reciprocal interactions between follicular helper T (TFH) cells and germinal center 
(GC) B cells. TFH cells promote survival, proliferation and terminal differentiation of B cells into 
memory B cells and class-switched affinity-maturated antibody-secreting plasma cells. In turn, these 
costimulatory signals enhance TFH cell effector functions. BCR: B-cell receptor, CD40L: CD40 ligand, 
ICOS(-L): inducible T cell co-stimulator (ligand), IL-4(R): interleukin 4 (receptor), IL-21(R): interleukin 
21 (receptor), MHC: major histocompatibility complex, PD-1, programmed death-1, PD-L2: 




GCs are the primary sites for somatic hypermutation (SHM), class-switch recombination 
(CSR), and terminal differentiation of B cells into antibody-secreting plasma cells and 
memory B cells (Figure 3).1,6,8 SHM introduces point mutations at high rates in the heavy 
chain and light chain regions important for antigen recognition and binding.1,2,8 This process 
expands the diversity of the antibody repertoire (secondary repertoire) and allows for the 
production of higher-affinity antibodies against the pathogen at hand.8 For that reason, SHM 
is also called affinity maturation.8 During SHM, B cells undergo several cycles of clonal 
deletion and selection to eliminate B cells with lower-affinity or autoreactive BCRs.1,2,4,8 
Immunoglobulin classes or isotypes, and their related effector functions, are determined by 
the constant regions of the heavy chain.1,7,8 CSR or isotype switching is the process that 
changes the B cell’s IgM/IgD co-production to a single isotype production (IgG, IgA, IgE, IgM 
or IgD), via somatic gene rearrangements of the heavy chain constant regions.1,6,8 CSR does 
not alter antigen specificity.8 Following SHM and CSR, B cells terminally differentiate into 
either memory B cells or long-lived antibody-secreting plasma cells (Figure 3).8 Memory B 
cells are long-lived and can rapidly differentiate into high-affinity antibody-secreting plasma 
cells upon re-exposure to the same antigen.7 Long-lived plasma cells migrate primarily to the 
bone marrow where they can reside for years.7 These plasma cells provide long-term 
antibody titers but do not self-renew.7 Together, memory B cells and long-lived high-affinity 
antibody-secreting plasma cells ensure sustained humoral immune protection.7 
 
1.1.2.4 Antigen-dependent T cell-independent B cell development 
The T cell-dependent antibody responses outlined above are only initiated after exposure to 
protein antigens.1,6 Hence, proteins are classified as T-dependent antigens.1,6 In contrast, 
nonprotein antigens such as polysaccharides, glycolipids and nucleic acids, cannot be 
presented to T cells in the context of MHC II molecules.1,6 They elicit T cell-independent 
antibody responses and are, therefore, classified as T-independent antigens.1,6  
In the absence of T cell help, B cells can be activated by different mechanisms.2,6 Some 
nonprotein antigens (e.g. bacterial capsular polysaccharides) contain multiple identical 
epitopes that facilitate BCR oligomerization and subsequent B cell activation.1,6 Other 
nonprotein antigens (e.g. certain nucleic acids) promote B cell activation by engaging so-
called Toll-like receptors (TLRs) (see also sections 1.5.2.5 and 1.6.2.1 and Figure 16).1,2,6 In 
addition, activated DCs can secrete the costimulatory molecules B cell activating factor 
belonging to the TNF family (BAFF) and a proliferation inducing ligand (APRIL) that bind a 
common receptor on B cells known as transmembrane activator and calcium modulator and 
cyclophilin ligand interactor (TACI) (see also Figure 16).6,9 TACI signaling is believed to 
trigger T cell-independent isotype switching, thereby enhancing antibody responses to 
Introduction 
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nonprotein antigens.2,6,10 The functions of BAFF, APRIL and TACI will be discussed in more 
depth in section 1.6.2.1, paragraph “TACI and BAFF-R”.  
T cell-independent antibody responses are predominantly mediated by marginal zone B cells 
in the spleen (Figure 2) and B cells residing in mucosa-associated lymphoid tissues.2,6 
Antibodies produced in the absence of T cell help are of lower affinity and consist mainly of 
IgM with limited isotype switching.1,2,6 However, T cell-independent antibody responses can 
be mounted more quickly, already providing protection during the first days of infection 
(Figure 1).2,6 
 
1.1.3 The role of antibodies in host defense 
Antibodies present in the blood and mucosal secretions are indispensable in host defense 
against extracellular bacteria, fungi and microbial toxins.1,11 Antibodies are also involved in 
immune responses against obligate intracellular microbes such as viruses, which can be 
targeted before they infect cells or when they are released from infected cells.1,11 Of note, T 
cell-independent antibody responses mounted by marginal zone B cells in the spleen 
constitute the first line of defense against blood-borne pathogens, and are particularly 
important for defense against polysaccharide encapsulated bacteria (see section 1.1.2.4).2,6 
Secreted antibodies provide protection by performing three main effector functions (Figure 
5).11 First, antibodies can neutralize the pathogenic effects of microbes and microbial toxins 
by blocking key sites for binding to cellular receptors.11 Second, antibodies can coat the 
surface of microbes to enhance their elimination by phagocytosis, a process referred to as 
opsonization.11 Third, antibodies coating a microbe can also trigger activation of 
complement proteins that, in turn, promote opsonization, recruitment of phagocytes and 
lysis of certain bacteria.11 
 
 
Figure 5. The main effector functions of secreted antibodies. Adapted from Murphy K. Janeway’s 
Immunobiology. 8th ed. New York: Garland Science, Taylor & Francis Group, LLC; 2012. 
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1.2 Inborn errors of the immune system 
1.2.1 Primary immunodeficiencies 
Primary immunodeficiencies (PIDs) are a heterogeneous group of disorders caused by 
genetically determined defects of the immune system.12 To date, more than 300 monogenic 
(i.e. single-gene) inborn errors of immunity have been described.12,13  
 
1.2.1.1 Historical perspectives 
When looking back, progress in the field of PID has always been driven by advances in 
science and medicine and the development of new technologies.14 The history of PIDs starts 
in 1952 with the discovery of X-linked agammaglobulinemia (XLA) by Ogden Bruton (see 
section 1.1.2.2).5 Yet, the groundwork had already been laid by 19th century pioneering 
scientists who introduced innovative ideas in pathology, microbiology, biochemistry, 
hematology and immunology.14 Before World War II, a few patients had been reported with 
typical clinical presentations that would be categorized as PIDs years later. Still, physicians 
and scientists at that time did not grasp the concept of immunodeficiency.14 In the late 
1940’s, advances in public sanitation and hygiene and the advent of antibiotics lowered the 
global burden of infectious diseases, thereby paving the last part of the way towards the 
recognition of PIDs.14 Finally, by using a novel electrophoresis apparatus that had just 
become available, Bruton was able to confirm his speculation that the recurrent pneumonias 
of the XLA patient were linked to abnormalities in serum antibodies.14 In the following 
decades, only a handful of new PID entities were described.14 However, in that same period, 
groundbreaking progress was taking place in molecular genetics: discovery of the DNA 
double helix structure by Watson and Crick in 1953, deciphering of the genetic code and 
mechanisms of DNA replication in the 1950s and 60s, development of Sanger sequencing 
and PCR in the 1970s and 80s, and the launch of the Human Genome Project in 1990.14 In 
the mid 1990s, encouraged by the possibilities of gene sequencing and increasing insights in 
basic immunology, physicians and scientists showed a renewed interest in PIDs.14,15 From 
then on, a multitude of novel PID diseases and genes were being reported at a continual 
pace.15 Since 2010, the field of PID has, again, been transformed by the advent of next-
generation sequencing (NGS) technologies.15 NGS technologies have facilitated the genetic 
diagnosis of PID patients and the identification of novel PID-causing genes.15 Even more, 
this most recent surge is substantially enhancing our understanding of disease 
pathophysiology as well as basic cellular pathways and mechanisms of host defense.16 
Considering that whole genome sequencing, genome editing technologies and functional 
methods keep on improving, we expect that research efforts in the field of PID will continue 




Individual PID disorders are very rare, but collectively they pose a health burden that is 
believed to be comparable with that of cystic fibrosis or leukemia.18,19 Despite enormous 
efforts, patient registration remains, however, incomplete and inconsistent across continents. 
Additionally, it is suspected that a considerable number of PID patients are undiagnosed. 
Estimates of the prevalence of PIDs from registry data worldwide range from 5.3 to 86.3 per 
100,000, with an estimated incidence of up to 10.3/100,000 per year.19 Despite the lack of 
accurate prevalence and incidence rates, PIDs seem to be more frequent than originally 
thought.19 Some authors state that the prevalence of PIDs may be as high as 1-2% of the 
population when taking into account all types and varieties.13 With the exception of X-linked 
conditions, PIDs seem to affect men and women equally.13 The age of onset is very 
variable.19 In general, the more severe the PID condition, the earlier the age of onset.20 More 
than 90% of PID patients registered worldwide were diagnosed under the age of 15 years.19 
However, an important bias to be considered is that registration is mainly done by pediatric 
centers.19 Although exact numbers are not available, patient registries as well as individual 
case reports clearly indicate that PIDs are not exclusively diseases of infancy or early 
childhood but can manifest at any age up to late adulthood.13,19 
 
1.2.1.3 Clinical phenotypes  
The genetic defects underlying PID diseases result in reduced expression and/or aberrant 
function of one or more components of the immune system.12 Accordingly, each PID disease 
is characterized by its own palette of clinical and immunological (laboratory) 
abnormalities.12,20 Some PIDs are severe or even life threatening, whereas others are mild 
and may go unnoticed for years.12 Notwithstanding this heterogeneity, the clinical features 
seen in PIDs can be categorized into five major phenotypes (i.e. physical characteristics) 
as shown in Figure 6.20 PID patients commonly have an increased susceptibility to 
infections.12,20 These infections are recurrent, severe, persistent, complicated and/or caused 
by unusual (opportunistic) organisms.12,20 The type of infection can sometimes provide a clue 
in which part of the body’s defense mechanisms the immune defect is situated.20 Infections 
are, however, not the only health problem faced by PID patients. Errors of immunity often 
cause an imbalance between the countless activating, inhibiting and regulating forces that 
are continually at play. This imbalance creates a situation of immune dysregulation that is 
reflected in autoimmunity, (auto)inflammation, and/or allergy.12,20,21 Finally, PID patients 
often have an increased risk of malignancies.12,20,22 This is attributed to aberrant immune 
surveillance resulting from defective elimination of abnormal or “transformed” host cells 




Figure 6. Venn diagram illustrating the variety of clinical phenotypes that underlie primary 
immunodeficiencies (PIDs). PID patients commonly present with recurrent, severe and/or unusual 
infections. In addition, they can demonstrate any combination of features related to autoimmunity, 
(auto)inflammation, allergy and/or malignancy. 
 
1.2.1.4 Monogenic but not always Mendelian 
Monogenic inborn errors of immunity can be inherited in an autosomal dominant, autosomal 
recessive or X-linked recessive manner, or can appear de novo.12,15 The molecular 
dissection of PID patients over the past two decades has made it clear that the disease 
phenotype is often not predictive of the underlying genotype (i.e. genetic defect) and vice 
versa.12,15 A single phenotype can, for example, be caused by mutations in different genes; a 
situation referred to as locus heterogeneity.15,20,24 Furthermore, different mutations in a 
single gene can underlie a spectrum of phenotypes with variable severity and age of onset 
(allelic heterogeneity).12,15,24 For the latter, a genotype-phenotype correlation is rarely 
observed.12,15,20 Moreover, the same mutant genotype can also be associated with large 
phenotypical variability (variable expressivity).12 In addition, a growing number of PID-
causing genes are associated with reduced or incomplete penetrance, meaning that not all 
individuals with a mutant genotype develop a phenotype.15,24 Indeed, it is becoming 
increasingly evident that PIDs do not always obey the rules of Mendelian inheritance.25 
Current understanding on the molecular basis of variable expressivity and incomplete 
penetrance is limited.26 They may be partially explained by the actions of modifier genes, 
epigenetic changes and/or environmental exposures such as pathogens and 
immunomodulatory treatments.15,26 Finally, in some PIDs the affected gene is more widely 
expressed in human tissues and involved in more universal cellular processes rather than 










immunological manifestations (e.g. skeletal or dental abnormalities); a phenomenon termed 
pleiotropy.15,27 Although many PIDs can be accompanied by some form of extra-
immunological manifestations, disorders are only referred to as syndromic PIDs when these 
extra-immunological abnormalities are prominent. 
The here-mentioned genetic concepts will be further illustrated in section 1.6. 
 
1.2.2 Primary antibody deficiencies  
PIDs are classified into different groups in accordance with their most pronounced and 
fundamental defect.12 Primary antibody deficiencies (or predominantly antibody 
deficiencies) (PADs) are the most common group of PIDs, accounting for 50 to 60% of all 
registered patients.13,22 PADs are characterized by markedly reduced serum levels of one or 
more immunoglobulin isotypes and/or impaired antibody responses to specific antigens due 
to genetically determined defects in B cell development and/or function (see section 1.1.2), 
without major impairments in other parts of the immune system.12,28 Disorders affecting other 
parts of the immune system (e.g. T cells) can also be accompanied by impaired antibody 
production (see section 1.1.2), but these are usually classified in other PID groups since 
antibody deficiency is not their most fundamental defect.12  
 
The degree of antibody deficiency differs across the various types of PADs.12,20,28 The 
prototype disorder of PADs is Bruton’s XLA caused by mutations in the BTK gene (see 
sections 1.1.2.2 and 1.2.1.1).5,28 The block in early B cell development is typically associated 
with very low to absent B cells and a profound decrease in all serum immunoglobulin 
isotypes.28 In other PADs, B cell development and/or function may be less severely affected, 
causing, for example, selective deficiencies in IgA, IgG subclasses, or antibody responses to 
specific antigens.12,20,28 Furthermore, the degree of antibody deficiency can sometimes 
evolve over time, either improving or getting worse.6,29 A well-known example is transient 
hypogammaglobulinemia of infancy, in which serum immunoglobulin levels spontaneously 
correct by the age of two to four years.6,30 It is believed that transient antibody deficiencies in 
young children represent a physiological delay in the maturation of the immune system.30,31 
In other cases, the antibody deficiency may only partially improve or, in contrast, aggravate 
over time with or without aggravation in additional parts of the immune system.6,29,32 The 
underlying mechanisms of these phenomena remain, thus far, enigmatic. 
 
Common variable immunodeficiency (CVID), the focus of this thesis, is one of the most 
frequently diagnosed PADs.13,29 Like for all PIDs, there are no precise data on the prevalence 
of CVID (see section 1.2.1.2).29 Prevalence estimates range from 1/100,000 to 1/10,000.33 
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The diagnostic, clinical and pathophysiological aspects of CVID will be reviewed in the 
following sections.  
 
1.3 CVID, a diagnosis of exclusion  
The term “common variable immunodeficiency” (CVID) was first introduced in 1971 by a 
committee of the World Health Organization.34 This new term had to distinguish less well-
defined forms of antibody deficiency from others that had a more coherent clinical picture 
and Mendelian inheritance such as XLA.29,34 So, from the start, CVID became a diagnosis of 
exclusion.29,34 In need of a clearer definition, the European Society for Immunodeficiencies 
(ESID) and Pan-American Group for Immunodeficiency (PAGID) formulated the first 
consensus diagnostic criteria of CVID in 1999:35  
Probable CVID  
Male or female patient who has a marked decrease (at least 2 standard deviations 
below the mean for age) in serum IgG and in at least one of the isotypes IgM or IgA, 
and fulfills all of the following criteria: 
1. Onset of immunodeficiency at greater than 2 years of age. 
2. Absent isohemagglutinins and/or poor response to vaccines. 
3. Defined causes of hypogammaglobulinemia have been excluded according to 
a list of differential diagnoses (Table 1). 
Possible CVID 
Male or female patient who has a marked decrease (at least 2 standard deviations 
below the mean for age) in one of the major isotypes (IgM, IgG, and IgA) and fulfills 
all of the following criteria: 
1. Onset of immunodeficiency at greater than 2 years of age. 
2. Absent isohemagglutinins and/or poor response to vaccines. 
3. Defined causes of hypogammaglobulinemia have been excluded according to 
a list of differential diagnoses (Table 1). 
 
The first criterion (onset over 2 years of age) mainly served to separate CVID from transient 
hypogammaglobulinemia of infancy (see section 1.2.2). The third criterion excluded 
secondary (acquired) causes of antibody deficiency as well as other primary (inborn) causes 




Table 1. Differential diagnoses of hypogammaglobulinemia (non-exhaustive list). 
Drug induced 
 Glucocorticoids, rituximab, captopril, carbamazepine, fenclofenac, penicillamine, phenytoin, 
sulfasalazine, gold salts, antimalarial drugs 
Single gene and other defects 
 Ataxia telangiectasia, severe combined immunodeficiency (SCID) and other forms of combined 
immunodeficiency (CID), hyper-IgM syndromes, X-linked agammaglobulinemia, X-linked 
lymphoproliferative disorder, transcobalamin II deficiency, some metabolic disorders 
Chromosomal anomalies 
 Trisomy 21, 18q deletion syndrome, monosomy 22, trisomy 8 
Infectious diseases 
 Human immunodeficiency virus, Epstein-Barr virus, cytomegalovirus, measles virus, congenital 
infection with rubella virus or Toxoplasma gondii 
Malignancy 
 Chronic lymphocytic leukemia, thymoma, non-Hodgkin lymphoma, monoclonal gammopathy 
(multiple myeloma, Waldenstrom macroglobulinemia) 
Other systemic disorders 
 Immunodeficiency caused by excessive loss of immunoglobulins (nephrotic syndrome, severe 
burns, lymphangiectasia, protein-losing enteropathy) 
 
Adapted from Bonhilla et al. J Allergy Clin Immunol Pract. 2016;4(1):38-59. 
 
The ESID/PAGID 1999 criteria stood firm for more than a decade, but with the expanding 
knowledge on PIDs there was a growing appreciation that the definition of CVID needed to 
be further refined.35 The main stumbling block was that the ESID/PAGID 1999 criteria did not 
always allow to discriminate CVID from overlapping PID disorders, particularly less severe 
forms of combined immune deficiencies (CIDs; i.e. associated with both B and T cell 
defects).36 Between 2013 and 2015, three different revisions of the ESID/PAGID 1999 criteria 
were proposed.37-39 In 2013, Ameratunga et al. suggested a diagnostic algorithm with 
limited major and multiple minor (supportive) criteria including various clinical, laboratory and 
histological features associated with CVID (see sections 1.4 and 1.5).37 Remarkably, neither 
IgA nor IgM was required to be low as only a reduction in serum IgG was incorporated in the 
major criteria.37 Furthermore, the authors introduced an additional category termed 
“hypogammaglobulinaemia of uncertain significance” (HGUS) for patients that did not 
meet any of the minor criteria.37 In 2014, ESID revised the criteria used for their online 
patient registration database, including the CVID criteria.38 Similar to the Ameratunga 2013 
criteria, the new ESID criteria encompassed the presence of clinical symptoms or a positive 
family history, an age at diagnosis above 4 years (although symptoms may be present 
before), and reduced switched memory B cells (see section 1.5.2) as an alternative criterion 
for poor vaccine responses.38 However, in contrast to the Ameratunga 2013 criteria, the 
revised ESID registry 2014 criteria also included the mandatory decrease of serum IgA and 
defined the exclusion of patients with profound T cell deficiency to facilitate distinction with 
CIDs.38 Finally, in 2015, a French group (DEFI) supported the mandatory decrease of IgA, 
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did not include poor vaccine responses and proposed more restrictive criteria for the 
exclusion of patients with T cell defects (occurrence of opportunistic infections and very low 
naive CD4+ T cells).39 Additionally, they included a category termed “idiopathic primary 
hypogammaglobulinemia (IPH) / HGUS”, reminiscent of the HGUS category by 
Ameratunga et al.37,39 However meritorious the three revisions were, the diagnostic criteria by 
Ameratunga et al.37 did not seem to find broad acceptance in the immunological community, 
and not all clinical immunologists agreed on the obligatory decrease in IgA incorporated in 
the revised ESID registry 201438 and DEFI 201539 criteria.  
 
In  2016, an expert committee published a new international consensus (ICON) definition 
of CVID, stating that all of the following criteria should be fulfilled:29  
1. Decrease in serum IgG according to the age-adjusted reference range. The IgG 
level must be repeatedly low in at least 2 measurements more than 3 weeks 
apart. Repeated measurement may be omitted if the level is very low (<100-300 
mg/dL depending on age). 
2. Decrease in serum IgA and/or IgM (low IgA preferred). 
3. If IgG >100 mg/dL: demonstrable impairment of response to at least one protein 
and/or polysaccharide vaccine.  
4. Other causes of hypogammaglobulinemia must be excluded, with special 
attention for CID characterized by T cell deficiency (Table 1). 
The expert committee strongly recommended not to confer a diagnosis of CVID to patients 
younger than 4 years of age. Furthermore, they provided supportive information how 
antibody responses to vaccines should be assessed. Of note, characteristic clinical 
manifestations (infection, autoimmunity, lymphoproliferation) can support a diagnosis of 
CVID but are not required. 
 
The definition of CVID is still a topic of ongoing debate.29,40 The latest CVID ICON 2016 
diagnostic criteria closely resemble the original ESID/PAGID 1999 criteria, although there is 
no longer a distinction between a “probable” and “possible” diagnosis of CVID.29,35 The 
biggest challenge is how to classify patients presenting clinical features reminiscent of CVID 
but with only a decrease in one major immunoglobulin class (IgG, IgM, IgA) or an IgG 
subclass (IgG1-4). The Ameratunga 2013 and DEFI 2015 criteria tried to meet that challenge 
by introducing an additional category in their diagnostic flow charts, which they termed 
HGUS or IPH.37,39 Other expressions used in literature to describe these patients are 
unspecified/unclassified hypogammaglobulinemia29,41 or CVID-like disorders42. Despite the 
lack of a clear definition or name, others and we have provided evidence that these milder 
Introduction 
 17 
forms of antibody deficiency might be part of the same disease spectrum as CVID (see 
Chapter 3).6,29,32,43-45 
 
1.4 Clinical characteristics of CVID 
Like most diagnoses of exclusion, CVID encompasses a heterogeneous patient population 
demonstrating a diversity of clinical and immunological (see section 1.5) manifestations with 
varying severity.46-48 Disease onset can occur at any age from infancy to late adulthood.48-51 
Two large cohort studies (n=248, n=2212) reported a peak incidence in the first and third 
decades of life.48,49 Approximately 25% of CVID patients receive a diagnosis in childhood.50 
CVID patients commonly suffer from recurrent infections, mainly of the respiratory and 
gastrointestinal tracts.48,51 Typical pathogens are encapsulated bacteria (e.g. Streptococcus 
pneumoniae), nontypeable Haemophilus influenzae, Enterobacteriaceae, Campylobacter 
spp., Giardia lamblia, Mycoplasma spp., and respiratory viruses.6,52 This reflects the 
important role of antibodies in host defense against these organisms (see section 1.1.3). 
Repeated infections of the lower airways may cause structural damage such as 
bronchiectasis.48,53   
Depending on the study cohort, between 33% and 80% of CVID patients have an “infections-
only” phenotype.51,54,55 Other patients additionally develop complications due to immune 
dysregulation: autoimmunity, enteropathy, polyclonal lymphoproliferation, granulomatous 
disease, and/or malignancy.47,48,51,53 These so-called noninfectious or disease-related 
complications can develop any time during the disease course. They can also be the first 
clinical presentation of disease before the onset of infections.47,53 Their presence is usually 
associated with abnormalities in B and/or T cell subsets, which will be explained in the 
following section (1.5). The pathogenesis of noninfectious complications in CVID remains, 
however, incompletely understood.56,57 Autoimmunity is seen in up to 25-30% of CVID 
patients and can affect any part of the body.48,53,57 Most frequent are autoimmune cytopenias, 
especially immune thrombocytopenic purpura and autoimmune hemolytic anemia.48,53 Other 
autoimmune diseases often encountered in CVID patients include pernicious anemia, thyroid 
disease, arthritis, vitiligo and systemic lupus erythematosus (SLE).48,57 Unexplained 
enteropathy with chronic diarrhea and malabsorption is a recurring feature in CVID.48 The 
cause of the chronic intestinal inflammation is unclear.33 In some cases, it may be associated 
with autoimmunity.33 At least one third of patients with CVID show signs of polyclonal 
lymphoproliferation.48,53 Generalized benign lymphadenopathy and splenomegaly are most 
frequently observed.48,53 Lymphocytes can also infiltrate other organs such as the liver, gut, 
brain and lungs.48,53 Lung infiltration may cause lymphocytic interstitial pneumonitis (LIP).48,53 
Another characteristic complication of CVID is the development of granulomatous disease. 
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Granulomas are typically seen in the lungs, but virtually any organ can be involved.48,53 The 
co-occurrence of granulomas and lymphoid infiltrates in the lungs is referred to as 
granulomatous-lymphocytic interstitial lung disease (GLILD).33 About 6-9% of CVID patients 
are diagnosed with malignancy, mostly lymphoma.56 Patients also have an increased risk 
for solid tumors, particularly gastric cancer.29,33  
 
1.5 Immunological abnormalities in CVID 
1.5.1 Introduction 
The hallmark immunological defect in CVID patients is, per definition, impaired 
immunoglobulin production by plasma cells resulting in hypogammaglobulinemia and poor 
vaccine responses.29 Besides defects in the B cell lineage, numerous abnormalities in the T 
cell and innate immune compartment have been reported.46 The broad distribution of defects 
supports the concept of CVID being a condition of generalized immune dysregulation rather 
than an isolated antibody deficiency.46  
The connection between B cell, T cell and innate immune cell abnormalities in disease 
development remains largely enigmatic. The various immunological abnormalities reported in 
the CVID population are unequally distributed across patient cohorts. Therefore, no coherent 
picture can be drawn from the myriad of immunophenotypical and functional studies 
performed in the past decades. Furthermore, it is difficult to determine whether 
immunological defects are primary (disease-intrinsic) or secondary (e.g. caused by chronic 
inflammation), especially because the underlying pathophysiological mechanisms are mostly 
unknown and likely to be heterogeneous.29,46  
 
1.5.2 B cell abnormalities  
In keeping with primary antibody failure as the hallmark of CVID, the B cell compartment has 
been the main subject of research. This section elaborates on the most important numerical 
and functional B cell defects described in CVID patients thus far. 
 
1.5.2.1 Total peripheral B cell numbers 
Total peripheral B cell numbers are variable. In more than half of patients, B cell numbers are 
within normal ranges for age.49,53,58-60 About 10% has reduced total B cells, and in 5-10% of 
patients B cells constitute less than 1% of total peripheral lymphocytes.49,53,58-60 In contrast, 




Low or absent B cells indicates a defect in B cell development and/or B cell survival.46,60 
Some CVID patients with low B cell counts were found to have a partial block in early B cell 
development or a decrease in hematopoietic precursor cells in the bone marrow (see also 
section 1.1.2.2).61,62 The authors postulated that this could result from a primary defect in 
bone marrow progenitor cells or from damage caused by an altered cytokine environment 
secondary to chronic or recurrent infections.61,62 The latter hypothesis has, to our knowledge, 
not yet been investigated. Still, in most patients with decreased peripheral B cells, bone 
marrow development appeared to be normal.61 Also, some patients with low B cells have a 
normal peripheral B cell differentiation pattern. These findings suggest that other factors are 
involved in peripheral B cell depletion, which may reduce survival and/or promote 
apoptosis.61 Survival of circulating B cells is dependent on BCR and BAFF-receptor (BAFF-
R) signaling (see also section1.6.2.1, paragraph “TACI and BAFF-R”).10 Several studies have 
provided evidence of impaired BCR-mediated signaling in CVID patients, such as 
decreased upregulation of costimulatory molecules or defective calcium mobilization upon in 
vitro stimulation.63-67 It was also shown that B cells of CVID patients, on average, have lower 
BAFF-R expression levels.68 Furthermore, in a subset of CVID patients, B cells showed a 
higher expression of the pro-apoptotic Fas receptor, implicating increased apoptosis and 
further depletion of the peripheral B cell pool.69,70 Note that defects in expression and/or 
signaling by the here-mentioned receptors were also reported in CVID patients with normal 
or increased B cell numbers, suggesting a broader functional impairment rather than a sole 
survival defect.63-70 A reduction in total B cells, especially when very low, is associated with a 
more severe clinical course.49,50,71 Importantly, (hypomorphic) mutations in BTK should be 
excluded in male patients with reduced B cell counts (see section 1.1.2.2).72,73  
Patients with increased total B cell numbers have been less intensively studied. Possible 
mechanisms are increased bone marrow output, prolonged survival and/or higher peripheral 
B cell replication.74 High total B cell counts have been associated with polyclonal lymphocytic 
infiltration and autoimmunity.53   
 
1.5.2.2 In vitro B cell functionality 
Besides changes in total B cell numbers, functional B cell alterations have also been 
documented in subgroups of CVID patients. For example, upon in vitro stimulation, some 
patients’ B cells can produce normal amounts of IgG and IgM, whereas others can only 
secrete IgM or are unable to produce any immunoglobulin at all.75 It is indeed puzzling that B 
cells of some CVID patients are able to produce normal immunoglobulin levels in vitro but not 
in vivo. One explanation could be that in vivo B cell activation by costimulatory cytokines 
and/or surface molecules is impaired in those patients.76 Alternatively, suppression of 
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intracellular B cell signaling may be overcome by the supraphysiological concentrations of 
the in vitro stimuli.76  
 
1.5.2.3 Peripheral B cell subsets  
One of the most well described immunological abnormalities in CVID is an alteration in 
peripheral B cell subsets, mainly in class-switched memory B cells, marginal zone-like B 
cells, transitional B cells and CD21low B cells (Figure 7) (see also section 1.1.2).  
 
 
Figure 7. Peripheral B cell subsets. The first graph shows total B cells gated as CD19+CD20+ cells 
in alive peripheral blood mononuclear cells (PBMCs). The second to fourth graphs depict B cell 
subsets gated on total B cells as indicated. Axes labels designate the markers used to discriminate 
(“gate”) cell populations. Numbers on the graphs represent the frequency (percentage) of the parent 
population. Graphs are derived from an adult healthy subject. CD: cluster of differentiation, CD21(low): 
CD21low B cells, Ig: immunoglobulin, MZ-like: marginal zone-like B cells, naive: naive mature B cells, 
sw mem: (class-)switched memory B cells, transitional: transitional B cells. 
 
About 80% of patients have reduced levels of class-switched memory (IgM-IgD-CD27+) B 
cells in the blood;58-60,77 a feature first recognized in 2000 by Brouet et al.78 In addition, 
several studies documented a depletion of plasma cells in lymphoid organs (bone marrow, 
lymph nodes, gut-associated lymphoid tissue) in the majority of the investigated patients.61,79-
84 Lack of switched memory B cells and plasma cells may indicate a block in late B cell 
development at the level of the GC reaction.83 The assumption of a disturbed GC reaction in 
a subgroup of CVID patients is further supported by studies showing reduced rates of SHM 
in memory B cells.77,85-88 However, not all patients with decreased switched memory B cells 
have impaired SHM.87 Alternatively, the reduction in terminally differentiated B cells may be 
caused by increased apoptosis or disturbed migration upon stimulation during an immune 
response; a defect situated at the post-GC level.89 Patients with low levels of switched 
memory B cells usually present a more severe clinical phenotype with a higher risk of 
developing noninfectious complications.58-60 
Marginal zone-like (IgM+IgD+CD27+) B cells, also known as natural effector B cells or non-
switched memory B cells, are considered to be the circulating counterpart of splenic marginal 
zone B cells and can be generated in the absence of T cell help and a GC reaction.90 
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Marginal zone-like B cells are less consistently affected in CVID and are reduced in about 
10% of patients.91 In some study cohorts, reduced levels of marginal zone-like B cells were 
associated with respiratory tract infections and chronic lung disease.87,91 
Subgroups of CVID patients show an expansion of functionally immature transitional 
(CD38highCD24highIgMhigh) B cells and/or so-called CD21low (CD21lowCD38low) B cells 
(Figure 7).60 A relative increase in transitional B cells is believed to indicate a defect in 
peripheral B cell maturation (see section 1.1.2.2).60 Elevated transitional B cells in CVID 
patients have been associated with the development of lymphadenopathy.60 CD21low B cells 
are an unusual peripheral B cell subset and their ontogeny is unclear.92-94 This subpopulation 
is thought to develop from memory B cells because their immunoglobulins have undergone 
CSR and SHM.52,94 Furthermore, CD21low B cells express an altered chemokine receptor 
repertoire compared to other circulating B cell subsets, indicative of homing to inflammatory 
tissues instead of peripheral lymphoid tissues.92 CD21low B cells show signs of previous 
activation and proliferation.92,95 However, in vitro these cells have a poor proliferation 
capacity, which suggests a partial anergic status.92,93 CD21low B cells are very infrequent in 
healthy individuals but increased levels have been reported in patients with autoimmune 
disorders (e.g. SLE, Sjögren syndrome, rheumatoid arthritis) and patients with chronic viral 
infections (e.g. HIV, hepatitis C virus).93,94,96-98 In summary, CD21low B cells are regarded as 
chronically activated or exhausted B cells, derived from terminally differentiated B cells, that 
are expanded in conditions of chronic immune stimulation.93,94,99,100 In CVID patients, 
increased CD21low B cells are associated with splenomegaly and autoimmune 
cytopenias.60,101  
 
1.5.2.4 Classifications of CVID patients based on peripheral B cell subsets 
Peripheral B cell immunophenotyping has been used to classify CVID patients into more 
homogeneous subgroups who share clinical phenotypes.58-60 The main objective of these 
classifications was the identification of CVID patients at risk for certain noninfectious 
complications, in order to optimize treatment and follow-up.29,46 Additionally, dividing CVID 
patients into subgroups could guide researchers to unravel the underlying pathophysiological 
mechanisms.29,46  
The Freiburg classification, published in 2002, distinguished three groups of patients 
based on the levels of switched memory and CD21low B cells (Figure 8A).58 The Paris 
classification from 2003 stratified CVID patients in three groups by means of total memory 
and switched memory B cell levels (Figure 8B).59 The Paris groups showed poor agreement 
with the Freiburg groups, which may be due to methodological differences.59  
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In 2008, a multicenter European study (n=303) developed a consensus classification based 
on the two previous ones named EUROclass.60 The EUROclass protocol distinguished more 
patient groups based on the levels of total B cells as well as switched memory, transitional 
and CD21low B cell subsets (Figure 8C).60 The associations found in the EUROclass trial 
corresponded partially with those found in the Freiburg and Paris studies. Severely reduced 
switched memory B cells were associated with splenomegaly and granulomatous disease, 
elevated CD21low B cells with splenomegaly, and increased transitional B cells with 
lymphadenopathy.60 For autoimmunity, no specific marker could be identified.60  
The distribution of peripheral B cell subsets is dynamic and can sometimes show substantial 
changes over time. However, the clinical importance of this was not investigated.102 Although 
the classifications based on peripheral B cell subsets have been valuable to some degree, in 
daily practice they turned out to be unsatisfactory. The associations between aberrant B cell 
subsets and clinical features were not consistently found in different CVID cohorts, and 




Figure 8. The Freiburg, Paris and EUROclass classifications. CVID patients are classified into 
clinically and immunologically more homogeneous groups based on flow cytometric phenotyping of 
peripheral B cell subsets. B cell subsets were expressed as percentages of peripheral blood 
lymphocytes (PBL) (Freiburg) or as percentages of total B cells (Paris, EUROclass). CD27+ B cells: 
total memory B cells. CD27+IgM-IgD-: switched memory B cells. Adapted from Bergbreiter A and 
Salzer U. Expert Rev Clin Immunol. 2009;5(2):167-80. 
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More recently, Driessen et al. distinguished five patient groups based on the composition, 
replication history and SHM rate of peripheral B cell subsets.77 These five groups represent 
five main B cell patterns that each correspond with a block at a critical stage in B cell 
development (Figure 9): (1) B cell production, (2) early peripheral B cell maturation or 
survival, (3) B cell activation and proliferation, (4) germinal center, and (5) post-germinal 
center.77 The work of Driessen et al. offered new pathophysiological insights on how defects 
at different stages in B cell development can lead to a final common pathway of CVID.77 
Moreover, the B cell pattern approach was also applicable to IPH patients, i.e. patients with 
hypogammaglobulinemia who do not fulfill all CVID diagnostic criteria (see section 1.3).106 
The B cell patterns showed little overlap with the EUROclass groups (Figure 8).77 
Noninfectious disease-related complications were mainly associated with defects in B cell 
production, early peripheral B cell maturation or B cell survival (patterns 1 and 2, Figure 9).106 
 
 
Figure 9. Peripheral B cell development with indication of the five stages of development block 
in CVID according to Driessen et al. The five B cell patterns delineate five immunological 
homogenous groups of CVID patients with different pathophysiological backgrounds. The curved 
arrows depict B cell proliferation. Adapted from Driessen GJ et al. Blood. 2011;118(26):6814-23. 
 
1.5.2.5 B cell chemokine and Toll-like receptors 
Migration (homing) of lymphocytes into and within lymphoid organs is regulated by 
chemokines and their receptors.107 Important chemokine receptors expressed by B cells 
are CXCR4, CXCR5 and CCR7. CXCR4 is involved in homing to the bone marrow.107 
CXCR5 and CCR7 direct trafficking to the B cell follicles/zones and T cell zones, 
respectively, in peripheral lymphoid tissues (Figure 3).107 CXCR4 expression on B cells was 
not significantly altered in CVID patients.108 In contrast, expression of CXCR5 and CCR7 on 
naive and memory B cells was, on average, reduced in CVID patients.45,108 These findings 




Toll-like receptors (TLRs) are membrane-spanning pattern recognition receptors that play a 
key role in the early innate immune response.109 TLR7 and TLR9 are related endosomal 
receptors predominantly expressed by B cells and plasmacytoid dendritic cells (pDCs) 
(Figure 10) (see also section 1.5.4.2).110 B cells differentially express these TLRs in the 
course of their life span: expression is very low in naive B cells, upregulated upon BCR-
mediated activation, and constitutively high in memory B cells.111 TLR7 and TLR9 signaling is 
triggered by specific microbial DNA and RNA motifs, and can induce T-independent B cell 
activation and antibody responses even in the absence of specific antigen (see also section 
1.1.2.4).110 Impaired TLR7 and TLR9 signaling in B cells and pDCs has been observed in a 
subgroup of CVID patients (Figure 10).112-116 In those patients, TLR mRNA and protein 
expressions were normal and no genetic mutations or associated polymorphisms could be 
identified.113,116,117 TLR7 and TLR9 signaling defects in CVID patients were independent of 
total B cell numbers or B cell memory phenotype.112,113,115 However, patients with the lowest 
levels of switched memory B cells presented the most dysfunctional TLR-induced 
responses.118,119 Taken together, dysfunction of TLR7 and TLR9 signaling appears to 
contribute to the pathophysiology of CVID, but is probably not the primary cause of 
disease.119 Moreover, despite that TLRs are considered potent B cell activators, they do not 
seem to be essential for antibody production because patients with monogenic defects in 
TLR signaling molecules do not generally have antibody deficiencies.118 
 
 
Figure 10. Toll-like receptor (TLR) 7 and TLR9 signaling in plasmacytoid dendritic cells (pDCs) 
and B cells are impaired in a subgroup of CVID patients. CSR: class switch recombination, CVID: 
common variable immunodeficiency, IFN: interferon, Ig: immunoglobulin, NFκB: nuclear factor of 





1.5.3 T cell abnormalities 
In parallel with the identification of B cell abnormalities, numerous studies have provided 
evidence that the T cell compartment is also misbalanced in CVID. Note that most of the T 
cell data were generated before the introduction of the revised ESID registry criteria for CVID 
in 2014, which for the first time emphasized the exclusion of patients with more severe T cell 
deficiency (see section 1.3). It would be of interest to reassess the T cell findings in a better 
delineated patient population, as we did in chapter 3. Still, much can be learned from the 
available reports on T cell abnormalities in CVID patients.120 
 
1.5.3.1 Peripheral CD4+ T cells 
CD4+ T lymphopenia is one of the most frequently reported T cell abnormalities in CVID and 
is estimated to affect up to one third of patients. Reduced CD4+ T cell numbers in CVID 
patients are associated with a higher risk of disease-related complications, especially 
granulomatous disease and splenomegaly.121-124 The decrease in CD4+ T cells can extend to 
all subsets but is predominately restricted to the naive pool (Figure 11).54,122-124  
 
 
Figure 11. Peripheral CD4+ T cell subsets. The first graph shows CD8+ and CD4+ T cells gated in 
the total T cell population. The remaining graphs depict CD4+ T cell subsets as indicated. Axes labels 
designate the markers used to discriminate (“gate”) cell populations. The parent population is depicted 
on top of each graph. Numbers represent the frequency (percentage) of the parent population. Graphs 
are derived from an adult healthy subject. CD: cluster of differentiation, cTfh: circulating follicular 
helper T cells, naive: naive T cells, RTE: recent thymic emigrants, TCM: central memory T cells, TEM: 
effector memory T cells, TEMRA: effector memory RA T cells, Treg: regulatory T cells. 
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Giovannetti et al. demonstrated that the degree of naive CD4+ T cell loss was linked to the 
degree of overall T cell dysfunction and disease severity.122 Based on these findings, the 
authors proposed an alternative CVID classification scheme using naive CD4+ T cell 
percentages as single parameter (Figure 12).122 A more severe depletion in naive CD4+ T 
cells was associated with more severe T and B cell abnormalities as well as a more severe 
clinical picture, especially splenomegaly.122 
 
 
Figure 12. The naive CD4+ T cell classification by Giovannetti et al. CVID patients are classified 
into clinically and immunologically more homogeneous groups based on the proportion of peripheral 
naive CD4+ T cells (CD4+CD45RA+CD62L+). Adapted from Bergbreiter A and Salzer U. Expert Rev 
Clin Immunol. 2009;5(2):167-80. 
 
Despite the fact that decreased naive CD4+ T cells were correlated with decreased switched 
memory B cells and increased CD21low B cells (see section 1.5.2.3), the Giovannetti groups 
showed little concordance with the previously published Freiburg groups (Figure 8A).122 
Similar to the classifications based on peripheral B cell subsets, the naive CD4+ T cell 
classification failed to capture the entire CVID picture and did not allow a satisfactory 
prediction of the risk of disease-related complications.46 
Peripheral CD4+ T cells are mainly replenished by output from the thymus, whereas CD8+ T 
cell numbers are predominantly conserved by proliferation of the existing peripheral pool.122 
Hence, a decrease of naive CD4+ T cells in CVID patients is suggestive of reduced thymic 
output. Additional evidence supporting thymic dysfunction in CVID patients includes a 
reduction of peripheral T cells carrying a T cell receptor excision circle (TREC),74,125,126 
reduced levels of CD4+ recent thymic emigrant (CD45RA+CD31+) cells (Figure 11),62,122,124 
and the presence of a more restricted T cell receptor (TCR) repertoire.122,127 Moreover, 
several studies provided evidence of increased T cell apoptosis, which could contribute to 
the (naive) CD4+ T lymphopenia.122,128,129  
 
A decrease of peripheral blood regulatory T (Treg) cells (CD4+CD25+FOXP3+ or 
CD4+CD25+CD127-) has also been described in a proportion of CVID patients (Figure 11).130-
135 Treg cells are known for their modulating role in immune responses, crucial for preventing 
autoimmune disease and chronic immune activation.136 It is, therefore, not surprising that 
reduced Treg cells in CVID patients are associated with disease-related complications such 
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as autoimmunity, granulomatous disease, lymphadenopathy and splenomegaly.130-135 Low 
Treg cells are also correlated with reduced switched memory B cells and increased CD21low 
B cells, two other known risk factors for disease-related complications (see section 
1.5.2.3).132,133 Treg cells either directly originate from the thymus or are peripherally induced 
from CD4+ T cells.136 Hence, decreased Treg cell levels in CVID patients could fit the broader 
picture of a disturbed thymopoiesis.120 Alongside a quantitative shortage, Treg cells isolated 
from CVID patients with autoimmunity also demonstrated a functional deficit. In particular, 
they expressed lower levels of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) that is 
essential for their regulatory function (see also section 1.6.2.1, paragraph “CTLA-4 
deficiency”), and showed an attenuated suppressive activity when co-cultured with 
autologous CD4+CD25− T cells.134,137,138 
 
Conflicting literature exists regarding the role of follicular helper T (Tfh) cells in the 
pathogenesis of CVID. As explained in section 1.1.2.3, Tfh cells orchestrate the GC reaction 
where B cells undergo terminal differentiation into high-affinity antibody-secreting plasma 
cells and memory B cells.8 Patients with monogenic inborn defects in inducible T cell co-
stimulator (ICOS) have reduced Tfh cells and abrogated GC reactions (see section 1.6.2.1, 
paragraph “ICOS deficiency”).139 In contrast, others and we have found increased levels of 
circulating Tfh (CD4+CD45RO+CXCR5+) cells in a subgroup of CVID patients in whom a 
genetic diagnosis had not been determined (Figure 11) (see Chapter 3).45,124,140 Furthermore 
and analogous to B cells, T cell expression of the chemokine receptor CCR7 was found to be 
reduced in CVID patients (see section 1.5.2.5).108 The latter suggests impaired migration of T 
cells to peripheral lymphoid tissues, which could contribute to the increased levels of 
circulating Tfh cells in some CVID patients. However, possible disease-influencing 
mechanisms of Tfh cells in CVID await further study. 
 
1.5.3.2 Peripheral CD8+ T cells 
As mentioned above, the conservation of peripheral CD8+ T cell numbers is less dependent 
on thymus activity than its CD4+ counterpart.122 Although CD8+ T cells can occasionally be 
reduced,141,142 up to 30% of CVID patients have an increase in CD8+ T cells.120,142-147 The 
latter was found to be correlated with a reduction in Treg cells and switched memory B cells 
and a higher risk of developing disease-related complications.55,124,135,143 The increased CD8+ 
T cells in CVID patients exhibit high levels of activation markers (e.g. HLA-DR, CD69), and 
mainly include effector memory (CD45RO+CCR7-) and terminally differentiated 
senescent (CD45RO-CCR7-) subsets (Figure 13).120,135,143,148-151 This immunophenotypical 
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profile of CD8+ T cells is indicative of chronic activation and suggests T cell 
exhaustion.149,150  
 
Figure 13. Peripheral CD8+ T cell subsets. The first graph shows CD8+ and CD4+ T cells gated in 
the total T cell population. The second graph depicts CD8+ T cell subsets as indicated. Axes labels 
designate the markers used to discriminate (“gate”) cell populations. Numbers on the graphs represent 
the frequency (percentage) of the parent population. Graphs are derived from an adult healthy subject. 
CD: cluster of differentiation, naive: naive T cells, TCM: central memory T cells, TEM: effector memory 
T cells, TEMRA: effector memory RA T cells. 
 
To date, it is unclear why CD8+ T cells in a significant proportion of CVID patients are 
expanded and driven towards exhaustion. Marashi et al. proposed a role for cytomegalovirus 
(CMV) in chronic activation of CD8+ T cells and subsequent development of inflammatory 
complications.152,153 In their cohort (n=71), CVID patients with unexplained enteropathy 
and/or lymphoproliferation had higher levels of CMV-specific CD8+ T cells compared to 
healthy controls, while Epstein-Barr virus (EBV)-specific CD8+ T cells were not elevated.152 
Furthermore, CMV-specific CD8+ T cells showed greatly increased activation and 
proliferation markers, suggesting a persistent and unregulated CD8+ T cell response.152,153 
However, direct causality between CMV, CD8+ T cell expansion and inflammatory 
complications could not be demonstrated and bystander activation of CMV-specific CD8+ T 
cells could not be excluded.152,153 Besides an underlying infectious driver, T cell exhaustion in 
CVID could also be the result of an exaggerated T cell response in a non-infectious context 
like autoimmunity.120 A possible role for autoimmunity in chronic CD8+ T cell activation and 
expansion in CVID patients remains to be investigated.120 
 
1.5.3.3 T cell proliferation and cytokine production 
In 40% to 70% of CVID patients, T cell proliferation responses to antigens (e.g. tetanus 
toxoid) or TCR antibodies are partially decreased.43,49,154,155 In some cohorts, suboptimal T 
cell proliferation responses were more pronounced in CVID patients with disease-related 
complications.43 The cause of impaired T cell proliferation is usually not known, but could be 
related to a state of T cell exhaustion in a subset of cases.120,156  
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T cell cytokines play an important role in B cell differentiation and antibody production (also 
see section 1.1.2.3). A plethora of studies have attempted to identify distinct cytokine profiles 
in CVID patients. However, conflicting data has been reported over the years, which was 
recently put together by Varzaneh et al. in a comprehensive review.157 In brief, there are 
indications of a cytokine imbalance in at least a portion of CVID patients, supported by the 
aberrant production of interleukin (IL)-2, IL-4, IL-5, IL-6, IL-10, IL-21, tumor necrosis factor 
(TNF)-α, interferon (IFN)-γ and other cytokines upon in vitro T cell stimulation.157 Depending 
on the study, the same cytokines could be either decreased or increased (e.g. IL-4, IL-10, 
IFN-γ), while other cytokines showed more consistency regarding the direction in which they 
deviated (e.g. decreased IL-2).157 This divergent cytokine image could be partially due to the 
heterogeneity of the CVID population and partially to the methodological differences of the 
studies (e.g. type of stimuli, cutoff levels).157 In addition, some authors reported that cytokine 
production might be influenced by polymorphisms in the coding and promoter regions of 
cytokine-coding genes.158-160 Immunoglobulin replacement therapy has been shown to affect 
serum cytokine concentrations to some degree,161,162 but it is uncertain whether this would 
also influence in vitro cytokine production.  
Interestingly, Wong et al. postulated that the cytokine signature in some CVID patients 
resembled an early phase of T cell exhaustion.120 In particular, the combination of a 
decreased IL-2 and an increased TNF-α and IFN-γ production reminded the authors of the 
cytokine alterations described in patients with T cell exhaustion caused by chronic viral 
infections.120 Reduced IL-2 production has been a recurrent finding in CVID patients for 
over 30 years.157 Preliminary studies from the 1990s demonstrated that treatment with 
recombinant IL-2 might be beneficial in selected CVID patients.163-166 In those studies, treated 
patients showed enhanced T cell function, increased antibody responses, and a reduction of 
severe infections.163-166 Trials in larger cohorts were not performed. In conclusion, future 
studies are necessary to dissect the conflicting cytokine data and to identify patient groups 
that might benefit from cytokine-targeted therapies.157 
 
1.5.4 Innate immune cell abnormalities 
A limited number of studies have described alterations in cells of the innate immune system 
in subgroups of CVID patients. This section gives an overview of current knowledge on 
innate immune cell dysfunction in CVID. 
 
1.5.4.1 Monocytes 
Blood monocytes play important roles in the initiation and resolution of inflammation during 
the innate immune response (Figure 14).167 They mainly function through phagocytosis, 
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generation of reactive oxygen species (ROS), secretion of inflammatory cytokines, and 
activation of cells of the adaptive immune system.167  
Arguments for chronic hyperactivity of blood monocytes have been found in a selection 
of CVID patients.168-170 In earlier studies, isolated monocytes from some CVID patients 
showed an enhanced ROS generation in vitro, which was associated with increased serum 
levels of TNF-α and soluble TNF receptors in those patients.168,169 In addition, raised serum 
levels of neopterin, a monocyte/macrophage activation marker, were observed in several 
patient cohorts.130,168,170 Monocyte hyperactivity in CVID patients was often associated with a 
generalized immune dysregulation state characterized by reduced switched memory B cells, 
increased CD21low B cells, expansion of activated effector T cells, and/or low CD4+ T 
cells.130,168,171  
Furthermore, some CVID patients demonstrated an altered monocyte cytokine profile 
with higher levels of IL-12.172,173 This cytokine environment does not favor antibody 
production and may thus contribute to the disease process of CVID.172,173  
Finally, impaired phagocytosis by monocytes in a subset of CVID patients may hamper 
both elimination of pathogens and antigen presentation to lymphocytes.174  
Altogether, monocyte dysfunction could be involved in the pathogenesis of CVID in a 
subgroup of patients. In most cases, impaired monocyte function seems to be part of an 
overall dysregulation or hyperactivity of the immune system, although a monocyte-intrinsic 
defect in a limited number of patients cannot be excluded. 
 
 
Figure 14. Peripheral innate immune cell subsets. Graphs depict innate immune cell subsets gated 
on peripheral blood mononuclear cells (PBMCs) as indicated. Axes labels represent the markers used 
to discriminate (“gate”) cell populations. The parent population is shown on top of each graph. 
Numbers represent the frequency (percentage) of the parent population. Graphs are derived from an 
adult healthy subject. CD: cluster of differentiation, cDCs: conventional dendritic cells, iNKT: invariant 
natural killer T cells, lympho: lymphocytes, NK: natural killer cells, NKT: natural killer T cells, pDCs: 





1.5.4.2 Dendritic cells 
Dendritic cells (DCs) occupy a central position in the immune system as they form a bridge 
between innate and adaptive responses.175 They are subdivided in three main groups: 
conventional DCs (cDCs), plasmacytoid DCs (pDCs; previously mentioned in section 
1.5.2.5), and monocyte-derived DCs (moDCs) (Figure 14).175 cDCs are specialized in 
antigen presentation and priming of naive T cells, and are, therefore, crucial for initiating T-
dependent antibody responses (see section 1.1.2.3).175 Note that cDCs can also directly 
stimulate B cells during T-independent antibody responses through the secretion of BAFF 
and APRIL (see section 1.1.2.4). pDCs are mainly involved in antiviral immunity by secreting 
abundant type I IFNs.175 IFN-α, a type I IFN, can also enhance antibody responses in the 
absence of T cell help.176 moDCs are generated in vitro from monocytes cultured with 
granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-4.175  
Peripheral blood cDC and pDC numbers were found to be decreased in a proportion of 
CVID patients. This was most pronounced in patients with decreased switched memory B 
cells and disease-related complications such as granulomatous disease, autoimmunity and 
splenomegaly.177-181  
As mentioned above (see section 1.5.2.5), TLR7 and TLR9 signaling in pDCs (and B cells) 
is impaired in subgroups of CVID patients.112-116  
In some cases, DCs derived from patients’ monocytes (patient moDCs) showed severely 
disrupted differentiation and maturation with poor upregulation of costimulatory molecules 
(CD80, CD86, HLA-DR), decreased IL-12 secretion and impaired T cell activation in co-
cultures.182-184 The patient moDC results should, however, be interpreted with caution since 
the authenticity of moDCs is controversial and they may not be a proper correlate of naturally 
occurring DCs.175 To determine whether myeloid-type DCs are truly malfunctioning, it would 
be of interest to revisit the moDC data in bona fide cDCs of CVID patients.  
 
1.5.4.3 Natural killer cells 
Natural killer (NK) cells are innate lymphocytes with cytotoxic capacities analogous to those 
of CD8+ cytotoxic T cells (Figure 14).185 NK cells express a variety of activating and inhibitory 
surface receptors.185 Some of these receptors sense alterations in MHC class I expression 
on host cells, which may be induced by intracellular pathogens. Others recognize (less well 
defined) changes in cell-surface glycoprotein composition induced by metabolic stresses 
such as infection or malignant transformation. Hence, NK cells are, similar to CD8+ T cells, 
important for the destruction of (virus-) infected and malignantly transformed cells.185  
Absolute numbers of circulating NK cells were markedly reduced in a subgroup of CVID 
patients.181,186,187 Curiously, patients with low NK cell counts did not appear to have an 
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increased susceptibility to viral infections.181,186,187 Moreover, in vitro NK cell cytotoxicity 
analyses were normal, suggesting that the function of the remaining NK cells could 
compensate for the low numbers.186,187 Despite the lack of obvious clinical consequences, 
NK cell deficiency in CVID patients may further compromise an already malfunctioning 
immune system by undermining control of viral infections and tumor immunosurveillance.188 
 
1.5.4.4 Natural killer T cells 
Natural killer T (NKT) cells are lymphoid cells that express NK cell receptors as well as CD3 
(i.e. T cell co-receptor) and a TCR, and are therefore situated at the interface between 
adaptive and innate immunity (Figure 14).189 They possess an exceptional TCR of limited 
diversity that recognizes (glyco)lipids presented by the MHC-like molecule CD1d.189 NKT 
cells can produce a wide array of cytokines and chemokines, and appear to have an 
immunoregulatory function.189 Moreover, NKT cells can enhance T-dependent antibody 
responses through interaction with CD1d on B cells.190 
Total NKT cells have only been examined in a limited number of CVID patients.187,191 In a first 
cohort (n=17), CVID patients had, on average, lower numbers of circulating NKT cells 
compared to healthy controls.191 NKT cells in those patients were skewed towards an 
activated phenotype, but associations with clinical features were not reported.191 In a second 
CVID patient cohort (n=20), no differences in total NKT cells were found, regardless of 
disease severity.187   
Invariant NKT (iNKT) cells are a subset of NKT cells that express an invariant TCR α chain 
with one of a limited number of β chains, which recognize lipid antigens in the context of 
CD1d (Figure 14).189 Recent studies have described a significant reduction in peripheral 
blood iNKT cell numbers, concerning up to 75% of investigated CVID patients.181,192-194 
Reduced iNKT cells in those patients was associated with impaired iNKT cell function, 
decreased switched memory B cells and lymphoproliferation.192,193 
It is unclear how a decrease in blood (i)NKT cells fits into the pathophysiology of CVID, 
whether it concerns primary, cell-intrinsic, defects or secondary phenomena due to, for 
example, sequestration in inflamed tissues. 
 
1.5.4.5 Innate lymphoid cells 
Innate lymphoid cells (ILCs) are a recently identified group of innate immune cells belonging 
to the lymphoid lineage.195 In contrast to lymphocytes of the adaptive immune system, ILCs 
do not have a recombined antigen receptor and are activated in the early phases of an 
immune response.196 ILCs are present in various tissues, but seem to be particularly 
important for immune defense at mucosal barriers.196 ILCs are divided in three groups based 
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on their cytokine and transcription factor profiles, which are analogous to the profiles of their 
adaptive Th1, Th2 and Th17 counterparts, respectively.196 The above-described cytotoxic NK 
cells (section 1.5.4.3), although originally considered a separate cell population, are now 
categorized under group 1 ILCs.196  
Thus far, a possible role of ILCs in CVID has only been investigated by a single study 
(n=55).197 CVID patients with inflammatory and/or autoimmune complications had an 
expanded population of IFN-γ+ IL-17A+ IL-22+ ILCs both in the peripheral blood and in 
biopsies of mucosal lymphoid tissues.197 These findings suggested that ILCs might be 
involved in inflammatory reactions and mucosal damage in at least a subgroup of CVID 
patients.197 Future study is required to confirm these data and to further define the place of 
ILCs in CVID pathogenesis.197 
 
1.5.5 Overview and concluding remarks 
A summary of the most important immunological abnormalities described in the CVID 
population is given in Table 2.  
 
Table 2. Summary of the most important immunological abnormalities reported in CVID. 
B cells T cells Innate immune cells 
↓total B cells ↓naive (or total) CD4+ T cells Monocytes : 
↓B cell bone marrow development ↓thymic output :     ↑activity 
↓BCR signaling     ↓TRECs     ↑IL-12 secretion 
↓BAFF-R expression (survival)     ↓CD4+ recent thymic emigrants        ↓phagocytosis 
↑Fas expression (apoptosis)        (CD45RA+CD31+) ↓conventional DCs  
↓class-switched memory B cells   ↑apoptosis ↓plasmacytoid DCs 
    (IgM-IgD-CD27+) ↓TCR repertoire ↓TLR7 and TLR9 signaling in pDCs 
↓plasma cells in lymphoid organs ↓Treg cells ↓maturation monocyte-derived DCs 
↓somatic hypermutation     (CD4+CD25+FOXP3+ / CD127-) ↓NK cells 
↓marginal zone-like B cells ↓Treg suppressive activity ↓NKT cells 
    (IgM+IgD+CD27+) ↓or↑circulating Tfh cells ↓invariant NKT cells 
↑transitional B cells     (CD4+CD45RO+CXCR5+) ↑IFN-γ+ IL-17A+ IL-22+ ILCs 
    (CD38highCD24highIgMhigh) ↑CD8+ T cells  
↑CD21low B cells     (mainly effector subsets)  
    (CD21lowCD38low) ↓T cell proliferation responses to    
↓CXCR5 and CCR7 expression     antigens and TCR antibodies  
↓TLR7 and TLR9 signaling  cytokine imbalance (e.g. ↓IL-2)  
 
↓: decreased, ↑: increased, BAFF-R: B cell activating factor belonging to the TNF family - receptor, BCR: B cell 
receptor, CD: cluster of differentiation, CVID: common variable immunodeficiency, DCs: dendritic cells, IFN: 
interferon, Ig: immunoglobulin, IL: interleukin, ILCs: innate lymphoid cells, NK: natural killer, NKT: natural killer T, 
pDCs: plasmacytoid dendritic cells, TCR: T cell receptor, Tfh: follicular helper T, TLR: Toll-like receptor, TRECs: T 
cell receptor excision circles, Treg: regulatory T.  
 
Note that each of these laboratory features is only present in a subgroup of patients, and that 
the parameters may also be normal or even deviant in the opposite direction in other CVID 
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patients. Remarkably, immunological abnormalities across all parts of the immune system 
seem to cluster together in patients suffering from severe disease-related complications.46 It 
is, therefore, suspected that at least a fraction of these abnormalities are secondary to a 
condition of immune dysregulation and chronic inflammation.46 Long-term prospective 
studies with regular follow-up of immunological parameters might help discriminate primary 
from secondary phenomena in CVID patients.36   
 
1.6 Genetic basis of CVID 
Adapted from: Bogaert DJ, Dullaers M, Lambrecht BN, Vermaelen KY, De Baere E, Haerynck F. 
Genes associated with common variable immunodeficiency: one diagnosis to rule them all? J Med 
Gen. 2016;53(9):575-90. 
 
1.6.1 “Out of one, many” 
Based on the fact that CVID is a diagnosis of exclusion together with the broad spectrum of 
clinical manifestations and immunological abnormalities seen in CVID patients, it quickly 
became apparent that this diagnosis does not cover one or a few disorders but many. This 
perception has been confirmed by the gradual elucidation of the genetic basis of CVID.  
 
The majority of CVID cases occur sporadically.29 About 5-25% of patients have a positive 
family history, of which most demonstrate an autosomal dominant inheritance.29 In contrast 
to other PIDs, a monogenic cause has only been identified in 2-10% of patients diagnosed 
with CVID (Figure 15).29,198 Thus far, 24 genes have been implicated in monogenic forms of 
CVID (Table 3). Each of these genetic subtypes is rare to very rare (Figure 15). The first 
CVID disease genes were discovered with a candidate gene approach because of their 
central role in B cell biology evidenced by single-gene knockout mice.199-202 This approach 
generally uncovered autosomal recessive genes. In recent years, NGS technologies have 
accelerated the identification of both autosomal recessive and dominant CVID disease genes 
(see also section 1.2.1.1). In parallel, it has become clear that the clinical diagnosis of CVID 
is an umbrella covering several genetic subtypes. In fact, many genes initially reported as 
CVID disease genes are now considered to be responsible for distinct disease entities (Table 
3). Moreover, there is accumulating evidence that at least a subgroup of CVID patients have 
a complex (multifactorial) rather than a monogenic etiology (see also section 1.2.1.4).29,198,203  
 
Current knowledge on the genetic basis of CVID is discussed in the next sections, covering 





Figure 15. Estimated proportion of each disease gene within the CVID population based on 
published cases. 
 
1.6.2 Genes associated with monogenic forms of CVID 
Table 3, at the end of this section, gives an overview of the genes implicated in monogenic 
CVID. Most genes are associated with variable (clinical and immunological) expressivity and 
some genes also with incomplete penetrance. As mentioned in section 1.2.1.4, the molecular 
basis of variable expressivity and incomplete penetrance is poorly understood and may 
involve modifier genes, epigenetic changes and/or environmental factors.15,26 
 
1.6.2.1 Genes encoding receptors and ligands 
ICOS deficiency  
ICOS is a T cell surface receptor that belongs to the CD28/CTLA-4 family (Figure 16).199 
Reciprocal ICOS-ICOS ligand (ICOS-L) interactions are essential for GC formation and 
terminal B cell differentiation (see section 1.1.2.3), effector T cell responses, and immune 
tolerance.199 ICOS was the first disease gene identified for monogenic forms of CVID, using 
a candidate gene approach based on prior evidence from single-gene knockout mice.199 
Hitherto, biallelic ICOS mutations resulting in complete loss of protein expression have been 
reported in seven families.199,204-207 Haplotype analysis in the four German/Austrian families 
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ICOS-deficient patients had a variable phenotype with variable age of onset and severity 
(Table 3).199,204-207 They commonly presented recurrent respiratory tract infections and 
autoimmune complications.199,204-207 Patients with two novel ICOS mutations published in 
2015 extended the clinical spectrum: early-onset inflammatory bowel disease, hepatomegaly 
with raised liver enzymes, CMV viremia, and Pneumocystis jirovecii pneumonia.206,207 
Enteropathy in one ICOS-deficient patient resolved after hematopoietic stem cell 
transplantation (HSCT) while diarrhea persisted in his non-transplanted sister. This suggests 
that inflammatory gut complications are disease-intrinsic.206  
All ICOS-deficient patients had very low to absent memory B cells and some also showed a 
loss of bone marrow plasma cells.199,204-208 This might be due to defective GC reactions in the 
absence of ICOS signaling.208 ICOS-deficient patients also demonstrated varying degrees of 
T cell defects (Table 3). In contrast to the first-reported German/Austrian families, the 
Japanese, Kuwaiti, and Pakistani sibling pairs demonstrated pronounced T cell defects with 
viral and opportunistic infections resembling CID rather than CVID.199,204-208 Therefore, ICOS 
mutations are no longer considered to cause a pure CVID phenotype but result in a separate 
disease entity (ICOS deficiency).206,207 
 
TACI and BAFF-R 
TACI (encoded by TNFRSF13B), BAFF-R (encoded by TNFRSF13C) and B cell maturation 
antigen (BCMA) are members of the TNF receptor superfamily (TNFRSF) important in 
peripheral B cell homeostasis.10 These receptors engage two ligands: BAFF and APRIL 
(Figure 16). Both ligand and receptor oligomerization are necessary for optimal downstream 
signaling.10 The TACI/BAFF-R/BCMA/BAFF/APRIL system signals through many 
pathways,10,209 of which a selection is depicted in Figure 16. How the TACI/BAFF-
R/BCMA/BAFF/APRIL system fine-tunes B cell homeostasis and the degree of mutual 
redundancy remain incompletely understood.10,209 TACI mediates CSR to IgA and IgG, 
differentiation and survival of plasma cells, and T-independent responses to polysaccharide 
antigens (see also section 1.1.2.4). TACI also acts as an immunoregulator involved in central 
B cell tolerance and inhibiting peripheral B cell expansion.10,209 BAFF-BAFF-R signaling 
promotes peripheral B cell survival and maturation in synergy with BCR signaling (see also 
section 1.5.2.1).10 BCMA plays a role in long-term plasma cell survival in bone marrow.10 
Variants in the genes encoding TACI and BAFF-R have been identified in CVID patients by 
means of a candidate gene approach based on single-gene knockout mice.200-202 Although 
initially thought to be fully penetrant, it is currently believed that monoallelic TNFRSF13B and 
mono- and biallelic TNFRSF13C variants are on itself not sufficient to cause a CVID 
phenotype (modifier genes, see section 1.2.1.4).210-214 
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TNFRSF13B (encoding TACI) variants  
Biallelic and monoallelic loss-of-function variants in TNFRSF13B have been registered in at 
least 2147 patients based on the Jeffrey Modell Centers Global Network report.13 Biallelic 
TNFRSF13B variants have always been associated with some degree of antibody 
deficiency,103,200,201,211,212,215-218 except for a homozygous C104R variant in a 25-year-old 
member of a CVID-affected family who was asymptomatic and had normal Ig levels at time 
of the study.216 The latter individual could still have developed antibody deficiency later in life, 
however.216 In contrast, monoallelic TNFRSF13B variants have also been detected in 
asymptomatic relatives and in 1-2% of the general population.210-213,216,218 
A large variety of variants, mostly missense and nonsense variants, located in all domains of 
the TACI protein have been reported.103,200,201,210-213,215-220 The monoallelic missense variants 
C104R and A181E account for 80% of all TNFRSF13B variants in CVID patients.103,200,201,210-
213,215-220 The majority of TNFRSF13B variants do not or only slightly reduce TACI protein 
expression.220 In particular, C104R interferes with ligand binding and A181E affects receptor 
oligomerization.220 Some CVID patients have variants located in a highly conserved 
cytoplasmic domain of TACI (e.g. S231R).219 In these patients, recruitment of MyD88 to the 
cytoplasmic TACI domain was disrupted, causing impaired CSR and IgG production (Figure 
16).219 Rarely, CVID patients with truncating TNFRSF13B variants have been reported.217 
CVID patients with mono- or biallelic TNFRSF13B variants can present with a variable 
phenotype encompassing the complete CVID clinical spectrum (Table 3).200,201,210-213 In some 
CVID-affected families, the same TNFRSF13B genotype has also been found in relatives 
with selective IgA deficiency (sIgAD) or IgG subclass deficiency (IgGSD).200,201,212,218 
Asymptomatic relatives carrying monoallelic TNFRSF13B variants have been shown to have 
in vitro functional B cell defects.213 
Because of the high frequency of heterozygous TNFRSF13B variants in the general 
population, it is believed that these variants alone cannot explain the clinical phenotype in 
CVID patients.210-213 Still, heterozygous TNFRSF13B variants can increase the risk for 
developing CVID by compromising B cell function and may influence the final 
phenotype.220,221 TACI cooperates synergistically with TLRs in driving B cell activation and Ig 
production (Figure 16).10 B cells in many CVID patients show impaired TLR7 and TLR9 
responses (see section 1.5.2.5).219 Loss-of-function TNFRSF13B variants might aggravate 
the effect of already impaired TLR signaling, or, alternatively might impose TLR signaling 
defects.219 Furthermore, CVID patients with heterozygous TNFRSF13B variants have a 
higher risk of developing autoantibody-mediated autoimmunity.209,221 In contrast, patients with 




TNFRSF13C (encoding BAFF-R) variants 
Biallelic and monoallelic TNFRSF13C variants have been reported in about 80 CVID 
patients.61,103,202,214,222-225 More than 90% of reported cases were hetero- or homozygous for 
the P21R missense variant.61,103,214,222-225 In addition, other CVID patients were found to be 
heterozygous for H159Y, compound heterozygous for P21R and H159Y, or compound 
heterozygous for P21R and a complex P21R/H159Y allele.103,222,223 One CVID patient had 
heterozygous P21R and H159Y variants in cis.225 Interestingly, the father and sister of the 
last-mentioned patient also had these variants in cis but presented with isolated IgM 
deficiency respectively sIgAD.225 Moreover, hetero- and homozygous P21R variants and 
heterozygous H159Y variants have also been identified in asymptomatic relatives and 
healthy controls.214,222 To our knowledge, biallelic variants that include H159Y and the 
heterozygous P21R/H159Y allele in TNFRSF13C have never been reported in asymptomatic 
individuals.103,223,225  
The P21R variant reduces BAFF ligand binding (Figure 16), suggestive for loss-of-
function.214 In contrast, the H159Y variant has been implicated in lymphoma development 
and was shown to increase TRAF recruitment and downstream BAFF-R signaling (Figure 16) 
when overexpressed in a HEK293 cell line, suggestive for gain-of-function.226 Further studies 
will be necessary to determine the role of H159Y variants in CVID pathogenesis. The vast 
majority of patients with mono- or bi-allelic TNFRSF13C variants had normal BAFF-R protein 
expression.214,222 Thus far, deficiency of BAFF-R protein expression was reported in four 
CVID patients.202,224,225 Two of those BAFF-R-deficient patients were a brother and sister 
born from consanguineous parents with a homozygous TNFRSF13C 24-bp deletion causing 
complete loss of BAFF-R expression.202 Furthermore, reduced (but not absent) BAFF-R 
expression was identified in one CVID patient with a homozygous P21R variant and the 
above-mentioned CVID patient with the heterozygous P21R/H159Y allele.224,225  
Most reported CVID patients with TNFRSF13C variants had adulthood-onset recurrent 
respiratory tract infections. Nonetheless, some patients already developed symptoms at 
young age and/or additionally suffered from severe CVID-related complications (Table 
3).61,103,202,214,222-225 Laboratory findings varied between patients (Table 3).61,103,202,214,222-225 
Curiously, the BAFF-R-deficient sibling pair had important B cell lymphopenia with a relative 
increase in transitional B cells, which seems contradictory with their late disease onset 
and/or relatively mild clinical phenotype.202  
Analogous to TNFRSF13B (TACI) variants, the role of TNFRSF13C (BAFF-R) variants in 
CVID is controversial. It is currently believed that an abnormal BAFF-R function predisposes 





One CVID pedigree with autosomal dominant inheritance had a mutation in tumor necrosis 
factor superfamily member 12 (TNFSF12), encoding TNF-like weak inducer of apoptosis 
(TWEAK) (Table 3).227 TWEAK mainly exerts effects on endothelial and innate immune 
cells.227 In addition to diminished TWEAK-induced signaling, mutant TWEAK associated with 
BAFF monomers thereby impeding BAFF-mediated signaling in B cells (Figure 16).227 More 
patients will need to be identified to determine if TWEAK deficiency should be considered as 
a form of CVID or as a separate disorder. 
 
B cell co-receptor complex deficiency 
The B cell co-receptor complex is composed of four cell-surface proteins: CD19, CD21 
(complement receptor 2, CR2), CD81 and Leu13 (Figure 16). It lowers the threshold for B 
cell activation upon antigen binding to the BCR.228 CD19, CD81 and CD21 deficiencies occur 
in autosomal recessive forms of CVID, and were identified by use of a candidate gene 
approach.228-230 
 
CD19 and CD81 deficiencies 
Biallelic CD19 mutations resulting in absent CD19 surface expression have been reported in 
seven CVID-affected families.228,231-236 In an additional CVID patient, absent CD19 surface 
expression was due to a biallelic CD81 splice site mutation.229 This CD81 mutation was 
initially assumed to completely abolish CD81 protein expression.229 Later, it was 
demonstrated that in fact a truncated CD81 protein was produced.237 Both the mutant CD81 
and the normal CD19 protein were retained intracellularly, resulting in absent CD81 and 
CD19 surface expression.237  
All CD19-deficient patients and the CD81-deficient patient developed symptoms in early 
childhood and suffered from recurrent infections.228,229,231-236 Only the CD81-deficient patient 
showed autoimmune and inflammatory complications (Table 3).229 This clinical discrepancy 
might be because CD81, in contrast to CD19, is involved in many immunological 
responses.229 All CD19- and CD81-deficient patients had normal total CD20+ B cell numbers 
but reduced switched memory B cells.228,229,231-236 Impaired BCR/co-receptor complex 
signaling in these patients resulted in defective SHM and CSR, as well as poor terminal 
differentiation into memory B cells and plasma cells (see section 1.1.2.3).238  
Interestingly, a female with isolated IgG1 deficiency was also found to have absent CD19 
expression due to a homozygous CD19 mutation.235 She had recurrent respiratory tract 
infections but mainly suffered from severe IgA nephropathy. In contrast to the above-
mentioned CD19-deficient CVID patients, memory B cells and responses to protein vaccines 
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were normal in this patient.235 It is unclear why the latter CD19-deficient patient developed 
isolated IgG1 deficiency and not CVID.235  
 
CD21 deficiency 
Biallelic CD21 mutations causing loss of CD21 protein expression have been published in 
two unrelated CVID patients.230,239 CD19 and CD81 expression were normal. Compared to 
CD19- and CD81-deficient CVID patients, CD21-deficient patients demonstrated a later age 
of onset, milder infections and less pronounced humoral immune defects (Table 3).230,239 
Wentink et al. provided evidence that CD21-deficient patients can still mount proper B cell 
responses against antigenic stimuli but with reduced memory formation, whereas CD19- and 
CD81-deficient patients have a more profoundly disturbed B cell response.239 On the other 
hand, CD21-deficient patients presented with chronic diarrhea, splenomegaly and/or severe 
myalgia, which was not seen in CD19- or CD81-deficient patients.228-236,239 
 
CD20 deficiency 
CD20 is part of a B cell surface complex involved in transmembrane Ca2+ transport, which is 
important in B cell signal transduction, proliferation and differentiation (Figure 16).240 
Knowledge on the exact biology of CD20 is, however, limited. CD20 is encoded by 
membrane-spanning 4A1 (MS4A1). Using a candidate gene approach, a homozygous 
MS4A1 mutation resulting in complete lack of CD20 protein expression has been identified in 
a single patient born from consanguineous parents.240 She did not completely fulfill 
diagnostic criteria for CVID as only serum IgG was decreased with normal IgM and IgA (see 
section 1.3).240 She presented with early-onset recurrent respiratory tract infections, markedly 
reduced class-switched memory B cells and impaired antibody responses to polysaccharide 
vaccines (Table 3).240 CD20 deficiency may disrupt normal Ca2+ fluxing in B cells thereby 
compromising cell cycle progression and optimal B cell activation, which may explain the 
CVID-like phenotype.240  
 
CD27 deficiency 
CD27, a lymphocyte surface receptor encoded by TNFRSF7, interacts with CD70 and 
regulates survival, function and differentiation of T, B, NK and plasma cells (Figure 16).241 
CD27 is also used as a marker of memory B cells, like in immunophenotypical classification 
of CVID (see section 1.5.2.3).242 A homozygous TNFRSF7 mutation was first identified by 
targeted gene sequencing in a patient with absent CD27 protein expression.241 So far, CD27 
deficiency has been reported in 17 patients of whom 15 had homozygous TNFRSF7 
mutations (all from a consanguineous kindred) and one had a compound heterozygous 
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TNFRSF7 mutation.241-243 Remarkably, in one CD27-deficient patient only a single TNFRSF7 
mutation was identified, even after extensive analysis of the entire gene locus.242 The authors 
concluded that transcription of the second allele could be influenced by a mutation in a 
distant regulatory element or by other regulatory mechanisms.242 The phenotype of CD27-
deficient patients varied, even between those with the same genotype (Table 3).241-243 
Importantly, almost all CD27-deficient patients suffered from severe and/or atypical EBV-
associated features (Table 3).241-243 Five patients died of disease-related complications.242 
Only three of all reported patients had primary hypogammaglobulinemia initially diagnosed 
as CVID.241-243 With more patients being reported, CD27 deficiency is currently considered a 
lymphoproliferative syndrome distinct from CVID.242  
 
IL-21 and IL-21R deficiencies 
IL-21 is predominantly produced by T cell subsets.244 In contrast, IL-21 receptor (IL-21R) is 
widely expressed on lymphoid and myeloid cells and exerts pleiotropic immune functions.244 
Regarding humoral immunity, IL-21-IL-21R signaling is involved in GC formation, B cell 
differentiation and CSR, and Tfh cell development (Figure 16) (see section 1.1.2.3).244 
Biallelic loss-of-function mutations in IL21 and IL21R were detected in consanguineous 
families using whole exome sequencing (WES) combined with either homozygosity mapping 
or candidate gene sequencing.245,246 To our knowledge, one patient with IL-21 deficiency and 
eight with IL-21R deficiency have been published.244-248 All IL-21(R)-deficient patients had a 
severe clinical presentation with high morbidity and mortality in childhood (Table 3).244-248 IL-
21(R)-deficient patients typically suffered from respiratory tract infections, inflammatory 
complications and/or opportunistic infections like Cryptosporidiosis and Pneumocystis 
jirovecii pneumonia.244-248 Some IL-21(R)-deficient patients showed an aberrant B cell 
phenotype with reduced switched memory B cells. In addition, some patients demonstrated 
functional defects in T and NK cells (Table 3).244-248 Several IL-21(R)-deficient patients were 
initially diagnosed with CVID, before the onset of opportunistic infections.245,247 However, 
over time it has become evident that IL-21 and IL-21R deficiencies represent forms of CID 
rather than CVID.244-248 
 
LRBA and CTLA-4 deficiencies 
Lipopolysaccharide-responsive beige-like anchor protein (LRBA) is a cytosolic protein 
localized in endoplasmatic reticulum, trans-Golgi apparatus, endocytosis vesicles and 
lysosomes.249 It is expressed by almost all cell types with higher expression levels in immune 
effector cells.249 LRBA functions in polarized vesicle trafficking and polarized responses of 
immune effector cells, autophagy, and positive regulation of cell survival.249  
Introduction 
 43 
CTLA-4 is an inhibitory T cell receptor that negatively regulates immune responses. It is 
upregulated on activated T cells and constitutively expressed by Treg cells (see also section 
1.5.3.1). CTLA-4 competes with the costimulatory protein CD28 for binding to CD80/CD86, 
thereby preventing excessive T cell activation and maintaining immune tolerance (Figure 
16).250,251 It was recently demonstrated that LRBA plays a role in CTLA-4 surface 
expression.252 LRBA is thought to rescue endosomal CTLA-4 from degradation via the 
lysosomal pathway and to facilitate its trafficking back to the cell surface upon TCR 
stimulation (Figure 16).252   
 
LRBA deficiency 
Biallelic loss-of-function LRBA mutations were identified by three independent groups by 
using linkage analysis in multiple consanguineous families or by using WES with or without 
homozygosity mapping in single consanguineous families.249,253,254 In the vast majority of 
patients, biallelic LRBA mutations resulted in reduced or absent protein expression.249,252-267  
The clinical and immunological phenotype of LRBA-deficient patients is very variable (Table 
3).249,252-267 Most reported LRBA-deficient patients were clinically diagnosed with CVID, some 
with autoimmune lymphoproliferative syndrome (ALPS)-like or immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX)-like disease.249,252-267 Typical presentations 
of LRBA deficiency are early-onset severe autoimmunity and enteropathy. Other recurring 
clinical features are recurrent infections and severe lymphoproliferative disease with 
increased risk of lymphoma.249,252-267 More than half of cases had varying degrees of 
hypogammaglobulinemia and most patients had decreased switched memory B cells.249,252-
267 Importantly, LRBA deficiency is characterized by a progressive course and a high 
mortality rate.249,252-267 Although first identified in CVID patients,249 it is currently considered 
an immune dysregulation syndrome separate from CVID.252-267 
 
CTLA-4 deficiency 
Heterozygous mutations in CTLA4 were identified by two independent groups using either 
WES combined with linkage analysis in a large family or WES combined with candidate gene 
sequencing.250,251 Most CTLA4 mutations resulted in reduced CTLA-4 expression suggesting 
haploinsufficiency.250,251,268-271 Other CTLA4 mutations were predicted to interfere with ligand 
binding or protein stability, which might exert a dominant-negative effect.251 Many CTLA-4-
deficient patients were clinically diagnosed with CVID.250,251,268,269 However, CTLA4 mutations 
were also detected in family members who were asymptomatic, suggesting incomplete 
penetrance, or who had a very mild form of antibody deficiency.250,251,268-271 Of note, since 
age of onset is variable, young CTLA4 mutation carriers who are currently asymptomatic 
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may still develop disease later in life.251 Overall, the phenotype of CTLA-4 deficiency is 
usually severe and reminiscent of that of LRBA deficiency: autoimmunity, recurrent 
infections, lymphoproliferative disease with increased risk of lymphoma, and varying Ig levels 
and B and T cell defects (Table 3).250,251,268-271 Treg cells were normal in numbers but had a 
markedly reduced suppressive function.250,251,268,269 Treg cells of asymptomatic CTLA4 
mutation carriers also had reduced suppressive activity although they did express higher 
levels of CTLA-4 compared to those of their symptomatic relatives.250,251 Analogous to LRBA 
deficiency, CTLA-4 deficiency was first described in CVID patients but is currently considered 
a new immune dysregulation syndrome.250,251,268-271 
 
1.6.2.2 Genes encoding intracellular signaling molecules 
Protein kinase C delta (PKCδ) is a key component in BCR-mediated signaling downstream of 
BTK, phospholipase C gamma 2 (PLCγ2), B-lymphoid tyrosine kinase (BLK), Vav guanine 
nucleotide exchange factor (VAV), and Ras-related C3 botulinum toxin substrate (RAC) 
(Figure 16).272 PKCδ propagates signaling to the nucleus by activating the canonical nuclear 
factor of kappa light chain enhancer of activated B cells (NF-κB) pathway.272 PKCδ is 
particularly important in B cell proliferation, apoptosis and tolerance.272  
Class IA phosphatidyl-inositol-3-kinase (PI3K) isoforms are crucial signaling molecules 
downstream of various B and T cell surface receptors (Figure 16).273,274 Consequently, PI3K 
is involved in many aspects of B and T cell homeostasis.273,274 The PI3K pathway activates a 
multitude of effector molecules and is interwoven with the PLC-PKC pathway, forming a 
complex signaling network (Figure 16).273,274 
The transcription factor IKAROS is a pleiotropic regulator of hematopoiesis.275 Besides key 
roles in T cells and non-lymphoid lineages, IKAROS is a critical regulator of B cell 
lymphopoiesis and function.275 IKAROS is triggered by (pre-)antigen receptor signaling 
though the precise signaling pathways remain unclear (Figure 16).275 
Interferon regulatory factor 2 binding protein 2 (IRF2BP2) is thought to act as a negative 
regulator of the nuclear factor of activated T cells (NFAT) transcription factor (Figure 16).276 
In B cell biology, IRF2BP2 might play a role in the differentiation and/or survival of memory B 
cells and plasmablasts.276 However, its function and interactome remain obscure.276 
Defects in the genes encoding PKCδ, PLCγ2, NF-κB2, NF-κB1, PI3K catalytic subunit p110δ, 
PI3K regulatory subunit p85α, VAV1, RAC2, BLK, IKAROS and IRFBP2 have been 




PKCδ  deficiency  
Biallelic PRKCD (encoding PKCδ) mutations abrogating protein expression have been 
described in six patients from four unrelated families.272,277-279 PRKCD was detected using 
WES combined with homozygosity mapping or linkage analysis in consanguineous 
families.272,277 PKCδ deficiency causes a variable phenotype (Table 3).272,277-279 A CVID-like 
phenotype was only observed in the first-reported patient.272 The other five patients were 
initially diagnosed with SLE or ALPS-like disease.277-279 Altogether, PKCδ deficiency 
represents a syndrome of immune dysregulation with prominent lymphoproliferation and 
systemic autoimmunity reminiscent of SLE.272,277-279 All patients displayed an aberrant B cell 
phenotype with decreased switched memory B cells and increased CD21low B cells.272,277-279 
However, only the first-reported patient developed hypogammaglobulinemia and, 
accordingly, prominent infections.272 Of interest, the first-reported PKCδ-deficient patient 
carried an additional heterozygous CTLA4 variant (Thr17Ala, allele frequency 0.4112), 
previously associated with autoimmune thyroiditis.272 This variant was also present in the 
father who had Behçet’s disease and autoimmune thyroiditis.272 It cannot be excluded that 
this CTLA4 variant exerted a disease-modifying effect.272  
 
PLCγ2-associated antibody deficiency and immune dysregulation (PLAID) 
PLCγ2-associated antibody deficiency and immune dysregulation (PLAID) is a newly defined 
immunodeficiency syndrome caused by heterozygous gain-of-function mutations in 
PLCG2.280,281 PLCG2 was identified by two independent groups, one using linkage analysis 
in three families combined with whole genome sequencing (WGS) in one of those families,280 
and another using WES in a multiplex family with an autosomal dominant inheritance 
pattern.281 PLAID is mainly characterized by cold urticaria from infancy, which is not typically 
seen in CVID.280 However, PLAID shares many hallmark clinical and immunological features 
with CVID (Table 3).280,281 Indeed, some of the initially published PLAID patients fulfilled the 
diagnostic criteria of CVID (see section 1.3).280 This phenotypic overlap might be explained 
by aberrant PLCγ2 signaling downstream of the BCR and Fcγ receptors on B cells (Figure 
16).280 
 
NF-κB2 and NF-κB1 deficiencies 
The NF-κB family of transcription factors regulates a diversity of biological processes.282,283 
The (noncanonical) NF-κB2 pathway is activated by a limited set of receptors, including 
ICOS, TACI, BAFF-R and BCMA (Figure 16).282,283 In contrast, the (canonical) NF-κB1 
pathway is targeted by a vast number of receptors, including cytokine receptors, BCR/co-
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receptor complex, TCR and TLRs (Figure 16).282,283 NF-κB signaling plays key roles in B cell 
maturation, survival, differentiation, class switching and tolerance to self-antigens.282,283 
 
NF-κB2 deficiency 
First described were heterozygous NFKB2 mutations detected by WES in a multiplex CVID 
pedigree with an autosomal dominant inheritance.282 Most NFKB2 mutations reported so far 
disrupted the conserved C-terminal region required for processing of the inactive precursor 
protein p100 into its active form p52, resulting in haploinsufficiency of NF-κB2 (also called 
NFKB p52/p100 subunit) (Figure 16).282,284-289 Some NFKB2 mutations also appeared to 
disrupt the canonical NF-κB1 pathway through a dominant-negative effect of the 
unprocessed p100 protein.284-288 All NF-κB2-deficient patients presented with a CVID(-like) 
phenotype in early childhood and suffered from recurrent respiratory tract infections.282,284-289 
About half of patients developed pituitary hormone deficiencies, which is an unusual feature 
in CVID.282,284-289 Two of them had pituitary hypoplasia on brain MRI scan.284 In addition, 
several patients developed autoimmune manifestations involving skin, hair and/or nails. 
Autoimmune cytopenia, usually the predominant autoimmune manifestation in CVID, was not 
documented except for one child with an episode of autoimmune thrombocytopenia.282,284-289 
Furthermore, NF-κB2-deficient patients demonstrated (pan)hypogammaglobulinemia, 




More recently, heterozygous mutations in the gene encoding NF-κB1 (also known as NFKB 
p50/p105 subunit) were uncovered by means of WES combined with linkage analysis in a 
large CVID-affected family with autosomal dominant inheritance (Figure 16).283 In total, 
heterozygous NFKB1 mutations have been reported in 10 families of which 9 harbored CVID 
patients.283,290-293 All mutant NFKB1 alleles resulted in loss-of-function, the larger part through 
haploinsufficiency and some by a dominant-negative effect.283,290-293 In contrast to NFKB2, 
NFKB1 mutations were also identified in family members who were asymptomatic, 
suggestive of incomplete penetrance, or who displayed milder forms of antibody 
deficiency.283,290-293 NF-κB1-deficient patients displayed a variable age of onset and a clinical 
phenotype different from that of NF-κB2-deficient patients (Table 3).283,290-293 Although most 
NF-κB1-deficient patients also had recurrent infections, autoimmune manifestations did not 
usually involve hair, skin or nails, but rather blood cells, thyroid gland and other organs 
(Table 3).283,290-293 Moreover, several patients suffered from autoinflammatory complications 
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such as enteropathy or Behçet-like aphthous ulcers (Table 3).283,290-293 Interestingly, 
polymorphisms in NFKB1 had been previously associated with inflammatory bowel disease 
and Behçet disease.294,295 None of the NF-κB1-deficient patients had pituitary hormone 
deficiencies.283,290-293 The majority of cases had varying degrees of antibody deficiency, 
though not always fulfilling CVID criteria. B, T and NK cell abnormalities also differed among 
patients (Table 3).283,290-293 
 
PI3K overactivity and deficiency 
PI3K p110δ overactivity 
A heterozygous mutation in the gene encoding the PI3K catalytic subunit p110δ (PIK3CD) 
was initially identified in a CVID patient in 2006 based on a mouse knockout model.296 Since 
2013, heterozygous PIK3CD mutations have been described in almost 50 families using 
WES.273,274,297-304 These mutations result in overactivity of the PI3K signaling pathway 
evidenced by enhanced p110δ membrane association and kinase activity.273,274 More than 
half of reported families were heterozygous for the missense mutation E1021K.273,274,296-304 
Haplotype analysis was suggestive for a recurrent rather than for a founder mutation.273 PI3K 
p110δ mutant patients showed phenotypic overlap with many other PID syndromes; the 
majority was diagnosed with CVID, CID or hyper-IgM syndrome.273,274,296-304 Therefore, the 
phenotype associated with dominant PIK3CD gain-of-function mutations was regarded as a 
novel disease named activated PI3Kδ syndrome (APDS).273 The clinical spectrum of APDS 
varies greatly (Table 3).273,274,296-304 Important is the increased risk of malignancy (mainly B 
cell lymphoma) even in patients with a seemingly milder phenotype.273,274,296-304 The 
constitutively activated PI3K pathway caused numerous defects in B and T cell differentiation 
and function (Table 3).273,274,296-304 Recurring features were increased serum IgM, decreased 
serum IgG and IgA, progressively decreasing B cells, expansion of transitional B cells, CD4+ 
T cell lymphopenia, and elevated CD8+ effector memory cells.302 
 
PI3K p85α deficiency 
Some patients with an APDS-like phenotype were found to have heterozygous loss-of-
function mutations in PIK3R1, encoding the PI3K regulatory subunit p85α, by means of 
WES.305-311 In particular, all mutations were located within the splice acceptor or donor site of 
exon 11 of the PIK3R1 gene, causing in-frame skipping of that exon and formation of a 
shortened p85α protein.305-311 Exon 11 forms part of the domain that inhibits p110δ catalytic 
activity.311 Loss of p85α-mediated inhibition of p110δ causes hyperactivity of the PI3Kδ 
signaling pathway in B and T lymphocytes (Figure 16), explaining the APDS-like phenotype 
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seen in these patients (Table 3).305-311 Accordingly, this disease entity is referred to as 
APDS2.311 As for patients with PIK3CD gain-of-function mutations (APDS1), the major 
complication in APDS2 is development of B cell lymphoma.311 Since all APDS2 patients had 
recurrent respiratory tract infections and more than 85% had decreased serum IgG and IgA, 
it is not surprising that many were previously diagnosed with CVID (Table 3).311  
Noteworthy, a homozygous PIK3R1 mutation resulting in a premature stop codon in exon 6 
and complete loss of p85α expression had been previously reported in a single patient born 
from consanguineous parents.312 In contrast to the above-described heterozygous splice site 
mutations, complete loss of p85α resulted in a significant reduction of PI3K signaling causing 
agammaglobulinemia and absence of B cells.312 Furthermore, heterozygous PIK3R1 
mutations downstream of exon 11 are known to cause SHORT syndrome associated with 
loss of PI3K activity.310,311,313 This syndrome is, among others, characterized by progeroid 
facial dysmorphism, short stature and in some cases immunodeficiency.313 Short stature was 
also observed in about 45% of patients with the above-mentioned PIK3R1 splice site 
mutations, and microcephaly in about 10% (Table 3).309,311 In conclusion, three different 
types of genetic defects affecting other sites of PIK3R1 give rise to three distinct phenotypes 
(APDS2, agammaglobulinemia and SHORT syndrome), suggesting a certain degree of 
genotype-phenotype correlation for PIK3R1 mutations. 
 
VAV1, RAC2 and BLK deficiencies 
A heterozygous Vav1 guanine nucleotide exchange factor (VAV1) mutation resulting in 
decreased protein expression was described in one patient diagnosed with CVID.314 Since 
this patient showed considerable T cell dysfunction (Table 3), VAV1 deficiency more likely 
causes CID rather than CVID.314 
A homozygous Ras-related C3 botulinum toxin substrate 2 (RAC2) mutation abolishing 
protein expression was identified in two siblings born from consanguineous parents.315 Both 
siblings presented with IgA deficiency that gradually evolved into CVID (Table 3).315 
Interestingly, heterozygous dominant-negative RAC2 mutations cause a complex neutrophil 
dysfunction.315 The RAC2-deficient CVID patients showed less severe defects in neutrophil 
function.315  
A heterozygous loss-of-function mutation in B-lymphoid tyrosine kinase (BLK) was detected 
in two related CVID patients.316 BLK plays a role in BCR signaling and recruitment of T cell 
help (Figure 16).316 This may explain the disturbed terminal B cell differentiation seen in 
these patients (Table 3).316 
More patients will need to be identified to determine if VAV1, RAC2 and BLK deficiencies 




A heterozygous mutation in IKZF1, encoding the transcription factor IKAROS, was first 
described in 2012 in a premature infant with fetal hydrops, pancytopenia and absent 
myelopoiesis who died of multi-organ failure after bone marrow transplantation.317 In 2016, 
the same mutation as well as 10 other heterozygous mutations involving IKZF1, were 
identified in 12 families affected with CVID or other forms of antibody deficiency.275,318 All 
mutations disrupt the DNA-binding domain of IKAROS, resulting in failure to bind target 
genes and haploinsufficiency (Figure 16).275,317,318 Incomplete penetrance was documented in 
about half of the currently reported families.275,318 Some asymptomatic individuals were 
children, however, who might still develop a clinical phenotype at older age.275,318 Manifesting 
IKAROS-deficient patients had a variable phenotype (Table 3).275,317,318 They mainly suffered 
from recurrent respiratory tract infections, four families had autoimmune manifestations, and 
acute leukemia was seen in two families (Table 3).275,317,318 Patients generally presented with 
severe B cell lymphopenia accompanied by a decrease in at least one major immunoglobulin 
isotype (Table 3).275,317,318 Moreover, disease course was seen to be progressive, with loss of 
B cells and serum immunoglobulins over time.275,318 The T cell compartment appeared less 
severely affected, although various alterations in peripheral T cell subsets were reported 
(Table 3).275,317,318 Since not all IKZF1 mutant patients developed a CVID phenotype, this 
disease entity is better referred to as IKAROS deficiency (Table 3).275,317,318 
 
IRF2BP2 overactivity 
Very recently, one family with an autosomal dominant pattern of CVID was identified with a 
heterozygous IRF2BP2 mutation cosegregating with disease.276 In vitro analyses 
demonstrated that the IRF2BP2 mutation impaired plasmablast differentiation of B cells.276 
Furthermore, subjects with the heterozygous IRF2BP2 mutation had increased levels of the 
corresponding transcripts and protein.276 The findings are suggestive for a gain-of-function 
mutation and for an augmented repression of NFAT transcriptional activity by IRF2BP2 
(Figure 16).276 However, additional studies are needed to uncover the mechanism by which 
the IRF2BP2 mutation disturbs B cell biology and causes a CVID phenotype.276 All patients 
with the heterozygous IRF2BP2 mutation were diagnosed with CVID in childhood. The main 
phenotypical features were recurrent sinopulmonary infections, decreased IgG (mainly IgG2), 
low to undetectable IgA and IgM levels, and very low memory B cells (Table 3).276 They did 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.6.2.3 Genes associated with other PID disorders  
The first disease stages of other PID disorders may sometimes resemble CVID. In addition, a 
large number of well-defined PIDs can be accompanied by CVID-reminiscent antibody 
deficiency.20 Mutations in GATA2, STAT1, PTEN, RAG1, IL2RG, JAK3 and DCLRE1C 
(encoding ARTEMIS), genes associated with other well-defined PID syndromes, were 
recently described in patients with a prior diagnosis of CVID.304,319-326 
Monoallelic loss-of-function mutations in GATA2 cause a PID syndrome typically 
characterized by decreased monocytes, B cells, NK cells and DCs, myelodysplasia, 
opportunistic infections and lymphedema.319 In a recent report, a boy with a heterozygous 
GATA2 mutation presented with hypogammaglobulinemia and defective antibody responses 
in early childhood diagnosed as CVID.319 However, during adolescence his monocyte and 
lymphocyte counts rapidly dropped resulting in a full-blown GATA2 deficiency syndrome.319  
Heterozygous STAT1 gain-of-function mutations underlie chronic mucocutaneous 
candidiasis as well as a wide range of other clinical features.327 A 10-year-old boy was 
diagnosed with CVID because of low serum immunoglobulins, impaired vaccine responses, 
low B cells and recurrent respiratory tract infections, despite multiple bouts of 
mucocutaneous candidiasis since early childhood.320 WES was required to reach a 
conclusive diagnosis of STAT1 gain-of-function syndrome.320 
Autosomal dominant loss-of-function mutations in PTEN cause a rare familial cancer 
syndrome known as PTEN hamartoma tumor syndrome or Cowden syndrome. In addition to 
multiple hamartomas and an increased risk of developing certain types of cancer, some 
patients demonstrate defects of the adaptive immune system.328 Recently, there have been 
several case series on patients with PTEN deficiency presenting varying degrees of antibody 
deficiency, autoimmunity and lymphoproliferative disease. Given the phenotypical overlap, 
some of these patients had received a prior diagnosis of CVID or APDS.304,321,329 
Bilallelic loss-of-function mutations in RAG1/RAG2, IL2RG, JAK3 and DCLRE1C are 
historically associated with severe combined immune deficiency, but hypomorphic mutations 
are known to cause a more insidious clinical picture.322-326 Occasionally, patients can present 
with early-onset antibody deficiency, impaired vaccine responses and (sub)normal 





1.6.3 Complex forms of CVID 
1.6.3.1 CVID, a complex disorder? 
It is increasingly believed that besides rare monogenic forms, CVID is a polygenic or 
multifactorial disorder. This is based on the following: (1) identification of pathogenic 
mutations in only 2-10% of CVID patients despite tremendous efforts, (2) large phenotypic 
variability between patients with the same primary genotype, (3) presence of variants in 
asymptomatic relatives and/or in the general population above a certain threshold frequency, 
(4) sporadic occurrence in about 90% of cases, and (5) delayed disease onset in many 
patients.198,203,211,222,250,251,283,330-332 
Widespread use of NGS technologies has fueled the idea of a possible polygenic nature of 
CVID.198,203,330,331 van Schouwenburg et al. performed WGS in 32 sporadic CVID patients and 
one grandmother-grandson pair combined with RNA sequencing of B cells in three sporadic 
patients.198 They observed that all patients had variants in multiple genes associated with 
CVID or other PID syndromes as well as an enrichment of variants in pathways important in 
B cell function.198 An average of 9.4 (range 5-15) variants possibly associated with CVID 
were found in each patient.198 Interestingly, predicted deleterious variants were identified in 
numerous genes not previously associated with CVID such as PRRC2A, LILRB5, PSMB9, 
TNIP1, ARID3A, INPP5D, SH3BP2, BANK1, GAB2, CAMLG, BCL2L11 and EBF1.198 Note 
that functional validation studies are still necessary to determine the contribution of these 
variants to CVID development. 
In a study on a monozygotic twin pair discordant for CVID, the CVID-twin demonstrated 
impaired DNA demethylation in key B cell genes such as PIK3CD, RPS6KB2, BCL2L1, 
TCF3, CORO1B/PTPRCAP, KCNN4 and KCNC4.333 The B cell genes that were 
hypermethylated in the CVID-twin covered diverse functions of B cell biology.333 Subsequent 
analysis of a larger CVID and healthy control cohort confirmed that CVID B cells had a 
reduced ability to demethylate these key genes during differentiation from naive to memory B 
cells.333 DNA methylation is an epigenetic mechanism to control gene expression and can be 
influenced by environmental factors like smoking and infections.333 The altered DNA 
methylation patterns in CVID B cells implicate a role for epigenetic and/or environmental 
factors in CVID pathogenesis.333 
 
1.6.3.2 Disease-modifying variants associated with CVID 
Some genetic variants seem to occur more frequently in the CVID population and may thus 
be a risk factor to disease development, although they do not suffice to establish a complete 
phenotype. Such disease-modifying variants have been reported in DNA repair genes (e.g. 
MSH5),334 and in FCGR2A.335 Furthermore, in individual CVID patients, certain variants may 
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influence the development of specific disease features like enteropathy or autoimmunity.336-
338  
 
1.6.3.3 Genome-wide association studies 
A genome-wide association study (GWAS) from 2011 (363 CVID patients, 3031 controls) 
found an association with the HLA region, consistent with findings from prior linkage 
studies.331,339 These researchers also identified a suggestive but non-significant association 
with a chromosome 8p locus containing ADAM28, ADAM7, ADAMDEC1 and STC1.331 In 
addition, CVID patients demonstrated an increased total copy number variation burden, 
suggesting a role for genomic instability in CVID pathogenesis.331 Intra-exonic duplications in 
ORC4L were found to be most highly associated with CVID.331 A GWAS in healthy Chinese 
males (n=3495) showed an association between serum IgG and the locus containing 
TNFRSF13B (encoding TACI).340 However, the 2011 GWAS did not detect associations with 
the TNFRSF13B locus.331 A GWAS from 2015 (778 CVID patients, 10999 controls) 
confirmed association with the HLA locus and also found associations with loci containing 
CD21, ICOS, MSH5, TNFRSF13B, and CLEC16A.203 The CLEC16A locus had previously 
been associated with autoimmune disorders.203 CLEC16A might provide a link between 
autoimmunity and B cell deficiency in CVID.203  
 
1.7 Treatment and prognosis of CVID 
The mainstay of treatment in CVID is lifelong immunoglobulin replacement therapy.29,341 In 
addition, prophylactic antibiotics are often used to treat chronic or recurrent rhinosinusitis. In 
case of bronchiectasis, antiflogistic maintenance treatment with azithromycin can be 
administrated.29,341 Autoimmune manifestations, lymphoproliferation and granulomatous 
disease are treated with corticosteroids and/or other immunosuppressive drugs.29,341 HSCT is 
rarely performed because of the high morbidity and mortality risks, but can be an effective 
curative treatment in CVID patients with hematological malignancies or severe immune 
dysregulation.33,342 Genetic testing can help to identify patients with monogenic disorders for 
which HSCT might be indicated, such as IL-21(R) deficiency, LRBA and CTLA-4 
deficiencies, and APDS (PI3K hyperactivity) (see also section 1.6.2).247,257,270,302 Identification 
of the molecular defect may also offer opportunities for targeted immunomodulatory 
treatments. Case studies have shown promise for the use of mTOR inhibitors in APDS, and 





CVID patients suffering from disease-related complications have a significantly higher 
morbidity and mortality compared to patients with an infections-only phenotype.53 In a 40-
year follow-up study, the risk of death related to noninfectious complications was increased 
11-fold.50 Median overall survival in patients with noninfectious complications was 
approximately 35 years following diagnosis, whereas those without complications appeared 
to have a life expectancy similar to the general population.50 Attempts to distinguish 
subgroups of patients at risk for complications by means of peripheral B or T cell 
immunophenotyping have failed (see sections 1.5.2.3 and 1.5.3.1).58-60,122 Furthermore, 
genetic variants that uniformly predict disease-related complications have, so far, not been 
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The general aim of this thesis was to utilize detailed immunological phenotyping to 
facilitate the identification of molecular genetic defects in pediatric and adult patients with a 
diagnosis of common variable immunodeficiency (CVID) or overlapping primary antibody 
deficiencies (PADs) followed in our center. As indicated in the introduction, a conclusive 
genetic diagnosis holds great importance in terms of patient management and the elucidation 
of underlying disease mechanisms. Moreover, since the genetic defects described thus far 
only encompass 2-10% of the CVID population, novel mutations in known CVID genes and 
novel candidate disease genes were assumed to be found.  
 
Objective 1. Clinical and immunological characterization of the study cohort.  
Although the clinical and immunological phenotype of CVID had already been extensively 
studied, reports on related PADs such as idiopathic primary hypogammaglobulinemia (IPH) 
and IgG subclass deficiency (IgGSD) were limited. In chapter 3, we examined the clinical 
features of the CVID, IPH and IgGSD patients from our cohort and performed detailed 
immunophenotyping of peripheral blood mononuclear cells (PBMCs) in these patients in 
comparison with their asymptomatic first-degree family members and unrelated age-matched 
healthy controls. Based on these data, we aimed to (1) phenotypically characterize our study 
cohort, (2) improve current understanding on immunological abnormalities in milder PAD 
disorders like IPH and IgGSD, and (3) discriminate subgroups in the patient population by 
using a more comprehensive range of immunophenotypical parameters. 
 
Objective 2. Genetic characterization of the study cohort.  
Next, we aimed to identify the disease-causing genetic defects in our PAD patient cohort (70 
index patients) by using one or more of the following methods: microarray-based 
comparative genomic hybridization (array CGH), targeted screening of candidate genes, 
whole exome sequencing (WES), and homozygosity mapping (in case of consanguinity). In 
chapter 4, it was our aim to compare the results of different genetic approaches and discuss 
the value of clinical and immunological characteristics to guide genetic assessment. We also 
proposed a strategy for genetic testing in patients with CVID and related antibody disorders, 
taking into account recent insights on a possible complex etiology in at least a subgroup of 
patients. 
 




Objective 3. Characterization of novel and rare mutations in known disease genes 
expanding phenotypical spectra. 
In our patient cohort, we aimed to characterize novel and rare variants found in genes 
associated with either syndromic primary immunodeficiencies (KMT2A, RNU4ATAC) or CVID 
(IKZF1), expanding both the clinical and immunological spectrum of these three disorders. 
Chapter 5 focused on familial cases of KMT2A-associated Wiedemann-Steiner syndrome 
and RNU4ATAC-associated Roifman syndrome, which exceptionally presented with a CVID-
reminiscent phenotype in early childhood while extra-immunological features were not initially 
apparent. In chapter 6, we aimed to study a novel autosomal dominant IKZF1 kindred with 
incomplete penetrance, and increase insights in early B cell development in symptomatic and 
asymptomatic mutation carriers.  
 
Objective 4. Functional validation of novel candidate disease genes. 
Finally, it was our objective to study novel candidate disease genes that we identified in our 
PAD cohort. In chapter 7, we described the discovery of novel compound heterozygous 
variants in GTF3A in two siblings with a clinical diagnosis of (possible) CVID. We aimed to 
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The etiology of primary antibody deficiencies is largely unknown.Beside rare monogenic forms, the majority of cases seem to have amore complex genetic basis. Whereas common variable immunode-
ficiency has been investigated in depth, there are only a few reports on
milder primary antibody deficiencies such as idiopathic primary hypogam-
maglobulinemia and IgG subclass deficiency. We performed flow cytomet-
ric immunophenotyping in 33 patients with common variable immunode-
ficiency, 23 with idiopathic primary hypogammaglobulinemia and 21 with
IgG subclass deficiency, as well as in 47 asymptomatic first-degree family
members of patients and 101 unrelated healthy controls. All three groups of
patients showed decreased memory B- and naïve T-cell subsets and
decreased B-cell activating factor receptor expression. In contrast, circulat-
ing follicular helper T-cell frequency and expression of inducible T-cell co-
stimulator and chemokine receptors were only significantly altered in
patients with common variable immunodeficiency. Asymptomatic first-
degree family members of patients demonstrated similar, albeit intermedi-
ate, alterations in naïve and memory B- and T-cell subsets. About 13% of
asymptomatic relatives had an abnormal peripheral B-cell composition.
Furthermore, asymptomatic relatives showed decreased levels of CD4+
recent thymic emigrants and increased central memory T cells. Serum IgG
and IgM levels were also significantly lower in asymptomatic relatives than
in healthy controls. We conclude that, in our cohort, the immunophenotyp-
ic landscape of primary antibody deficiencies comprises a spectrum, in
which some alterations are shared between all primary antibody deficien-
cies whereas others are only associated with common variable immunode-
ficiency. Importantly, asymptomatic first-degree family members of
patients were found to have an intermediate phenotype for peripheral B-
and T-cell subsets.
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with primary antibody deficiencies is partially
present in their asymptomatic first-degree 
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Primary antibody deficiencies (PAD) are the most preva-
lent primary immune deficiencies and are characterized
by impaired production of one or more immunoglobulin
(Ig) isotypes. Since the description of Bruton agammaglob-
ulinemia in 1952,1 our understanding of PAD has
improved substantially.2 Nonetheless, the etiology of
many PAD remains largely unknown.2 Common variable
immunodeficiency (CVID) is one of the most common
PAD and is a clinically and immunologically heteroge-
neous disorder.2,3 Indeed, the definition of CVID is a topic
of ongoing debate. The term CVID was introduced in
1971 to distinguish less well-defined PAD from those with
a consistent phenotype and inheritance.4 In 1999, CVID
was redefined by the European Society for
Immunodeficiencies (ESID) and the Pan-American Group
for Immunodeficiency (PAGID): a marked decrease in
serum IgG with a marked decrease in serum IgM and/or
IgA, poor antibody response to vaccines and/or absent iso-
hemagglutinins, and exclusion of secondary or other
defined causes of hypogammaglobulinemia.5 About 15
years later, two different revisions of the ESID/PAGID
1999 criteria were made: the Ameratunga 2013 criteria6
and the revised ESID registry 2014 criteria.7 Remarkably,
both revisions proposed reduced (switched) memory B
cells as an alternative criterion for impaired vaccine
responses.7 The revised ESID registry 2014 criteria addi-
tionally stated that both IgG and IgA must be decreased to
confer a diagnosis of CVID.7 However, not all practitioners
agree on the obligatory decrease in IgA.3 In 2016, an inter-
national consensus statement on CVID proposed less
stringent diagnostic criteria, closely resembling the
ESID/PAGID 1999 criteria and not including a reduction in
memory B cells.3
CVID patients have an increased susceptibility to infec-
tions, predominantly of the respiratory tract.3,8 Moreover,
they are prone to developing non-infectious complications
such as autoimmunity, polyclonal lymphoproliferation,
and malignancies.3,8 Patients with hypogammaglobuline-
mia showing clinical features reminiscent of CVID but not
fulfilling all laboratory criteria are often encountered in
daily practice.2,3 For the latter group of patients, consensus
diagnostic criteria, prevalence rates and clinical and
immunophenotypic data are scarce.9 These patients are
henceforth referred to as having idiopathic primary
hypogammaglobulinemia (IPH),9 although various other
terminologies have also been used such as CVID-like dis-
orders10 and unclassified hypogammaglobulinemia.11
Patients with a marked decrease in one or more IgG sub-
classes but normal total IgG are diagnosed with IgG sub-
class deficiency (IgGSD).12 Since IgG1 constitutes 66% of
total IgG, IgG1 deficiency typically results in decreased
total IgG.12 IgG4 only forms a minor portion of total IgG
(3%), and isolated IgG4 deficiency is usually asympto-
matic.12 Patients with isolated IgG2 and/or IgG3 deficiency
can suffer from recurrent infections and some develop
non-infectious, especially autoimmune, complications.12,13
However, subnormal Ig isotype levels and in particular
subnormal IgG subclass levels are not always accompa-
nied by a clinical phenotype.2,13 On the other hand, milder
PAD phenotypes can sometimes evolve into a complete
CVID phenotype over time.3
There is increasing evidence that besides rare monogenic
forms, the majority of PAD are complex disorders in which
multiple genes and/or environmental factors determine the
final phenotype.3 This has been best documented for
CVID.14 A monogenic cause has only been identified in 2-
10% of cases of CVID (e.g. ICOS, CD19, CD21), and in
several families the same primary genotype resulted in a
large phenotypic variability from asymptomatic over
milder PAD forms to complete CVID (e.g. TACI, BAFF-R,
NFKB1, CTLA4).14 Furthermore, it has been recently report-
ed that sporadic patients with CVID have variants in mul-
tiple CVID-associated genes and an enrichment of variants
in pathways important in B-cell function, suggesting a
polygenic nature of CVID.15 In addition, B cells in CVID
patients have been shown to have DNA methylation alter-
ations in genes critical for B-cell function, implicating a role
for epigenetic factors in the pathogenesis of CVID.16
While the immunological phenotype of CVID has been
investigated in depth, there are only few reports on IPH and
IgGSD and none on cohorts of asymptomatic PAD family
members. We, therefore, performed a detailed
immunophenotypic analysis of CVID, IPH and IgGSD
patients as well as asymptomatic first-degree relatives of
the PAD patients included in the study (asymptomatic fam-
ily members, AFM) and unrelated healthy controls (HC).
With this study, we demonstrate for the first time in a rela-
tively large cohort that the spectrum of immunophenotypic
alterations ranges from AFM through milder PAD entities,
such as IPH and IgGSD, to the most severe entity, CVID,
supporting the notion of a multifactorial origin of PAD.
Methods
Study population
The study populations consisted of 33 patients with CVID, 23
with IPH, 21 with IgGSD, 47 AFM, and 101 HC. Patients were
recruited between October 2013 and November 2015 at the
Departments of Pediatrics, Hematology and Pulmonology at
Ghent University Hospital. Clinical data were retrospectively col-
lected from patients’ medical records. CVID was defined as
decreased [from hereon always meaning: at least 2 standard devi-
ations (SD) below the age-adjusted mean according to the local
laboratory reference values, measured at least twice] IgG,
decreased IgA and/or IgM, and poor antibody responses to protein
and/or polysaccharide vaccines.3 IPH was defined as decreased
IgG, normal or decreased IgA and/or IgM, and good antibody
responses to protein and/or polysaccharide vaccines. IgGSD was
defined as decreased IgG2 and/or IgG3, normal total IgG and IgM,
normal or decreased IgA, and good or poor antibody responses to
protein and/or polysaccharide vaccines. Patients with other
defined causes of antibody deficiency and/or profound T-cell
defects, as determined by the ESID registry criteria for CVID
(http://esid.org/Working-Parties/Registry/Diagnosis-criteria),
were excluded from the study. At the time of analysis, 32 of 33
CVID patients, 21 of 23 of those with IPH, and 15 of 21 patients
with IgGSD were receiving regular immunoglobulin replacement
therapy. One of the CVID patients was being given tacrolimus and
rapamycin as maintenance immunosuppressive drugs after liver
transplantation; the remaining patients were not on immunosup-
pression.
AFM were defined as first-degree family members of included
patients who did not suffer from recurrent infections, autoimmu-
nity or other signs of immune deficiency or dysregulation. HC
were recruited from hospital and university staff and their chil-
dren. Exclusion criteria for HC were pregnancy, medical condi-
tions that affect the immune system, and treatment with immuno-
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suppressive or immune-modulating drugs. To obtain medical
information regarding AFM and HC, a detailed clinical history was
taken at the time of their inclusion in the study.
The study was approved by the ethical committee of Ghent
University Hospital (2012/593). All reported subjects (or their par-
ents in the case of pediatric subjects) provided written informed
consent to participation in the study, in accordance with the
Helsinki Declaration of 1975.
Serum immunoglobulins, flow cytometry, unsupervised
computational clustering analysis, and statistics
Details on measurement of serum Ig levels and absolute white
blood cell counts, flow cytometric analysis of peripheral blood
mononuclear cells, unsupervised computational clustering meth-
ods, the statistical analysis and conversion into z-scores are pro-
vided in the Online Supplementary Methods.
Results 
Characteristics of the study population
A comprehensive analysis was performed of the clinical
and immunological phenotype of 77 patients with PAD
(33 with CVID, 23 with IPH, and 21 with IgGSD), 47
AFM, and 101 HC. The demographics of the study popu-
lation are shown in Table 1. One IPH patient was born
from a consanguineous marriage; both parents were
asymptomatic and included as AFM. 
Median levels of IgG at diagnosis were significantly
lower in CVID than in IPH (Figure 1A). As expected from
the clinical definition, median IgG levels were also signifi-
cantly lower in CVID than in IgGSD, and median IgA and
IgM levels were significantly lower in CVID than in either
IPH or IgGSD (Figure 1A). None of the HC or AFM had
severely decreased Ig levels (i.e. z-score below 2.5), except
for one AFM (mother of an IPH patient) who had a total
IgG level of 3.5 SD below the age-adjusted mean (Figure
1A). Interestingly, mean IgG and IgM levels were signifi-
cantly lower in AFM than in HC (Figure 1A). 
Details on absolute white blood cell counts from routine
laboratory evaluations are provided in the Online
Supplementary Results, Online Supplementary Figure S1 and
Online Supplementary Table S2. Patients’ clinical characteris-
tics are summarized in Online Supplementary Table S3. At the
time of analysis, all patients suffered from recurrent infec-
tions, predominantly of the respiratory tract. A higher pro-
portion of IPH patients developed warts or fungal infections
(8.7% and 17.4%, respectively) compared to CVID patients
(3.0% and 3.0%, respectively) and IgGSD patients (0% and
9.5%, respectively), although these differences were not
statistically significant (P=0.312 and P=0.184, respectively).
Bronchiectasis was seen in 54.2% of CVID patients, 30.8%
of IPH patients and 16.7% of IgGSD patients, which fits
with their gradually milder defects in Ig production (Online
Supplementary Table S3). The overall occurrence of non-
infectious disease-related complications was significantly
higher in CVID patients than in IPH patients (P=0.031), and
also higher in patients with CVID than in those with IgGSD
although in this case the difference did not reach statistical
significance (P=0.070) (Figure 1B). In particular, autoim-
mune manifestations (symptoms related to autoimmune
disease) and benign lymphadenopathy (cervical, mediasti-
nal and/or abdominal lymph nodes >1 cm diameter, detect-
ed at least twice on medical imaging) were significantly
greater in CVID than in IPH or IgGSD (Figure 1C).
Abnormalities in peripheral B-cell subsets
An abnormal distribution of peripheral B-cell subsets is
one of the best-established features in CVID.3 We, there-
fore, examined peripheral B-cell subsets extensively. A
representative gating strategy is shown in Online
Supplementary Figure S2. Mean total B-cell percentages
were comparable between all groups of patients (Online
Supplementary Figure S3), but absolute B-cell numbers were
significantly lower in CVID than in IPH or IgGSD (Online
Supplementary Figure S1). On average, the B-cell phenotype
was most deviant in CVID with significantly decreased
IgD+CD27+ marginal zone-like B cells, IgD–CD27+ memory
B cells and plasmablasts and significantly increased naïve,
transitional and CD21low B cells (Figure 2). Although differ-
ences did not always reach statistical significance, IPH and
IgGSD patients as well as AFM showed a similar trend
towards a decrease in antigen-experienced B-cell subsets
and an increase in immature/naïve B-cell subsets (Figure
2). The levels of IgD–CD27+ memory B cells, in particular,
were significantly decreased in all three groups of patients
compared to the levels in HC. IgD–CD27+IgG+ memory B
cells were reduced in CVID and IPH but not in IgGSD, cor-
responding with the inclusion criteria. Remarkably, IgD–
CD27+IgG+ memory B-cell levels were also significantly
lower in AFM than in HC (Figure 2). IgD–CD27+IgA+ mem-
ory B-cell levels were significantly lower in CVID but
unexpectedly higher in IgGSD than in HC (Figure 2). As
expected, IgD–CD27+IgG+ and IgA+ memory B-cell levels
showed strong positive correlations with serum IgG and
IgA levels, respectively (both P<0.001, data not shown).
Mean levels of IgD–CD27+IgM+ memory B cells were sig-
nificantly higher in CVID and IPH, probably reflecting the
relative decrease in IgG+ and IgA+ memory B cells (Online
Supplementary Figure S3). No significant differences were
found in plasma cells or IgM+IgD+CD27+ marginal zone-
like B cells (Online Supplementary Figure S3).
Based on the composition of peripheral B-cell subsets,
Driessen et al. distinguished five patterns indicating at
what stage (early to late) in peripheral B-cell development
a defect may be located, as explained in the legend to
Figure 2B.17 Here, study subjects were categorized using
age-adjusted B-cell subset proportions (z-scores) instead of
absolute counts. All HC and the majority of AFM, IPH and
IgGSD showed a normal peripheral B-cell composition
(pattern 5), whereas CVID patients were divided over the
five patterns (Figure 2B). B-cell patterns 1 and 2 were only
seen in CVID and IgGSD patients, whereas patterns 3 and
4 were observed in CVID, IPH, and IgGSD patients and,
remarkably, even in AFM (Figure 2B). The distribution of
B-cell patterns was significantly different in patient groups
D.J.A. Bogaert et al.
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Table 1. Demographics of the study population.
Number (male/female) Age at inclusion 
in years (mean, range)
HC 101 (44/57) 30.8 (4.5 - 82.2)
AFM 47 (23/24) 45.1 (6.2 - 71.0)
CVID 33 (19/14) 28.0 (7.7 - 83.2)
IPH 23 (9/14) 35.6 (10.3 - 86.5)
IgGSD 21 (3/18) 39.0 (11.9 - 65.0)
AFM: asymptomatic family member; CVID: common variable immunodeficiency; HC:
healthy control; IgGSD: IgG subclass deficiency; IPH: idiopathic primary hypogamma-
globulinemia.
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and AFM compared to HC (all P!0.001). In addition, B-cell
patterns in CVID differed significantly from those in IPH,
IgGSD and AFM (all P<0.01). B-cell patterns were not sig-
nificantly different between IPH, IgGSD and AFM.
Abnormalities in B-cell co-stimulatory molecules and
chemokine receptors
Defects in B-cell co-stimulatory molecules and
chemokine receptors have been associated with CVID.3 In
this study we examined the expression of various co-stim-
ulatory molecules [B-cell activating factor belonging to the
TNF family - receptor (BAFF-R), human leukocyte antigen
– antigen D-related (HLA-DR), cluster of differentiation 40
(CD40) and transmembrane activator and calcium modu-
lator and cyclophilin ligand interactor (TACI)] and
chemokine receptors [CXC-chemokine receptor 5
(CXCR5) and CC-chemokine receptor 7 (CCR7)]. 
Average BAFF-R expression on B cells was severely
decreased in CVID and moderately decreased in IPH and
IgGSD (Figure 2C). Mean HLA-DR expression on B cells
Immunological PAD fingerprint in asymptomatic relatives
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Figure 1. Serum immunoglobulin levels and clinical phenotype. (A) Serum immunoglobulin (Ig) levels at diagnosis (CVID, IPH, IgGSD) or at inclusion in the study (HC,
AFM). For IgG2 and IgG3 levels, IgGSD patients were subdivided in accordance with the decreased IgG subclasses. Graphs represent mean ± SD. Ig values were
expressed as z-scores to adjust for age. Values normal for age have a z-score between -2 and 2 (dotted lines). (B) The clinical phenotype of CVID, IPH and IgGSD
patients. Non-infectious complications included benign lymphadenopathy, lymphocytic interstitial pneumonitis, granulomata, splenomegaly, hepatomegaly, unex-
plained enteropathy and/or autoimmunity. (C) Prevalence of autoimmune manifestations (symptoms related to autoimmune disease) and benign lymphadenopathy
(cervical, mediastinal and/or abdominal lymph nodes >1 cm diameter, detected at least twice on medical imaging) in CVID, IPH, and IgGSD patients. AFM: asympto-
matic family member; CVID: common variable immunodeficiency; HC: healthy control; IgGSD: IgG subclass deficiency; IPH: idiopathic primary hypogammaglobuline-






was markedly elevated in CVID and to a lesser extent in
IgGSD (Online Supplementary Figure S4). All groups of
patients had similarly increased mean CD40 expression on
B cells compared to the mean expression on B cells from
HC (Online Supplementary Figure S4). Mean TACI expres-
sion was lower in IgGSD but was not aberrant in the other
groups of patients (Online Supplementary Figure S4). On
average, AFM did not have deviant expression of the
investigated co-stimulatory molecules (Figure 2C, Online
Supplementary Figure S4). 
CXCR5 and CCR7 are implicated in B- and T-cell
migration to secondary lymphoid organs and in differen-
tial localization of these cells in follicles.18 In our cohort,
CXCR5 and CCR7 expression on B cells was severely
reduced in CVID but not in the other groups of patients
or in AFM (Figure 3A). Furthermore, CXCR5 and CCR7
expression on B cells was positively correlated with levels
of IgD–CD27+ memory B cells, IgD–CD27+IgG+ and IgA+
memory B cells and IgD+CD27+ marginal zone-like B cells,
and negatively correlated with CD21low B-cell levels
(Figure 3B). 
Abnormalities in the T-cell compartment
Alongside B-cell abnormalities, multiple alterations have
been described in the T-cell compartment of CVID
patients.3 Online Supplementary Figure S5 depicts a repre-
sentative gating strategy of the here-examined T-cell sub-
sets.  
CVID patients showed, on average, skewing towards
memory T-cell subsets evidenced by significantly
increased central memory T (TCM) cells and decreased
naïve T cells and CD4+ recent thymic emigrants (RTE)
(Figure 4). A similar though less pronounced trend was
also observed in AFM and patients with IPH: both groups
D.J.A. Bogaert et al.
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Figure 2. Peripheral B-cell subsets and BAFF-R expression on B cells. (A) Total B cells were gated as CD19+CD20+ in living cells. Within B cells, naïve B cells were
gated as IgD+CD27-, transitional B cells as CD24highCD38high, CD21low B cells as CD21lowCD38low, marginal zone-like B cells as IgD+CD27+, memory B cells as IgD–CD27+,
and plasmablasts as CD38highCD24-. Graphs represent mean ± SD. B-cell subsets were expressed as z-scores to adjust for age if applicable. Values normal for age
have a z-score between -2 and 2 (dotted lines). (B) B-cell patterns according to Driessen et al.17 using age-adjusted B-cell subset proportions (z-scores). B-cell pattern
1: reduced transitional and IgD-CD27+ memory B cells, indicative of a defect in B-cell production and germinal center function. B-cell pattern 2: normal transitional
B cells and reduced naïve, IgD+CD27+ marginal zone-like and IgD-CD27+ memory B cells, indicative of a defect in early B-cell maturation or survival. B cell pattern 3:
reduced IgD+CD27+ marginal zone-like and IgD-CD27+ memory B cells, indicative of a defect in B-cell activation and proliferation. B-cell pattern 4: isolated reduction
of IgD-CD27+ memory B cells, indicative of a defect in germinal center function. B-cell pattern 5: normal IgD+CD27+ marginal zone-like and IgD-CD27+ memory B cells;
in individuals with decreased serum immunoglobulin levels, this could be indicative of a post-germinal center defect. (C) BAFF-R expression on B cells. The graph
represents mean ± SD. Representative flow cytometric analysis is shown on the left. The full black line represents a CVID patient, the dashed black line represents
a HC. Relative mean fluorescence intensity (MFI) was calculated by dividing the MFI of the positive population (black line) by the MFI of the “fluorescence minus one”
(FMO) population (gray). AFM, asymptomatic family member; CVID, common variable immunodeficiency; HC, healthy control; IgGSD, IgG subclass deficiency; IPH,
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displayed significantly increased CD8+ TCM cells, and
AFM also had increased CD4+ TCM cells and decreased
CD4+ RTE (Figure 4). In contrast, IgGSD patients showed
skewing towards naïve T-cell subsets evidenced by signif-
icantly increased levels in naïve T cells and CD4+ RTE,
without significant differences in memory T-cell subsets
(Figure 4). 
HLA–DR+CD8+ T-cell counts were significantly elevated
in CVID patients and AFM compared to HC. CVID
patients also had higher numbers of HLA–DR+CD4+ T
cells (Online Supplementary Figure S6). This is analogous to
the increase in mean HLA-DR expression on B cells in
CVID (Online Supplementary Figure S4). We found no
important differences in regulatory T cells and double neg-
ative T cells (Online Supplementary Figure S6).
Follicular helper T (Tfh) cells orchestrate the formation
of high-affinity antibody-producing plasma cells and
memory B cells, and inducible T-cell co-stimulator (ICOS)
is a key molecule in the differentiation and function of Tfh
cells.19 In our cohort, mean levels of circulating Tfh (cTfh)
cells were significantly higher in CVID patients than in
HC (Figure 5A). Within the CVID group, a higher propor-
tion of cTfh cells expressed ICOS in the resting condition
(Figure 5A). Upon stimulation, however, ICOS expression
on CD4+ T cells was markedly lower in CVID patients
than in HC, despite adequate T-cell activation as evi-
denced by the normal CD69 upregulation (Figure 5B). A
similarly decreased ICOS upregulation was also seen on
CD8+ T cells in CVID patients (Online Supplementary Figure
S7). IPH and IgGSD patients and AFM did not demon-
strate alterations in mean cTfh cell percentages or ICOS
expression (Figure 5A,B). 
cTfh cells in CVID patients displayed a highly signifi-
cant reduction in mean CCR7 expression (Figure 5C).
Additionally, CVID patients had decreased CCR7 expres-
sion on total T cells and naïve, RTE and central memory T-
cell subsets (Online Supplementary Figure S8), analogous to
the decrease in mean CCR7 expression levels on B cells
(Figure 3). IPH and IgGSD patients and AFM demonstrat-
ed normal mean CCR7 expression on cTfh cells and naïve
and memory T-cell subsets (Figure 5C and Online
Supplementary Figure S8). Interestingly, CCR7 expression
on cTfh cells was significantly correlated with the level of
cTfh cells (Figure 5D). Furthermore, CCR7 expression on
total T cells was positively correlated with levels of naïve
T-cell subsets, and negatively correlated with levels of
memory T-cell subsets except for CD8+ TCM cells (Online
Supplementary Figure S9).
Abnormalities in natural killer cells and dendritic cells
Besides B and T lymphocytes, innate immune cells have
also been shown to be affected in CVID patients.3 We,
therefore, screened for relevant innate immune cell sub-
sets (the gating strategy is shown in Online Supplementary
Figure S10). On average, levels of total natural killer (NK)
cells were significantly lower in all PAD groups compared
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Figure 3. CXCR5 and CCR7 expression on B cells. (A) Graphs represent mean ± SD. Representative flow cytometric analysis is shown on the left. Full black lines rep-
resent CVID patients, dashed black lines represent HC. Relative mean fluorescence intensity (MFI) was calculated by dividing the MFI of the positive population (black
line) by the MFI of the “fluorescence minus one” (FMO) population (gray). AFM, asymptomatic family member; CVID, common variable immunodeficiency; HC, healthy
control; IgGSD, IgG subclass deficiency; IPH, idiopathic primary hypogammaglobulinemia. *P!0.05, ***P!0.001, ns not significant (Mann-Whitney test with the
Bonferroni correction for multiple comparisons). (B) Significant correlations between CXCR5 and CCR7 expression on B cells and levels of B-cell subsets. Correlations






to the group of HC, while NK-cell subsets were only aber-
rant in CVID (Figure 6). In our cohort, CVID patients had
relatively increased levels of CD56bright NK cells (a more
immature NK phenotype) and relatively decreased levels
of CD16bright NK cells (a more effector NK phenotype)
(Figure 6). This suggests a more immature NK-cell profile
in CVID patients, analogous to their immature B-cell pro-
file but opposite to their exhausted T-cell profile. Mean
NKT- and invariant NKT-cell percentages were similar
across groups (Figure 6). The levels of dendritic cells were,
however, significantly decreased in all groups of patients
(Figure 6). The relative proportion of conventional and
plasmacytoid dendritic cells was not significantly altered
in any of the patients (Figure 6). On average, there were no
significant differences in the examined innate immune
cells between AFM and HC, contrasting with the findings
in the B- and T-cell compartments (Figure 6).
Unsupervised computational clustering analysis
Since significant associations between clinical features
and immunological parameters had been found (see Online
Supplementary Results and Online Supplementary Table S4),
we investigated whether subgroups of the study subjects
could be distinguished based on immunophenotypic data.
We performed unsupervised computational clustering
analysis of flow cytometric parameters by means of hier-
archical clustering with heatmaps and principal compo-
nent analysis. We could neither distinguish entire patient
groups from healthy groups, nor distinguish subgroups
among patients stratified according to diagnosis or clinical
phenotype (Online Supplementary Figure S11). Furthermore,
there was no clustering according to age or between mem-
bers of the same family (data not shown). Similarly, princi-
pal component analysis could not reveal patient subgroups
from the immunological data and could not distinguish
patients from AFM or HC (data not shown). Different com-
binations of immunological parameters or patient stratifi-
cations did not improve the clustering (data not shown). 
Discussion
Here we show for the first time in a relatively large
cohort of subjects that there is a spectrum of peripheral
immunophenotypic abnormalities in PAD, ranging from
those present in AFM across those found in IgGSD and
IPH patients to those in CVID patients, with the differ-
ences being most notable in naïve and memory T- and B-
lymphocyte subsets. A summary of significantly different
parameters in the patient and AFM groups compared to
D.J.A. Bogaert et al.
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Figure 4. Naïve and memory T-cell subsets.  Total T cells were gated as CD3+ in alive cells. CD4+ and CD8+ T cells were gated in !" T cells. Within CD4+ and CD8+ T cells,
naïve cells were gated as CD45RO-CCR7+, central memory cells (TCM) as CD45RO+CCR7+, effector memory cells (TEM) as CD45RO+CCR7-, and terminally differentiated
cells (TEMRA) as CD45RO-CCR7-. In naïve CD4+ T cells, recent thymic emigrants (RTE) were gated as CD31+. Graphs represent mean ± SD. Naïve and memory T-cell sub-
sets were expressed as z-scores to adjust for age. Values normal for age have a z-score between -2 and 2 (dotted lines). AFM, asymptomatic family member; CVID, com-
mon variable immunodeficiency; HC, healthy control; IgGSD, IgG subclass deficiency; IPH, idiopathic primary hypogammaglobulinemia. * P#0.05, **P#0.01,
***P#0.001, ns not significant (Mann-Whitney test with the Bonferroni correction for multiple comparisons).
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the HC group is shown in Figure 7. The results presented
support the notion of a complex basis of CVID and related
milder PAD disorders, in which an accumulation of multi-
ple genetic and/or environmental factors contributes to
the final phenotype.3,15,16 Monogenic defects have only
been identified in a minority of cases with CVID.14
Remarkably, some relatives with the same monogenic
defect were found to be asymptomatic or suffer from a
milder PAD phenotype such as IgGSD.20-23 A multifactorial
basis in the majority of CVID, and in extension PAD,
would explain the vast variations in the clinical and
immunological landscape seen in these patients.2,14
The immunophenotypic characteristics found in our
CVID group are comparable to those reported previously
in the literature: increased naïve and transitional B cells,
CD21low B cells and cTfh cells, and decreased memory B-
cell subsets, total CD4+ T-cell counts, naïve CD4+ T cells
and CD4+ RTE;24-30 heterogeneous distribution of peripher-
al B-cell patterns;9,17,31 decreased proportions of NK cells
and dendritic cells;32,33 lower ICOS upregulation on activat-
ed T cells;34 increased HLA-DR expression on B and T
cells;35,36 decreased BAFF-R, CXCR5 and CCR7 expression
on B cells;37,38 and decreased CCR7 expression on T cells,
especially on cTfh cells.38,39 It should be noted that the
observed reduction of BAFF-R in CVID might be an over-
estimation because BAFF-R expression levels are lower on
CD27– B cells, the predominant B-cell subset in these
patients. 
While CVID has been studied in depth over the past
four decades, there are few immunophenotypic reports on
milder forms of PAD, such as IPH and IgGSD. Our find-
ings in IPH and IgGSD patients are compatible with previ-
ous published information on milder forms of PAD.9,10,40,41
IPH and IgGSD patients showed an abnormal distribution
of naïve and memory B- and T-cell subsets, similar to that
observed in CVID patients, albeit to a lesser extent with a
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Figure 5. Circulating follicular helper T (cTfh) cells and expression of ICOS and CCR7 on cTfh cells.  (A) Circulating follicular helper T (cTfh) cells were gated as
CXCR5+CD45RO+ in CD4+ T cells. ICOS+ cTfh cells were gated based on “fluorescence minus one” (FMO). A representative gating strategy is shown on the left. Graphs
represent mean ± SD. cTfh cells were expressed as z-scores to adjust for age-related differences in memory cells. Values normal for age have a z-score between -2
and 2 (dotted lines). (B) ICOS and CD69 expression on CD4+ T cells stimulated with phytohemagglutinin for 72 h. CD69 was used as a positive control for T-cell acti-
vation. Graphs represent mean ± SD. Representative flow cytometric analysis is shown on the left. Full black lines represent CVID patients, dashed black lines rep-
resent HC. Relative mean fluorescence intensity (MFI) was calculated by dividing the MFI of the positive population (black line) by the MFI of the FMO population
(gray). (C) CCR7 expression on cTfh cells. The graph represents mean ± SD. Representative flow cytometric analysis is shown on the left. The full black line represents
a CVID patient, the dashed black line represents a HC. Relative mean MFI was calculated by dividing the MFI of the positive population (black line) by the MFI of the
FMO population (gray). AFM: asymptomatic family member; CVID: common variable immunodeficiency; HC: healthy control; IgGSD: IgG subclass deficiency; IPH: idio-
pathic primary hypogammaglobulinemia. *P!0.05, **P!0.01, ***P!0.001, ns not significant (Mann-Whitney test with the Bonferroni correction for multiple com-






block later in B-cell development and a less pronounced T-
cell skewing towards memory subsets. Furthermore, com-
pared to the CVID group, IPH and IgGSD patients had less
severely decreased serum levels of all Ig isotypes. Like the
CVID group, the IPH and IgGSD groups in our cohort had
significantly reduced proportions of NK cells and dendritic
cells. Moreover, they had a similar though less pro-
nounced decrease in BAFF-R and increase in HLA-DR and
CD40 expression on B cells. In contrast to CVID patients,
IPH and IgGSD patients did not have significant alter-
ations in mean cTfh cell levels, in mean chemokine recep-
tor expression on B and T cells, or in mean ICOS upregu-
lation on activated T cells. To our knowledge, this is the
first report on co-stimulatory molecules and chemokine
receptors on B and T cells in milder forms of PAD. While
the immunophenotypic parameters of CVID, IPH and
IgGSD patients appear to form a continuous spectrum, we
observed small differences in the type of infections they
developed. In particular, compared to CVID and IgGSD
patients, a higher proportion of IPH patients had unusual
infections (i.e. warts, fungal infections), although the dif-
ference was not statistically significant.
There have been no detailed immunophenotypic stud-
ies in cohorts of asymptomatic relatives of patients with
PAD. Two previous studies investigated serum Ig levels in
first-degree relatives of Iranian (n=64) and Turkish (n=63)
CVID patients.42,43 The proportion of asymptomatic rela-
tives with reduced total IgG, IgM and/or IgA in the
Iranian (13%) and Turkish (19%) cohorts was comparable
to that in our cohort (8/47, 17%).42,43 In our cohort, mean
IgG and IgM levels were significantly lower in AFM than
in HC suggesting that AFM are genetically and/or envi-
ronmentally predisposed to the development of PAD.
This hypothesis is further supported by the fact that sev-
eral flow cytometric abnormalities detected in PAD
patients were also found in AFM (Figure 7). Especially,
AFM showed a similar trend regarding the profile of naïve
and memory B and T cells, with significantly increased
transitional B cells, CD4+ TCM cells and CD8+ TCM cells
and significantly decreased IgD–CD27+ memory B cells,
plasmablasts and CD4+ RTE compared to HC. Moreover,
the distribution of peripheral B-cell patterns among AFM
was similar to that among IPH and IgGSD patients and
indicated that some AFM have a defect in later stages of
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Figure 6. Innate immune cells: natural killer cells, natural killer T cells, dendritic cells and subsets.  Natural killer (NK) cells were gated as CD3-CD56+ in CD19-HLA-
DR- lymphocytes. NK-cell subsets were determined by their relative expression of CD56 and CD16. Natural killer T (NKT) cells were gated as CD3+CD56+ in CD19-HLA-
DR- lymphocytes, and invariant NKT (iNKT) cells as invariant TCR (TCR V!24-J!18) positive in NKT cells. Dendritic cells (DC) were gated as lineage-CD4+HLA-DR+ cells.
Within DC, conventional DC (cDC) were gated as CD11c+CD123- and plasmacytoid DC (pDC) as CD123+CD11c-. Graphs represent mean ± SD. AFM: asymptomatic
family member; CVID: common variable immunodeficiency; HC: healthy control; IgGSD: IgG subclass deficiency; IPH: idiopathic primary hypogammaglobulinemia.
*P!0.05, **P!0.01, ***P!0.001, ns not significant (Mann-Whitney test with the Bonferroni correction for multiple comparisons).
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peripheral B-cell development. As opposed to B- and T-
cell naïve and memory subsets, mean expression levels of
the here-examined co-stimulatory molecules and
chemokine receptors on B and T cells were not signifi-
cantly altered in AFM compared to HC. Furthermore,
AFM had, on average, normal levels of cTfh cells, NK
cells, and dendritic cells (total and subsets). Together, our
data suggest that a broader impairment of the immune
system, including alterations in co-stimulatory molecules,
lymphocyte trafficking and innate immune cells, is
required to develop a clinical phenotype. It would be
interesting to follow IPH and IgGSD patients as well as
AFM over time (especially young individuals), to see
whether their immunophenotype approaches that of
patients with CVID. It should be noted that early Ig
replacement therapy might interfere with the natural pro-
gression of the disease.
Several classifications have been proposed to distin-
guish subgroups among CVID patients, mainly using
peripheral B- and/or T-cell immunophenotyping.24-27,44,45
However, the plethora of immunological abnormalities
and their unequal distribution among different cohorts
have made it challenging to uniformly identify subgroups
in the CVID population.10,46-48 In our cohort, unsupervised
computational clustering techniques were unable to
reveal subgroups of subjects using different combinations
of immunological and/or clinical parameters. The inabili-
ty to distinguish clusters might be due to the relatively
small groups. More probably, however, this reflects the
heterogeneous nature of CVID and related PAD, and is in
line with the fact that mild immunophenotypic abnor-
malities are already present in AFM. Possibly, genetic
and/or environmental elements predisposing to the devel-
opment of PAD may be more prevalent in the general
community than initially thought. Depending on the
degree to which these elements congregate, a wide range
of phenotypes arises. 
While we recognize that the small sample size of our
study means that the findings warrant confirmation in
larger cohorts, we conclude that the immunophenotypic
landscape in CVID and other PAD comprises a varied and
overlapping spectrum in which asymptomatic relatives
show an intermediate immunophenotype, supporting the
notion of a complex etiological basis of PAD.
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Supplementary Information  
 
SUPPLEMENTARY METHODS 
Serum immunoglobulin levels 
Serum samples of AFM and HC were cryopreserved at -80°C and immunoglobulin (Ig)G, 
IgG2, IgG3, IgA and IgM concentrations were measured on thawed serum by nephelometry 
(Behring Nephelometer Analyzer II). Ig levels of patients had been previously determined at 
time of diagnosis, on fresh serum samples using nephelometry (Behring Nephelometer 
Analyzer II). 
 
Absolute white blood cell counts 
Absolute white blood cell counts and differentiations were determined on EDTA whole blood 
of patients during routine lab evaluations by means of a Sysmex XE-5000 (Sysmex), within a 
six-month range around time of inclusion in the study. On the same sample, B, T and NK 
cells were measured using a BD FACSCanto II flow cytometer (BD Biosciences) and 
FACSDiva software version 8 (BD Biosciences). 
Due to practical reasons, absolute white blood cell counts on EDTA whole blood could not be 
assessed in asymptomatic family members (AFM) or healthy controls (HC).  
 
Flow cytometric analysis of peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated from EDTA whole blood by Ficoll-Paque density gradient centrifugation 
and cryopreserved at -150°C for batch analysis. Thawed PBMCs were stained with fixable 
viability dye 506 (eBioscience) and fluorescently labeled monoclonal antibodies under 
saturation conditions. Following monoclonal antibodies were used (clones specified between 
brackets): CD8 (RPA-T8), CD14 (MΦP9), CD16 (3G8), CD19 (HIB19), CD20 (2H7), CD21 
(B-LY4), CD27 (M-T271), CD31 (WM59), CD40 (5C3), CD138 (MI15), CXCR5 (RF8B2), IgD 
(IA6-2), IgM (G20-127), γδTCR (11F2) (all BD Biosciences); CD3 (SK7), CD4 (SK3), CD11c 
(BU15), CD19 (HIB19), CD20 (2H7), CD24 (ML5), CD25 (BC96), CD34 (581), CD45RO 
(UCHL1), CD123 (6H6), CD197(CCR7) (G043H7), CD267(TACI) (1A1), CD268(BAFF-R) 
(11C1), CD278(ICOS) (C398.4A), HLA-DR (L243) (all Biolegend); CD4 (RPA-T4), CD38 
(HIT2), CD56 (TULY56), Foxp3 (PCH101) (all eBioscience); IgA (IS11-8E10), IgG (IS11-
3B2.2.3), iNKT (6B11) (all Miltenyi Biotec). 
To analyze ICOS upregulation on T cells, thawed PBMCs were incubated with 1% PHA (Life 
Technologies) for 72 hours at 37°C in 5% CO2 at a density of 1.25 x 106 PBMCs/mL in 
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supplemented RPMI medium (Gibco). Afterwards, cells were stained with fixable viability dye 
506 (eBioscience) and fluorescently labeled monoclonal antibodies under saturation 
conditions: CD69-BV605 (FN50) (BD Biosciences); CD3-PerCP-Cy5.5 (SK7), CD4-Pacific 
Blue (SK3), CD278(ICOS)-FITC (C398.4A) (all Biolegend); CD8-APC (BW135/80) (Miltenyi 
Biotec). CD69 expression was used as a positive control for T cell activation.  
Cells were acquired on an LSR Fortessa flow cytometer with 3 lasers (488nm blue laser, 405 
nm violet laser, 640nm red laser) that can measure up to 12 colors simultaneously (BD 
Biosciences). At least 100 000 events per sample were recorded. Data were analyzed with 
FlowJo version X (Tree Star Inc.).  
 
Unsupervised computational clustering analysis 
Unsupervised clustering analysis was performed on log2 transformed serum Ig levels and 
flow cytometry variables using the R programming language (v3.1.1) (1). The immunological 
data was studied for sample subgroups by means of hierarchical clustering – implementing 
the “manhattan” distance method and the “ward.D2” clustering method – through the R 
package “pheatmap” (v1.0.7) (2) to provide the accompanying heatmaps. Additionally, 
principal component analysis (PCA) was performed using the base R function “prcomp()”. 
Both clustering methods were evaluated on data from (i) all samples included in the study, (ii) 
patients and AFM, (iii) patients only and (iv) each individual PAD entity. 
 
Statistics 
Statistical analysis was performed with SPSS Statistics version 22 (IBM®). Variables were 
not normally distributed; therefore non-parametrical statistical tests were used throughout. 
Continuous variables between multiple groups were compared using the Kruskal-Wallis test. 
If the former indicated significant differences, pairwise comparison of groups was done using 
the Mann-Whitney test with Bonferroni’s post hoc correction for multiple comparisons. 
Categorical variables between multiple groups were compared using the chi square test. If 
this indicated significant differences, pairwise comparison of groups was done using the 
Fisher’s Exact test with Bonferroni’s post hoc correction for multiple comparisons. 
Correlations were calculated with Spearman Rank Correlation. A two-sided p value ≤ 0.05 
was considered statistically significant. 
Continuous variables were converted into z-scores to adjust for age-dependent differences 
when required. A z-score is the number of standard deviations (SD) the measured value is 
above or below the normal mean for age: z = x −µ
σ
, x  being the measured value, µ  the 
mean value of the age-based reference population, and σ  the SD of the age-based 
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reference population (3). Values normal for age have a z-score between -2 and +2 (i.e. 2 SD 
below and above the age-adjusted mean). Z-scores of Ig levels and absolute white blood cell 
counts were calculated using age-based reference values from the routine lab. Z-scores of 
naive and memory PBMC subsets were calculated using age-based reference values 
derived from the HC group. The division of the healthy controls into age groups and the 






Characteristics of the study population: absolute white blood cell counts. 
Absolute white blood cell counts were only determined in patients during routine lab 
evaluations. These routine lab evaluations were done within a six-month range around time 
of analysis for the study.  
Mean lymphocyte, B cell, and CD4+ T cell counts were significantly lower in CVID compared 
to IPH and IgGSD (Figure S1). At individual level, lymphopenia was observed in six of 33 
CVID patients (Table S2). Eleven CVID patients and one IgGSD patient had reduced B cell 
counts (Table S2). Total absolute T cell counts were mildly decreased in five CVID patients 
of whom two had decreased CD4+ T cells, one decreased CD8+ T cell numbers and two 
decreased CD4+ and CD8+ T cell numbers (Table S2). Note that for B, T, CD4+ T, CD8+ T, 
and NK cells, absolute counts measured in the routine lab were strongly correlated with 
percentages determined on flow cytometry (all p<0.001; data not shown).  
 
Associations between clinical features and the immunophenotype in patients. 
Flow cytometric B and/or T cell phenotyping is frequently used to discriminate CVID patients 
at risk for non-infectious complications (4, 5). Therefore, associations between clinical 
features and immunological parameters were examined in all PAD patients together and in 
CVID, IPH and IgGSD patients separately. Statistical data on the here-discussed 
associations are provided in Table S4.  
In our cohort, PAD patients with chronic lung disease (i.e. bronchiectasis, lung granulomata 
and/or lymphocytic interstitial pneumonitis; n=22) (Table S3) had significantly increased 
CD21low B cells as well as significantly decreased IgG, IgM, IgA, absolute B cell numbers and 
IgD-CD27+ memory B cells compared to PAD patients without chronic lung disease. Within 
the separate groups of CVID, IPH and IgGSD patients, we could not detect a significant link 
between chronic lung disease and any of the immunological parameters, which could be due 
to the small group sizes.  
Polyclonal lymphoproliferative disease was defined as the presence of benign 
lymphadenopathy (cervical, mediastinal and/or abdominal lymph nodes > 1 cm diameter, 
detected at least twice on medical imaging), hepatomegaly (as protocolled upon abdominal 
ultrasound), and/or splenomegaly (as protocolled upon abdominal ultrasound) (Table S3). 
PAD patients with polyclonal lymphoproliferative disease (n=17) had significantly higher 
naive B cells, CD21low B cells, CD4+ TCM cells and cTfh cells compared to those without. 
Furthermore, PAD patients with lymphoproliferative disease had significantly lower IgG, IgM, 
IgA, IgD-CD27+ memory B cells, naive CD4+ T cells, CD4+ RTE, naive CD8+ T cells, CXCR5 
and CCR7 expression on B cells, and CCR7 expression on cTfh cells. Within CVID patients 
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separately, those with polyclonal lymphoproliferation (n=14) were found to have significantly 
increased CD4+ TCM cells and cTfh cells and significantly decreased IgG, naive CD4+ T 
cells, IgD-CD27+IgA+ memory B cells, and CXCR5 expression on B cells compared to those 
without lymphoproliferative disease. There were no immunological differences between IPH 
patients with and without polyclonal lymphoproliferative disease. None of the IgGSD patients 
had developed lymphoproliferative disease at time of analysis. 
PAD patients with autoimmunity (i.e. symptoms related to autoimmune disease; n=19) (Table 
S3) had significantly increased CD4+ TCM cells and cTfh cells and significantly decreased 
IgA, naive CD4+ T cells and CD4+ RTE. PAD patients with autoimmunity also showed a trend 
towards increased TACI expression on B cells but this did not reach statistical significance. 
However, in PAD patients with autoimmune cytopenia (n=6), TACI expression was 
significantly higher compared to those without autoimmune cytopenia. Within CVID patients 
separately, those with autoimmunity (n=13) showed significantly higher CD4+ TCM cells and 
TACI expression on B cells compared to those without autoimmune manifestations. The 
increased TACI expression on B cells was even more significant in CVID patients with 
autoimmune cytopenias (n=5) compared to those without. IPH patients with autoimmunity 
(n=3) also demonstrated a non-statistically significant trend towards higher CD4+ TCM cells 
compared to those without autoimmunity. IgGSD patients with and without autoimmunity did 
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Table S2. White blood cell counts of the patients. 
Patient Diagno-
sis 








CD4+ T  
(/µL) 






P1 CVID Male 61.9 6690 690 2010 1670 362 1250 121 221 
P2 CVID Male 14.3 2470* 700 1700 1260 663 442 255 153 
P3 CVID Female 17.0 3860 550 2060 1774 1296 476 99 46* 
P4 CVID Male 13.6 5290 910 1190* 940 643 274 36* 179 
P5 CVID Female 10.8 6080 960 2410 1740 1080 603 48* 554 
P6 CVID Female 14.1 1870* 260* 1580 1200 664 427 253 126 
P7 CVID Female 49.0 4070 362 1538 1170 769 369 246 108 
P8 CVID Male 14.6 1490* 350* 580* 447* 290* 122* 87* 23.2* 
P9 CVID Male 18.2 2230 420 3610 2100 1360 679 1050 170 
P10 CVID Male 7.8 6980 690* 3990 2630 1600 838 798 479 
P11 CVID Male 7.8 3150 570* 3480 2580 1640 800 592 244 
P12 CVID Male 7.7 1550* 560* 1430 849 449 349 200 175 
P13 CVID Female 24.7 2340 330 1380 1310 804 459 115 180 
P14 CVID Female 14.0 4060 980 2350 1370 659 575 17* 304 
P15 CVID Female 9.4 3280 470* 2150 1700 862 583 117* 489 
P16 CVID Female 33.1 2601 213* 1160 1170 471 638 152 197 
P17 CVID Female 23.4 10400 2000 2580 2000 942 667 184 115 
P18 CVID Male 71.8 3368 590 868* 590* 174* 434 0* 234 
P19 CVID Male 43.7 5050 510 860* 559* 430 112* 155 120 
P20 CVID Female 83.2 4900 740 3020 2473 1389 1084 255 130 
P21 CVID Male 16.6 2780 530 1880 2270 1010 982 706 92.1 
P22 CVID Female 28.8 2884 831 4642 2880 1440 1390 1440 232 
P23 CVID Male 17.3 3090 760 2030 1400 974 365 386 223 
P24 CVID Male 16.6 2750 420* 2200 1780 781 805 317 293 
P25 CVID Male 32.3 3230 430 2480 1440 521 843 50* 918 
P26 CVID Female 45.0 3865 475 1966 1320 923 308 325 68.4* 
P27 CVID Male 53.6 6350 630 1370 740 480 219 41* 534 
P28 CVID Male 11.6 6210 1400 1680 1100 389 443 142* 478 
P29 CVID Male 13.8 780* 300* 1300* 552* 256* 280 200 32* 
P30 CVID Male 17.8 4000 580 1640 935 476 394 246 426 
P31 CVID Male 80.8 5890 680 1280 1210 604 574 30* 227 
P32 CVID Female 36.7 3800 390 1870 1570 617 879 243 37.4* 
P33 CVID Female 14.6 1130* 360* 650* 496* 306* 132* 174* 149 
P34 IPH Female 20.2 2200 320 1410 1640 1010 560 314 269 
P35 IPH Male 15.2 2860 260* 2080 2110 1300 572 312 156 
P36 IPH Female 22.6 1700 320 2210 2819 1879 766 487 139 
P37 IPH Female 37.4 7380 690 2070 1770 1230 517 492 172 
P38 IPH Female 37.5 3555 289 1879 939 543 352 132 358 
P39 IPH Female 30.5 4030 390 2010 1880 1010 746 265 241 
P40 IPH Female 68.6 4590 390 1240 982 742 241 149 75* 
P41 IPH Male 13.4 1890* 560 1950 1270 761 312 332 312 
P42 IPH Female 52.8 3520 440 1309 1140 940 198 379 115 
P43 IPH Male 14.2 3330 310* 1640 1000 623 279 476 131 
P44 IPH Female 50.9 4181 212* 2552 1910 1580 332 434 179 
P45 IPH Male 37.3 4600 730 2260 1780 725 681 220 198 
P46 IPH Male 86.5 2840 530 1570 1046 600 446 94 320 
P47 IPH Female 38.2 3929 315 2874 2302 1517 785 316 139 
P48 IPH Female 30.2 2440 350 1630 1320 848 424 147 163 
P49 IPH Male 50.1 2890 370 2770 2350 1270 942 249 139 
P50 IPH Male 11.9 1660* 320* 1810 1320 796 416 253 199 
P51 IPH Male 10.4 1800* 460* 2730 1100 713 356 300 146 
P52 IPH Female 81.6 8930 860 3930 3152 2727 424 150 393 
P53 IPH Female 28.7 3788 302 5490 877 525 352 99 58* 
P54 IPH Female 52.8 5770 1000 3020 2140 1540 604 513 302 
P55 IPH Male 10.3 3730 350* 2840 2240 909 1160 227 341 
P56 IPH Female 17.3 3010 300* 3010 2468 1355 903 361 151 
P57 IgGSD Female 49.8 4130 580 2600 2132 1482 624 182 260 
P58 IgGSD Female 11.9 3550 460* 4040 2200 1170 722 361 452 
P59 IgGSD Female 21.5 3820 1080 4190 3430 2300 1090 609 304 
P60 IgGSD Female 34.1 2800 650 2700 1660 1100 430 301 172 
P61 IgGSD Female 46.4 3280 890 2920 2316 1559 756 225 208 
P62 IgGSD Female 35.2 7469 747 2241 2960 1810 1020 165 165 
P63 IgGSD Female 34.7 5790 930 3360 2130 1450 568 454 227 
P64 IgGSD Female 42.9 2270 500 1620 2070 1540 498 249 174 
P65 IgGSD Female 57.5 3070 550 2300 1750 1290 437 322 230 
P66 IgGSD Female 42.2 4720 490 1490 1200 909 271 232 483 
P67 IgGSD Male 40.6 2434 667 2240 2120 1290 647 441 323 
P68 IgGSD Female 51.3 2843 202* 1444 1140 881 260 188 87 
P69 IgGSD Female 65.0 6969 481 1362 1140 708 409 41* 163 
P70 IgGSD Female 51.3 4045 502 1772 1520 1050 472 328 185 
P71 IgGSD Female 31.5 7669 327 1374 1060 715 289 206 96 
P72 IgGSD Female 56.4 5766 255 1123 831 550 269 123 157 
P73 IgGSD Female 32.5 3930 550 1420 852 650 308 270 209 
P74 IgGSD Female 46.0 5070 300 1750 1420 910 490 140 175 
P75 IgGSD Female 35.1 6465 172* 1853 1480 982 463 204 167 
P76 IgGSD Male 17.9 3090 460* 1990 1510 856 537 179 279 
P77 IgGSD Male 15.3 1590* 320* 1900 1060 494 494 380 437 
 
*Below age-based reference values. CVID: common variable immunodeficiency, IgGSD: IgG subclass deficiency, IPH: idiopathic primary 





Table S3. Clinical characteristics of the patients. 
 CVID IPH IgGSD 
Infections and infection-related complications    
Recurrent upper respiratory tract infections 32/33 (97.0%) 23/23 (100%) 21/21 (100%) 
Recurrent and/or severe lower respiratory tract infections 25/33 (75.8%) 20/23 (87.0%) 13/21 (61.9%) 
Recurrent gastrointestinal infections 6/33 (18.2%) 3/23 (13.0%) 1/21 (4.8%) 
Bacterial skin infections 2/33 (6.1%) 3/23 (13.0%) 2/21 (9.5%) 
Deep abscesses (organ/muscle) 2/33 (6.1%) 1/23 (4.3%) 0/21 (0%) 
Recurrent or invasive herpes simplex infections 1/33 (3.0%) 1/23 (4.3%) 1/21 (4.8%) 
Recurrent herpes zoster infections 2/33 (6.1%) 3/23 (13.0%) 0/21 (0%) 
Recurrent warts 1/33 (3.0%) 2/23 (8.7%) 0/21 (0%) 
Recurrent fungal infections 1/33 (3.0%) 4/23 (17.4%) 2/21 (9.5%) 
Bronchiectasis on HRCT thorax 13/24* (54.2%) 4/13* (30.8%) 2/12* (16.7%) 
Non-infectious complications    
Unexplained enteropathy 13/33 (39.4%) 7/23 (30.4%) 9/21 (42.9%) 
Benign lymphadenopathy on medical imaging$ 11/33 (33.3%) 3/23 (13.0%) 2/21 (9.5%) 
Lymphocytic interstitial pneumonitis 2/33 (6.1%) 0/23 (0%) 0/21 (0%) 
Granulomata on CT thorax and/or coloscopy 6/32* (18.8%) 0/23 (0%) 0/21 (0%) 
Splenomegaly on abdominal ultrasound 8/28* (28.6%) 1/14* (7.1%) 0/10* (0%) 
Splenectomy 1/33 (3.0%) 0/23 (0%) 0/21 (0%) 
Hepatomegaly on abdominal ultrasound 6/28* (21.4%) 2/14* (14.3%) 0/10* (0%) 
Acute non-infectious hepatitis 2/33 (6.1%) 1/23 (4.3%) 1/21 (4.8%) 
Liver transplantation 1/33 (3.0%) 0/23 (0%) 0/21 (0%) 
Solid organ tumor 3/33 (9.1%) 0/23 (0%) 1/21 (4.8%) 
Autoimmune manifestations 13/33 (39.4%) 3/23 (13.0%) 3/21 (14.3%) 
     - Autoimmune cytopenia 5/33 (15.2%) 1/23 (4.3%) 0/21 (0%) 
     - Inflammatory bowel disease 1/33 (3.0%) 0/23 (0%) 0/21 (0%) 
     - Autoimmune thyroid disease 1/33 (3.0%) 1/23 (4.3%) 1/21 (4.8%) 
     - Rheumatic disease (JIA, RA) 2/33 (6.1%) 0/23 (0%) 1/21 (4.8%) 
     - Pernicious anemia 1/33 (3.0%) 0/23 (0%) 0/21 (0%) 
     - Raynaud phenomenon 1/33 (3.0%) 0/23 (0%) 0/21 (0%) 
     - Sicca syndrome 0/33 (0%) 1/23 (4.3%) 0/21 (0%) 
     - Alopecia 1/33 (3.0%) 1/23 (4.3%) 0/21 (0%) 
     - Vitiligo 1/33 (3.0%) 1/23 (4.3%) 0/21 (0%) 
     - Lichen ruber planus 0/33 (0%) 0/23 (0%) 1/21 (4.8%) 
Other    
Growth delay 5/33 (15.2%) 1/23 (4.3%) 0/21 (0%) 
 
*Missing data (no medical imaging performed). $Cervical, mediastinal and/or abdominal lymph nodes > 1 cm diameter, detected at least twice on 
medical imaging. CVID: common variable immunodeficiency, (HR)CT: (high-resolution) computed tomography, IgGSD: IgG subclass deficiency, 
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Table S4. Most important associations between with clinical features and immunological parameters in patients. 
 PAD with chronic lung disease*  (n=22) 
PAD without chronic lung 
disease* (n=27) P value 
Serum IgG (z-score, mean ± SD) -3.2 ± 1.1 -2.0 ± 1.6 0.005 
Serum IgM (z-score, mean ± SD) -2.2 ± 1.2 -1.0 ± 1.6 0.003 
Serum IgA (z-score, mean ± SD) -2.5 ± 0.6 -1.3 ± 1.7 0.004 
Absolute B cell numbers (z-score, mean ± SD) -1.4 ± 1.6 0.28 ± 2.1 0.021 
IgD-CD27+ memory B cells (z-score, mean ± SD) -1.7 ± 1.5 -0.63 ± 1.1 0.007 
CD21low B cells (z-score, mean ± SD) 5.8 ± 11.7 1.5 ± 5.1 0.016 
 PAD with polyclonal lymphoproliferation$ (n=17) 
PAD without polyclonal 
lymphoproliferation$ (n=60) P value 
Serum IgG (z-score, mean ± SD) -3.6 ± 0.82 -2.0 ± 1.4 <0.001 
Serum IgM (z-score, mean ± SD) -2.1 ± 0.75 -1.3 ± 1.4 0.003 
Serum IgA (z-score, mean ± SD) -2.8 ± 0.38 -1.5 ± 1.7 <0.001 
Naive B cells (z-score, mean ± SD) 1.5 ± 1.3 0.53 ± 1.6 0.01 
IgD-CD27+ memory B cells (z-score, mean ± SD) -1.8 ± 1.1 -0.95 ± 1.4 0.005 
CD21low B cells (z-score, mean ± SD) 6.6 ± 14.1 0.81 ± 3.7 0.037 
Naive CD4+ T cells (z-score, mean ± SD) -1.6 ± 2.1 0.31 ± 1.5 <0.001 
CD4+ RTE (z- score, mean ± SD) -1.18 ± 1.5 0.15 ± 1.3 0.005 
CD4+ TCM cells (z-score, mean ± SD) 1.6 ± 1.6 -0.07 ± 1.4 <0.001 
cTfh cells (z-score, mean ± SD) 3.5 ± 3.7 0.12 ± 2.2 <0.001 
Naive CD8+ T cells (z-score, mean ± SD) -0.61 ± 1.1 0.17 ± 1.2 0.019 
CXCR5 expression on B cells (rMFI, mean ± SD) 44.8 ± 20.4 66.0 ± 22.6 0.002 
CCR7 expression on B cells (rMFI, mean ± SD) 15.0 ± 6.4 20.9 ± 8.9 0.01 
CCR7 expression on cTfh cells (rMFI, mean ± SD) 19.7 ± 6.9 23.9 ± 7.2 0.027 
 CVID with polyclonal lymphoproliferation$ (n=14) 
CVID without polyclonal 
lymphoproliferation$ (n=19) P value 
Serum IgG (z-score, mean ± SD) 3.7 ± 0.82 -2.7 ± 1.5 0.032 
IgD-CD27+IgA+ memory B cells (mean ± SD) 6.3% ± 10.8% 16.6% ± 9.7% 0.002 
Naive CD4+ T cells (z-score, mean ± SD) -1.8 ± 2.2 -0.22 ± 1.9 0.036 
CD4+ TCM cells (z-score, mean ± SD) 1.7 ± 1.7 0.22 ± 1.7 0.032 
cTfh cells (z-score, mean ± SD) 3.9 ± 3.8 0.63 ± 2.8 0.006 
CXCR5 expression on B cells (rMFI, mean ± SD) 42.9 ± 19.4 56.3 ± 14.5 0.045 
 PAD with autoimmunity  (n=19) 
PAD without autoimmunity  
(n=58) P value 
Serum IgA (z-score, mean ± SD) -2.4 ± 1.1 -1.5 ± 1.7 0.012 
Naive CD4+ T cells (z-score, mean ± SD) -0.93 ± 1.76 0.16 ± 1.75 0.012 
CD4+ RTE (z- score, mean ± SD) -0.78 ± 1.3 0.06 ± 1.4 0.033 
CD4+ TCM cells (z-score, mean ± SD) 1.4 ± 1.6 -0.06 ± 1.4 0.001 
cTfh cells (z-score, mean ± SD) 2.8 ± 3.9 0.21 ± 2.2 0.002 
TACI expression on B cells (rMFI, mean ± SD) 166.3 ± 78.7 128.3 ± 67.1 0.052 (ns) 
 CVID with autoimmunity  (n=13) 
CVID without autoimmunity  
(n=20) P value 
CD4+ TCM cells (z-score, mean ± SD) 1.8 ± 1.6 0.20 ± 1.7 0.018 
TACI expression on B cells (rMFI, mean ± SD) 175 ± 64 122 ± 38 0.022 
 IPH with autoimmunity (n=3) 
IPH without autoimmunity  
(n=20) P value 
CD4+ TCM cells (z-score, mean ± SD) 1.2 ± 0.86 0.10 ± 1.1 0.061 (ns) 
 PAD with autoimmune cytopenia  
(n=6) 
PAD without autoimmune 
cytopenia (n=71) P value 
TACI expression on B cells (rMFI, mean ± SD) 213.3 ± 65.4 131.3 ± 68.7 0.003 
 CVID with autoimmune cytopenia  
(n=5) 
CVID without autoimmune 
cytopenia (n=72) P value 
TACI expression on B cells (rMFI, mean ± SD) 217 ± 72 130 ± 41 0.008 
 
*Bronchiectasis, lung granulomata and/or lymphoid interstitial pneumonia. $Benign lymphadenopathy, hepatomegaly, and/or splenomegaly. cTfh: 
circulating follicular helper T, CVID: common variable immunodeficiency, Ig: immunoglobulin, IPH: idiopathic primary hypogammaglobulinemia, ns: 
not significant, PAD: primary antibody deficiency, rMFI: relative mean fluorescence intensity, RTE: recent thymic emigrants, SD: standard 








Figure S1. Absolute white blood cell counts in patients. Absolute white blood cell counts in CVID, 
IPH and IgGSD patients determined in routine lab evalutions. Graphs represent mean ± SD. Cell 
counts were expressed as z-scores to adjust for age. Values normal for age have a z-score between -
2 and 2 (dotted lines). CVID: common variable immunodeficiency, IgGSD: IgG subclass deficiency, 
IPH: idiopathic primary hypogammaglobulinemia. * p≤0.05, ** p≤0.01, *** p≤0.001, ns not significant 
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Figure S2. Representative flow cytometric analysis of B cell subsets in an adult healthy 
control. PBMCs were sequentially gated on lymphocytes (gating out debris and monocytes), single 
cells (gating out doublets) and alive cells (gating out dead cells). B cells were gated as CD19+CD20+ 
in alive cells. Plasma cells were gated as CD138+CD19low in alive cells. Within B cells, transitional 
(trans) B cells were gated as CD24highCD38high, plasmablasts as CD38highCD24-, CD21low B cells as 
CD21lowCD38low, memory (mem) B cells as IgD-CD27+, naive B cells as IgD+CD27-, and marginal zone 
(MZ)-like B cells as IgD+CD27+. Within IgD+CD27+ marginal zone-like B cells, IgM+ marginal zone-like 
B cells were gated based on a Fluorescence Minus One (FMO). Within IgD-CD27+ memory B cells, 







Figure S3. Total B cells, IgD-CD27+IgM+ memory B cells, IgM+IgD+CD27+ marginal zone-like B 
cells, and plasma cells. B cells were gated as CD19+CD20+ and plasma cells as CD138+CD19low in 
alive cells. IgD-CD27+ memory B cells and IgD+CD27+ marginal zone-like B cells were gated within B 
cells. Graphs represent mean ± SD. Plasma cells were expressed as z-scores to adjust for age. 
Values normal for age have a z-score between -2 and 2 (dotted lines). AFM: asymptomatic family 
member, CVID: common variable immunodeficiency, HC: healthy control, IgGSD: IgG subclass 
deficiency, IPH: idiopathic primary hypogammaglobulinemia. * p≤0.05, ** p≤0.01, *** p≤0.001, ns not 
significant (Mann-Whitney test with Bonferonni’s correction for multiple comparisons). 
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Figure S4. TACI, CD40 and HLA-DR expression on B cells. Graphs represent mean ± SD. 
Representative flow cytometric analysis is shown on the left. Full black line represents CVID patient, 
dashed black line represents HC. Relative mean fluorescence intensity (MFI) was calculated by 
dividing the MFI of the positive population (black line) by the MFI of the Fluorescence Minus One 
(FMO) population (gray). AFM: asymptomatic family member, CVID: common variable 
immunodeficiency, HC: healthy control, IgGSD: IgG subclass deficiency, IPH: idiopathic primary 
hypogammaglobulinemia. * p≤0.05, ** p≤0.01, *** p≤0.001, ns not significant (Mann-Whitney test with 
Bonferonni’s correction for multiple comparisons). 































































Figure S5. Representative flow cytometric analysis of naive and memory T cell subsets, DN T 
cells and Treg cells in an adult healthy control. PBMCs were sequentially gated on cells (gating 
out debris), single cells (gating out doublets) and alive cells (gating out dead cells). Total T cells were 
gated as CD3+ in alive cells. αβ T cells were gated as γδTCR- and γδ T cells as γδTCR+ in total T cells. 
CD4+ and CD8+ T cells were gated in αβ T cells. Double negative (DN) T cells were gated as CD4-
CD8- in αβ T cells. In CD4+ and CD8+ T cells, naive cells were gated as CD45RO-CCR7+, central 
memory cells (TCM) as CD45RO+CCR7+, effector memory cells (TEM) as CD45RO+CCR7-, and 
terminally differentiated cells (TEMRA) as CD45RO-CCR7-. In naive CD4+ T cells, recent thymic 
emigrants (RTE) were gated as CD31+. Regulatory T (Treg) cells were gated as CD25+Foxp3+ in CD4+ 
T cells based on Fluorescence Minus One (FMO). Circulating follicular helper T (cTfh) cells were 
gated as CXCR5+CD45RO+ in CD4+ T cells. Within cTfh cells, ICOS+ cTfh cells were gated based on 
FMO. L/D: live/dead marker. 
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Figure S6. T cell subsets: total T cells, αβ  T cells, γδ  T cells, Treg cells, DN T cells, HLA-
DR+CD4+ and HLA-DR+CD8+ T cells. Total T cells were gated as CD3+ in alive cells. αβ T cells were 
gated as γδTCR- and γδ T cells as γδTCR+ in total CD3+ T cells. Regulatory T (Treg) cells were gated 
as CD25+Foxp3+ in CD4+ T cells. Double negative (DN) T cells were gated as CD4-CD8- in αβ T cells. 
HLA-DR+ cells were gated in CD4+ and CD8+ T cells. Graphs represent mean ± SD. AFM: 
asymptomatic family member, CVID: common variable immunodeficiency, HC: healthy control, IgGSD: 
IgG subclass deficiency, IPH: idiopathic primary hypogammaglobulinemia. * p≤0.05, ** p≤0.01, *** 
p≤0.001, ns not significant (Mann-Whitney test with Bonferonni’s correction for multiple comparisons). 
 
 





















































































































































Figure S7. ICOS upregulation on stimulated CD8+ T cells. ICOS and CD69 expression on CD8+ T 
cells stimulated with PHA for 72 hours. CD69 was used as a positive control for T cell activation. 
Graphs represent mean ± SD. Representative flow cytometric analysis is shown on the left. Full black 
line represents CVID patient, dashed black line represents HC. Relative mean fluorescence intensity 
(MFI) was calculated by dividing the MFI of the positive population (black line) by the MFI of the 
Fluorescence Minus One (FMO) population (gray). AFM: asymptomatic family member, CVID: 
common variable immunodeficiency, HC: healthy control, IgGSD: IgG subclass deficiency, IPH: 
idiopathic primary hypogammaglobulinemia. * p≤0.05, ns not significant (Mann-Whitney test with 
Bonferonni’s correction for multiple comparisons). 
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Figure S8. CCR7 expression on T cell subsets. Total T cells were gated as CD3+ in alive cells. 
CD4+ and CD8+ T cells were gated in αβ T cells. Within CD4+ and CD8+ T cells, central memory cells 
(TCM) were gated as CD45RO+CCR7+ and naive cells as CD45RO-CCR7+. In naive CD4+ T cells, 
recent thymic emigrants (RTE) were gated as CD31+. Relative mean fluorescence intensity (MFI) of 
CCR7 was calculated by dividing the MFI of the positive population by the MFI of the Fluorescence 
Minus One (FMO) population. Graph represents mean ± SD. AFM: asymptomatic family member, 
CVID: common variable immunodeficiency, HC: healthy control, IgGSD: IgG subclass deficiency, IPH: 
idiopathic primary hypogammaglobulinemia. * p≤0.05, ** p≤0.01, *** p≤0.001, ns not significant (Mann-


































































































































Figure S9. Correlation between CCR7 expression on total T cells and levels of T cell subsets. 
Total T cells were gated as CD3+ in alive cells. CD4+ and CD8+ T cells were gated in αβ T cells. Within 
CD4+ and CD8+ T cells, naive cells were gated as CD45RO-CCR7+, central memory cells (TCM) as 
CD45RO+CCR7+, effector memory cells (TEM) as CD45RO+CCR7-, and terminally differentiated cells 
(TEMRA) as CD45RO-CCR7-. In naive CD4+ T cells, recent thymic emigrants (RTE) were gated as 
CD31+. Circulating follicular helper T (cTfh) cells were gated as CXCR5+CD45RO+ in CD4+ T cells. All 
naive and memory T cell subsets, including cTfh cells, were expressed as z-scores to adjust for age. 
CCR7 expression on total T cells is the relative mean fluorescence intensity (MFI) of CCR7 on total T 
cells, calculated by dividing the MFI of the positive population by the MFI of the Fluorescence Minus 
One (FMO) population. Correlations were calculated with Spearman Rank Correlation.  
 

























































































p<0.001 p<0.001 p<0.001 p<0.001 p=0.001 
p<0.001 p<0.001 p=0.23 p<0.001 
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Figure S10. Gating strategy for innate immune cell subsets in an adult healthy control. PBMCs 
were sequentially gated on cells (gating out debris), single cells (gating out doublets) and alive cells 
(gating out dead cells). Lymphocytes and monocytes were gated on SSC and CD14. B cells were 
gated as CD19+HLA-DR+ in lymphocytes; thereafter gating was continued on the NOT-gate. T cells 
were gated as CD56-CD3+, natural killer (NK) cells as CD3-CD56+ and natural killer T (NKT) cells as 
CD3+CD56+ in CD19- lymphocytes. NK cell subsets were determined by their relative expression of 
CD56 and CD16. Invariant NKT (iNKT) cells were gated as invariant TCR (TCR Vα24-Jα18) positive 
in NKT cells. Dendritic cells (DCs) were gated as CD4+HLA-DR+ in non-T-non-NK cells. Within DCs, 
conventional DCs (cDCs) were gated as CD11c+CD123- and plasmacytoid DCs (pDCs) as 







Figure S11. Unsupervised computational clustering analysis: hierarchical clustering and 
heatmap. Unsupervised clustering of the study cohort based on 46 flow cytometric parameters. Study 
subjects are stratified according to diagnosis and patients are also stratified according to clinical 
phenotype (infections only versus non-infectious complications). Hierarchical clustering, plotted in the 
dendrogram on the left hand side, shows that subjects do not cluster according to diagnosis or clinical 
phenotype. The heatmap of log-transformed flow cytometric data does not reveal subgroups among 
patients nor distinguish patient from AFM or HC. AFM: asymptomatic family member, cTfh: circulating 
follicular helper T, CVID: common variable immunodeficiency, DCs: dendritic cells, DN T: double 
negative T, HC: healthy control, IgGSD: IgG subclass deficiency, IPH: idiopathic primary 
hypogammaglobulinemia, MFI: mean fluorescence intensity, NK: natural killer, RTE: recent thymic 
emigrants, TCM: central memory T, TEM: effector memory T, TEMRA: effector memory RA T, Treg: 
regulatory T. 
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4 GENETIC TESTING IN PATIENTS WITH PRIMARY ANTIBODY 
DEFICIENCIES: OVERVIEW OF THE GHENT COHORT 
 
4.1 Introduction 
A human has about 20,000 to 25,000 protein-coding genes, constituting 1-2% of the entire 
genome (i.e. the complete set of genetic material).1 The non-protein-coding part of the 
genome (~98%) also has important biological functions, such as regulation of gene 
expression. However, the exact function of non-coding DNA remains largely elusive. In 
medicine, genetic testing involves the analysis of genetic material to obtain information 
related to an individual’s disease status. Cytogenetic techniques are used to screen for 
chromosomal alterations, and molecular genetic techniques to analyze DNA sequence 
alterations in genes (i.e. mutation analysis).1  
Genetic testing in primary immunodeficiencies (PIDs) has, so far, mainly focused on DNA 
sequence alterations in protein-coding genes.2 Since the 1980s, Sanger sequencing has 
been the gold standard for DNA-based screening of disease genes.3 The past decade, 
massively parallel or next-generation sequencing (NGS) technologies have been developed, 
enabling the simultaneous analysis of millions of DNA sequences.4 Like for other genetically 
determined disorders, NGS technologies have facilitated the discovery of numerous novel 
PID-associated genes.2 Still, little progress has been made in patients with common variable 
immunodeficiency (CVID) and related primary antibody deficiencies (PADs) (see also 
chapter 1, section 1.6).5,6 
The goal of this chapter is to outline the types of genetic testing that have, so far, been 
performed in the Ghent PAD cohort of 70 index patients and the results obtained by each 
approach. In addition, we propose a strategy for genetic testing in patients with CVID and 
related antibody disorders. 
 
4.2 Methods 
4.2.1 Recruitment of the study cohort 
Seventy index patients with PADs were recruited between October 2013 and November 
2015 at the pediatrics, adult hematology and adult pulmonology departments at Ghent 
University Hospital.7 The definitions of the clinical diagnoses were determined before start of 
recruitment and, if possible, based on the diagnostic criteria formulated by the European 
Society for Immunodeficiencies (ESID) and the Pan-American Group for Immunodeficiency 
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(PAGID) in 1999 (Table 1) (see also Chapter 1, section 1.3).8 In addition, affected and 
unaffected family members of the index patients were also included in the study. 
The study was approved by the ethical committee of Ghent University Hospital (2012/593). 
All subjects (or their parents in case of pediatric subjects) provided written informed consent 
to participation in the study, in accordance with the Helsinki Declaration of 1975. 
 
Table 1. Diagnostic criteria for the Ghent cohort of PAD patients. 




Serum IgG at least 2 SD below mean for age 
AND serum IgA and/or IgM at least 2 SD below mean for age 
AND poor response to protein and/or polysaccharide vaccines 





Serum IgG at least 2 SD below mean for age 
AND not fulfilling CVID criteria  
AND other causes of antibody deficiency have been excluded*   
9 
IgG subclass deficiency 
(IgGSD) 
Serum IgG2 and/or IgG3 at least 2 SD below mean for age 
AND normal total serum IgG and serum IgM 
AND normal or decreased serum IgA 
AND good or poor response to protein and/or polysaccharide vaccines 
AND other causes of antibody deficiency have been excluded*   
10 
Selective IgM deficiency 
(sIgMD) 
Serum IgM at least 2 SD below mean for age 
AND normal serum IgG and IgA  
AND good response to protein and polysaccharide vaccines 
AND other causes of antibody deficiency have been excluded*   
11 
Selective IgA deficiency 
(sIgAD) 
Serum IgA at least 2 SD below mean for age 
AND normal serum IgG and IgM  
AND good response to protein and polysaccharide vaccines 
AND other causes of antibody deficiency have been excluded*   
8,12 
Agammaglobulinemia Less than 2% circulating B cells  
AND onset of recurrent bacterial infections before 5 years of age  
AND serum IgG, IgA and IgM at least 2 SD below mean for age 
AND poor response to protein and/or polysaccharide vaccines 
AND other causes of antibody deficiency have been excluded*   
8,13 
Syndromic PAD Serum IgG, IgA and/or IgM at least 2 SD below mean for age 
AND congenital malformations, dysmorphic features and/or other pheno-
typical abnormalities not directly associated with the immune defect 
AND secondary causes of antibody deficiency have been excluded*   
14 
 
All laboratory parameters were measured at least twice. *Defined by ESID/PAGID 1999.8 Ig: immunoglobulin, 
PAD: primary antibody deficiency, Ref.: References, SD: standard deviations. 
 
4.2.2 DNA extraction 
Blood samples were retrieved from all subjects included in the study. Genomic DNA (gDNA) 
was isolated from whole blood leukocytes using the QIAamp DNA Mini Kit (QIAGEN), Gentra 
Puregene Blood Kit (QIAGEN), or Wizard Genomic DNA Purification Kit (Promega), 
according to manufacturer’s instructions.  
The QIAamp procedure yields lower amounts of gDNA (~nanograms) typically used to 
sequence a small number of targets after polymerase chain reaction (PCR)-based 
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enrichment. The Gentra Puregene and Promega methods provide higher amounts of gDNA 
(~micrograms) as needed for whole exome sequencing (WES). 
 
4.2.3 Polymerase chain reaction (PCR)-based target enrichment 
To analyze the DNA sequence of a gene or target of interest, this sequence needs to be 
amplified (i.e. enriched) before genetic testing can be performed. PCR is a commonly used 
technique to generate millions of copies of a particular DNA sequence.1 To selectively enrich 
the DNA segment of interest, the PCR technique makes use of forward and reverse primers. 
Primers are custom-made oligonucleotide sequences (~20 base pairs [bp]) designed in such 
a manner that they specifically flank each side of the target DNA region.1 In this study, 
primers for amplification and sequencing were manually designed by use of Primer3Plus 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/)15, based on reference DNA 
sequences obtained from UCSC Genome Browser (https://genome.ucsc.edu).  
Singleplex PCR reactions were performed according to an in-house optimized (“generic”) 
protocol.16 In summary, each PCR reaction mixture consisted of 2.5 µL gDNA template (20 
ng/µL), 2.5 µL amplification primers (forward and reverse primer mixed, 2 µM), and 5 µL 
KAPA2G Robust Hotstart Ready Mix (KAPA Biosystems). Next, PCR reactions were run on 
a MJ Research PTC-200 Thermal Cycler (MJ Research Inc.): an initial denaturation step at 
95°C for 3 min; 35 cycles of (1) denaturation at 95°C for 15 sec, (2) annealing at 60°C for 10 
sec, and (3) extension at 72°C for 15 sec; and a final extension step at 72°C for 1 min. 
Afterwards, amplification specificity and quality of the PCR product were assessed using 
automated capillary electrophoresis (LabChip GX, PerkinElmer).  
PCR-based target enrichment is most suitable for sequencing of a small number of genes, 
and was therefore used in combination with Sanger sequencing or NGS-based targeted 
resequencing (see below). 
 
4.2.4 Sanger sequencing 
DNA sequencing entails the determination of the exact nucleotide composition of the DNA 
segment of interest. The sequencing method developed by Frederic Sanger (Sanger 
sequencing) is based on chain termination by the random incorporation of fluorescently-
labeled dideoxynucleotides during a classical PCR reaction.3 After several cycles of 
denaturation, annealing and elongation, the final sequencing product is a mixture of DNA 
fragments terminated at different lengths. These fragments are separated according to their 
length by means of capillary electrophoresis, after which a laser detects the fluorescent 
labels of the incorporated dideoxynucleotides at the end of each fragment. The generated 
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output is a sequence read (electropherogram) showing the exact nucleotide composition of 
the target of interest. By comparing this output to the human reference sequence, nucleotide 
variations (e.g. pathogenic mutations, benign variants) can be identified.1 
In this study, PCR products of the prior enrichment step were enzymatically purified with 
Exonuclease I and Antarctic phosphatase (both New England BioLabs Inc.). Purified PCR 
products were then Sanger sequenced using the BigDye Terminator v3.1 Cycle Sequencing 
kit (Applied Biosystems) on a 3730xl DNA Analyzer (Applied Biosystems). Sequence reads 
were analyzed with SeqScape v2.5 (ThermoFisher Scientific). 
 
4.2.5 Next-generation sequencing (NGS) 
4.2.5.1 Sequencing technology 
Several NGS technologies have been developed in recent years. In this thesis, we used the 
Illumina sequencing technology known as sequencing by synthesis, which is the most widely 
adopted NGS technique.17 gDNA first undergoes several preparation steps before it can be 
sequenced (i.e. library preparation). In particular, DNA is randomly fragmented and known 
adaptor sequences are ligated at both ends of each DNA fragment. The adaptor-ligated DNA 
fragments are then amplified with PCR using primers that carry a specific index. With this 
index, the DNA fragments can later be traced back to the original sample when fragments of 
different samples are sequenced simultaneously. Next, the DNA library is denatured and 
applied to a glass flow cell of the sequencing instrument. The adaptors at the end of the DNA 
fragments hybridize with complementary oligonucleotides on the flow cell, followed by 
multiple cycles of so-called bridge amplification.17 Single nucleotides are detected continually 
as they are incorporated into the growing DNA strands. To enable this, Illumina has designed 
fluorescently labeled reversible terminator nucleotides. During each sequencing cycle, the 
fluorescent signals of the newly incorporated nucleotides are detected. Afterwards, the 
fluorophore and blocking site of the nucleotides are cleaved and washed away, allowing the 
incorporation of new nucleotides in the next cycle. The final output consists of a multitude of 
sequencing reads, which are aligned or mapped to the human reference genome and 
subsequently analyzed using specific software tools. “Read depth” refers to the number of 
sequence reads that include a particular nucleotide. “Coverage” is sometimes used as a 
synonym for read depth, but may also refer to the percentage of target regions that is 
sequenced to a preset read depth (e.g. 98% of target regions have a minimal read depth of 
20x).2 
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4.2.5.2 NGS-based targeted resequencing 
NGS technologies can be used to sequence a selected panel of genes or targets, a method 
known as targeted resequencing. For this, the selected genes of interest need to be isolated 
and enriched. In-house, a platform for targeted resequencing was developed using 
singleplex PCR for target enrichment.16 In brief, targets of different samples (individuals) 
were first enriched with singleplex PCR as explained in section 4.2.3. Next, several pooling 
steps, DNA fragmentation and library preparation were performed (Nextera XT DNA Library 
Preparation Kit, Illumina). Finally, sequencing was done on a MiSeq instrument (Illumina).  
 
4.2.5.3 Whole exome sequencing (WES) 
Protein-coding genes consist of exons and introns. Exons contain the actual code for protein 
synthesis whereas introns are spliced out during RNA maturation. Whole exome sequencing 
(WES) aims to sequence all coding exons (collectively called exome) in a single person. The 
exonic regions are enriched via a “capture” procedure.18 In particular, adaptor-ligated DNA 
(see section 4.2.5.1) is hybridized with oligonucleotide probes that bind or capture the exonic 
regions of the DNA fragments. These probes are then pulled-down by specific beads, taking 
the captured exonic sequences with them. Next, the captured regions are, again, amplified 
with PCR, followed by massively parallel sequencing. The main limitation of the capture-
based enrichment method is that not all exons are sufficiently covered, especially those with 
a high GC content. Furthermore, off-target capturing is often seen for highly homologous 
regions.16  
In this thesis, whole exome enrichment or capturing was performed with SureSelectXT 
Human All Exon (+/-UTR) kits (Agilent Technologies). Massively parallel sequencing (paired-
end 150 cycles) was performed on a NextSeq 500 (Illumina). 
 
4.2.5.4 Analysis of NGS data 
Read mapping against the human genome reference sequence (NCBI, GRCh37), and post-
mapping duplicate read removal, quality-based variant calling and coverage analysis were 
performed with CLC Genomics Workbench v6.0.4 (CLC bio). Called variants with read depth 
≥ 3 were annotated with Alamut Batch (Interactive Biosoftware). Only variants with 
population frequencies less than 10% were considered, according to public databases NCBI 
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/), NHLBI Exome Sequencing Project - 
Exome Variant Server (http://evs.gs.washington.edu/EVS/), ExAC Browser 
(http://exac.broadinstitute.org/), and 1000 Genomes Project Browser 
(http://browser.1000genomes.org/). Variants were further prioritized based on allele 
frequency, in silico pathogenicity prediction scores (e.g. SIFT, PolyPhen2, MAPP, 
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MutationTaster, Grantham distance, Align GVGD), nucleotide and amino acid conservation 
scores (e.g. phyloP, PhastCons), and biological relevance.19 Both Mendelian and non-
Mendelian inheritance patterns were taken into account. Afterwards, variants of interest were 
further evaluated using Alamut Visual mutation interpretation software v2.7 rev. 1 (Interactive 
Biosoftware), Ingenuity Variant Analysis (QIAGEN, 2015 Release Spring), CADD scores v1.3 
(http://cadd.gs.washington.edu/home), genome Aggregation Database (gnomAD) Browser 
(http://gnomad.broadinstitute.org), literature search, segregation analysis in available family 
members, and frequency in an in-house database containing variants of more than 1000 
exomes at time of analysis.  
Validation of variants and segregation analysis were performed by means of Sanger 
sequencing (see section 4.2.4). 
 
4.2.6 Microarray-based comparative genomic hybridization (array CGH) 
Microarray-based comparative genomic hybridization (array CGH) is a technique to detect 
copy number variations (CNVs), i.e. deletions or duplications of DNA regions > 1 kb, on a 
genome-wide level.1 Patient and control gDNA are fluorescently labeled with a different color. 
After mixing patient and control samples, DNA is hybridized to known oligonucleotides fixed 
on an array. For each location on the array, fluorescent signals of patient and control are 
compared, allowing the identification of deleted or duplicated regions in the patient.1   
In this thesis, we used an 180K oligonucleotide array with an average genome-wide 
resolution of 100 kb (SurePrint G3 Human CGH Microarray Kit, Agilent Technologies). 
Hybridizations were performed according to manufacturer's instructions. Results were 
analyzed using arrayCGHbase.20 
 
4.2.7 Homozygosity mapping 
Homozygosity mapping or identity-by-descent (IBD) mapping is used to determine large 
homozygous genomic regions in patients with a consanguineous background, based on the 
assumption that the causal mutation will be homozygous and located in a run of 
homozygosity identical by descent.21 Homozygous regions can be distinguished by use of a 
genome-wide single nucleotide polymorphism (SNP) chip array. Patient gDNA is fragmented 
and hybridized on a chip array coated with oligonucleotides. These oligonucleotides 
correspond to thousands of SNPs equally spread out over the entire genome. Next, the 
genotype of each SNP (hetero- or homozygous) is determined, enabling the localization of 
larger homozygous regions within the patient genome. To narrow down the number and 
length of the homozygous regions of interest, homozygosity mapping can also be performed 
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in affected and/or non-affected siblings of the patient. Importantly, SNP chip arrays can also 
be used for CNV analysis.1 
In this thesis, the HumanCytoSNP-12 BeadChip platform (Illumina) was used for 
homozygosity mapping in patients from consanguineous families. Homozygous regions 
larger than 1 Mb were retained for further analysis. 
 
4.3 Results 
4.3.1 The Ghent PAD cohort: characteristics and genetic approach 
The Ghent PAD cohort consisted of 70 index patients including 33 males and 37 females. 
About 90% of the index patients were clinically diagnosed with CVID (n=28), idiopathic 
primary hypogammaglobulinemia (IPH) (n=19), or IgG subclass deficiency (IgGSD) (n=16). 
The remaining 10% included selective IgM deficiency (sIgMD) (n=1), selective IgA deficiency 
(sIgAD) (n=1), agammaglobulinemia (n=1) and syndromic PAD (n=4). All patients were 
Caucasian and from European or North African descent. The average age at time of 
inclusion was 31.8 years (range 22 months to 86 years). One patient was born to healthy 
consanguineous parents. Twenty-one patients (30%) had a family history suggestive of PID; 
symptomatic family members were available in 16 out of these 21 cases.  
In total, 98 family members of the index patients were also included in the study: 82 (84%) 
first-degree (parents, siblings, children) and 16 (16%) second- and third-degree 
(grandparents, aunts, uncles, first cousins) relatives. Twenty-five out of 98 (25.5%) included 
family members were given a clinical diagnosis of PAD, which were similar to the diagnoses 
of the corresponding index patients. 
 
As a first approach, candidate genes based on the patients’ phenotype were screened by 
means of Sanger sequencing. Furthermore, array CGH was used to screen for large (> 100 
kb) CNVs. Once NGS technologies became available in-house, the genetic testing toolbox 
was expanded with targeted resequencing of selected genes and WES. In the following 
paragraphs, we aimed to outline the types of genetic testing that were, so far, performed in 
our cohort and the results obtained by each approach. It is important to note that some 
types of genetic testing were only performed in a subset of patients, and that genetic 
analyses are still ongoing in this cohort. Detailed discussion of the mentioned genes and 




4.3.2 Array CGH 
Array CGH (resolution ~100 kb) is a valuable technique to screen for large CNVs, which 
would be missed using PCR-based approaches (Sanger sequencing, targeted NGS) or 
WES. In our cohort, array CGH was performed in 31 index patients, including all four patients 
with syndromic PAD.  
 
Patient 1 had a heterozygous deletion involving the distal section of the long arm of 
chromosome 18 (Table 2), rendering him a genetic diagnosis of 18q deletion syndrome.22 
The patient presented with antibody deficiency, recurrent infections, intellectual disability and 
other syndromic features (Table 3). Variable degrees of antibody deficiency were known to 
be associated with 18q deletion syndrome, and both the immunological and extra-
immunological phenotype of the patient matched the underlying genotype (Table 3).22-24  
Array CGH findings in other patients were considered not to be pathogenic by experienced 
clinical geneticists (data not shown). Hence, the array CGH approach had a success rate of 
3% (1/31) (Figure 1, left graph). 
 
 
Figure 1. Comparison of three methods of genetic testing in the Ghent PAD cohort. Microarray-
based comparative genomic hybridization (array CGH) was performed in 31 index patients, screening 
of candidate genes in all 70 index patients (2 to 5 genes per patient), and whole exome sequencing 
(WES) in 13 index patients. The percentage of tested patients for which the specified result was 
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4.3.3 Candidate gene approach 
Based on the patients’ phenotypes, selected genes were screened using either Sanger 
sequencing or NGS-based targeted resequencing: NFKB1, NFKB2, SAP, XIAP, PIK3CD, 
PIK3R1, CTLA4, RAG1, RAG2, GATA2, BTK, IGLL1, IKZF1, and RNU4ATAC. Sequencing 
covered all coding exons and intron-exon borders, as well as the unique noncoding exon of 
RNU4ATAC and intron 5 of GATA2 that had been previously implicated in disease. A total of 
162 genes were sequenced in the 70 index patients (minimum 2, maximum 5 and average 
2.3 genes per patient). The candidate gene approach revealed four disease-causing 
mutations, meaning a clinical detection rate of 5.7% (4/70) (Figure 1, middle graph).  
 
Patient 2 was a 22-month-old boy born to healthy non-consanguineous parents. He was 
identified with a known pathogenic missense variant in BTK, located on the X chromosome 
(Table 2). BTK is a key molecule in early B cell development and accounts for 85% of 
patients with agammaglobulinemia.27 The here-identified mutation disrupts a highly 
conserved residue in the catalytic kinase domain of BTK, resulting in loss of protein function 
despite normal protein expression.28,29 The patient presented with a typical laboratory 
phenotype of X-linked agammaglobulinemia, although he had an unusually mild clinical 
course (Table 3). The mother was an unaffected carrier of the mutant BTK allele. 
Patient 3 had a history of atypical acute myeloid leukemia (AML) in childhood and post-AML 
perseverance of panhypogammaglobulinemia and B cell loss (Table 3). The latter initially 
gave her a tentative diagnosis of CVID. However, she also had reduced NK cells and 
monocytes (Table 3), which prompted us to sequence GATA2. GATA2 is a transcription 
factor important for early differentiation of hematopoietic cells in the bone marrow.27 In case 
of pronounced antibody defects, GATA2 deficiency can show considerable phenotypical 
overlap with CVID.5 Moreover, there had been previous reports on GATA2 mutations in 
patients with a prior diagnosis of CVID.30 Indeed, in patient 3, we detected a heterozygous de 
novo mutation in the regulatory region of intron 5 known to cause GATA2 deficiency (Table 
2).31,32  
In patient 4, an adult female with IPH and autoimmune manifestations (Table 3), we found a 
novel heterozygous missense variant in NFKB1 (Table 2). The NFKB1 variant was also 
detected in one of her two sons (11 years) and in her mother (70 years), although neither of 
them displayed clinical signs of immune deficiency. Interestingly, immunological laboratory 
assessment demonstrated IgA deficiency in the mutation-carrying son and IgG deficiency in 
the mother. The asymptomatic wild type son had no laboratory abnormalities. Autosomal 
dominant inheritance with incomplete penetrance as well as variable expressivity and 
variable age of onset had been previously described in NFKB1 kindreds.33 Altogether, the 
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here-reported novel heterozygous NFKB1 variant was strongly suggestive to be disease-
causing for the following reasons: in silico pathogenicity predictions for the variant were 
strong (Table 2), the index patient’s phenotype was comparable to that of previously 
published NFKB1 patients (Table 3)33, and the variant segregated with the laboratory 
phenotype over three consecutive generations. Functional validation studies will be planned 
in the future. 
Male index patient 5 and his younger sister were both diagnosed with CVID in early 
childhood. With aging, however, syndromic features gradually became more conspicuous. In 
particular, the combination of antibody deficiency, spondyloepiphyseal dysplasia and retinal 
dystrophy in the male index patient raised a tentative diagnosis of Roifman syndrome (Table 
3). This was later confirmed by the detection of compound heterozygous variants in the 
noncoding RNA gene RNU4ATAC (Table 2).34 The unaffected parents each carried one of 
the RNU4ATAC variants. We elaborate on the siblings with RNU4ATAC-associated Roifman 
syndrome in Chapter 5. 
 
4.3.4 Genome-wide approach using WES 
WES was performed in 13 index patients: 9 patients with CVID, 2 patients with IPH, and 2 
patients with syndromic PAD initially diagnosed as CVID. These patients were selected for 
WES because they fulfilled at least one of the following criteria: early disease onset, signs of 
immune dysregulation such as autoimmunity, positive family history of PAD, and/or 
consanguineous parents.5 To facilitate variant analysis, WES was also performed in 27 
(symptomatic and asymptomatic) family members of the 13 selected index patients.  
With this approach, we found disease-causing variants in two out of 13 index patients (15%) 
and disease-modifying variants in four additional index patients (31%) (Figure 1, right graph).  
 
Patient 6, one of monozygotic twins, was found to have a novel heterozygous variant in 
KMT2A causing Wiedemann-Steiner syndrome (Table 2).35 The heterozygous KMT2A 
variant was also present in the other twin as well as in the mother. Similar to the siblings with 
RNU4ATAC-associated Roifman syndrome, the twins with KMT2A-associated Wiedemann-
Steiner syndrome presented with a CVID-like phenotype in early childhood with syndromic 
features being initially less evident (Table 3). The mutation-carrying mother demonstrated 
congenital anomalies of the urogenital tract, recurrent respiratory tract infections, 
undetectable IgM serum levels and reduced switched memory B cells. This family is further 
discussed in Chapter 5. 
We also identified a novel heterozygous variant in IKZF1, a gene only very recently 
associated with CVID (Table 2).36 The variant was not only present in patient 7 and her 
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younger sister who both had a CVID-like phenotype (Table 3), it was also shared by the 
asymptomatic mother. In Chapter 6, we provide evidence for the pathogenicity of the novel 
IKZF1 variant found in this family. 
 
In 4 of the 11 unsolved exomes (i.e. exomes in which we did not find a disease-causing 
variant), we found known disease-modifying variants: 2 patients had variants in 
TNFRSF13B (encoding TACI) and 2 other patients in TNFRSF13C (encoding BAFF-R) 
(Figure 1, right graph). All four patients were clinically diagnosed with CVID (Table 3, patients 
8-11). As explained in chapter 1, section 1.6.2.1, variants in TNFRSF13B and TNFRSF13C 
are by themselves not sufficient to establish disease but are considered to be modifier 
variants contributing to CVID.5 Patients 8 and 9 were heterozygous for the known 
p.Cys104Arg variant in TNFRSF13B. Patient 10 and patient 11 were heterozygous and 
homozygous, respectively, for the known p.Pro21Arg variant in TNFRSF13C (Table 2).37-39 
Thus far, no (likely) pathogenic variants could be identified in these four patients.  
 
In 3 other unsolved exomes we identified novel candidate disease-causing genes: 
GTF3A, TAB1 and RGL2 (Figure 1, right graph). Compound heterozygous variants in GTF3A 
were uncovered in two siblings manifesting a CVID-like phenotype. TAB1 was found in a 
CVID/IPH pedigree showing autosomal dominant inheritance with incomplete penetrance 
and variable expressivity; and we recently identified a second family in our cohort with 
heterozygous mutations in TAB1. Finally, in a patient with IPH born to consanguineous 
parents, a homozygous variant in RGL2 was revealed by combining WES with homozygosity 
mapping. In the latter patient, homozygous regions larger than 1 Mb were identified and used 
to facilitate WES variant filtering. For all three novel candidate disease-causing genes, there 
is strong in silico and genetic evidence of pathogenicity. Functional validation studies are 
currently ongoing, and are discussed in Chapter 7 for GTF3A.  
 
Finally, in the 4 remaining unsolved exomes (4/11, 31%) (Figure 1, right graph), we did not 
detect known disease-modifying variants or novel candidate disease-causing genes. Sanger 
sequencing of insufficiently covered CVID-associated genes was also negative. Importantly, 
one of these exomes belonged to the patient with RNU4ATAC-associated Roifman 
syndrome described above (patient 5). When WES was performed in patient 5, no gene had 
been associated with this syndrome and the noncoding RNA gene RNU4ATAC was not 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Together, disease-causing mutations were, so far, found in 7 out of 70 index patients (10% of 
the cohort): two patients clinically diagnosed with CVID, one with IPH, one with 
agammaglobinemia and three with syndromic PAD (Figure 2A). Besides unaffected carriers 
of recessive alleles, the disease-causing mutations were also identified in four symptomatic 
family members as well as in three family members without PAD-associated clinical features 
(Figure 2B). In four additional index patients, WES revealed variants in TNFRSF13B 
(encoding TACI) or TNFRSF13C (encoding BAFF-R), considered to be modifier genes 
contributing to CVID.5 Furthermore, we discovered three novel candidate disease genes by 
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Figure 2. Overview of the Ghent PAD cohort and the identified disease-associated variants. (A) 
The Ghent PAD cohort of 70 index patients was divided over 7 different clinical diagnoses. Genes in 
which disease-associated variants were identified, are indicated on the graph per clinical diagnosis. 
PAD: primary antibody deficiency, CVID: common variable immunodeficiency, IPH: idiopathic primary 
hypogammaglobulinemia, IgGSD: IgG subclass deficiency, sIgMD: selective IgM deficiency, sIgAD: 
selective IgA deficiency, 18q del: 18q deletion. (B) 98 family members of the index patients were 
included in the study, of which 25 were symptomatic and diagnosed with a form of PAD. Relatives in 
which disease-causing variants were identified, are indicated on the graph. Unaffected carriers of 















100% (1/1): BTK 
75% (3/4): 18q del,  
RNU4ATAC, KMT2A 
5% (1/19): NFKB1 
7% (2/28): GATA2, IKZF1 
14% (4/28): TNFRSF13B, TNFRSF13C 
symptomatic family members (n=25) 
asymptomatic family members (n=73) 
disease-causing variants 
4% (3/73): NFKB1, IKZF1 





4.4 Proposed strategy for genetic testing in CVID and related disorders 
At the start of this doctoral research project, the technologies used to obtain a genetic 
diagnosis in PID patients had come at a turning point. Up to 2012-2013, the most commonly 
used method was Sanger sequencing of one or more candidate genes based on the patient’s 
phenotype. However, this was a very time consuming and expensive approach with relatively 
low success rates.40 Since then, the implementation of NGS technologies in genetics labs 
worldwide has drastically changed the PID landscape (see chapter 1, section 1.2.1.1).2 In 
brief, NGS-based methods as targeted resequencing of gene panels and WES allowed for 
large numbers of genes to be screened simultaneously, increasing the diagnostic success 
rate in PID patients.2,40 In parallel, the use of NGS technologies in research setting has 
greatly facilitated the discovery of novel PID-causing genes, which allows for more patients 
to receive a genetic diagnosis.2 However, with the discovery of numereous new genes over 
the past few years, it has become clear that many monogenic PIDs do not obey Mendelian 
laws of inheritance, showing variable expressivity and even incomplete penetrance. For 
CVID and CVID-like disorders, the situation is even more complex because, since 2015-
2016, it is increasingly believed that the majority of these patients have a polygenic or 
multifactorial rather than a monogenic etiology (see chapter 1, section 1.6).5 Altogether, this 
makes it difficult to develop guidelines for the genetic workup in CVID(-like) patients, both 
from a clinical and research point of view. 
 
Based on our experience from the Ghent cohort, we propose a workflow for genetic 
testing in patients with CVID and related antibody disorders in whom a monogenic 
cause is suspected, applicable in both a clinical and research setting (Figure 3). As 
mentioned above, a monogenic cause is more probable in case of early disease onset, 
features of immune dysregulation such as autoimmunity/inflammation, a positive family 
history, and/or consanguinity.5,6 First, we recommend low-cost screening of CNVs by means 
of array CGH in all patients (Figure 3). Although disease-causing CNVs have, so far, not 
often been detected in CVID(-like) patients, they should be excluded. Homozygosity mapping 
is the preferred approach in consanguineous families, and our SNP chip array-based method 
can also be used for CNV analysis (Figure 3). Next, targeted sequencing of a selected set of 
genes can be useful if the patient’s phenotype is typical for a limited number of specific 
genotypes (Figure 3).2 This is, however, rarely the case. NGS-based gene panels enable us 
to screen all PID-causing genes at the same time, but these are very hard to keep up to date 
because of the unseen pace at which new genes are discovered (Figure 3).2 Furthermore, 
gene panels limit the discovery of new disease-causing genes making them less attractive 
for researchers. Therefore, WES is currently the most cost-effective approach both from a 
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clinical and research point of view (Figure 3).2 Whole genome sequencing (WGS) is not yet 
widely available, but has several technical advantages over WES and also allows for more 
reliable identification of structural variants including CNVs.2 As the costs for WGS are going 
down, this technique will most likely replace the combined array CGH - WES approach in the 









Figure 3. Flowchart for genetic testing in patients with CVID and related antibody disorders in 
whom a monogenic cause is suspected. Microarray-based comparative genomic hybridization 
(array CGH) is recommended as a first, low-cost, step to screen for copy number variations (CNVs). In 
patients born to consanguineous parents, homozygosity mapping (also called autozygosity mapping or 
identity-by-descent (IBD) mapping) is preferred. If generated using SNP chip arrays, IBD data can also 
be used for analysis of CNVs, omitting the need for array CGH. If a genetic diagnosis cannot be 
obtained by a specific approach, proceed to the next step in the flowchart up until whole exome 
sequencing (WES). WES data can be filtered against gene lists to narrow down the number of 
variants. Alternatively, all variants can be explored. Variants identified with NGS-based techniques are 
usually confirmed using Sanger sequencing. Novel variants or genes need to be functionally validated 
to prove their causality. Note that this flowchart can be extended to all patients with primary 
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4.5 Discussion 
So far, genetic testing of the Ghent PAD cohort rendered a genetic diagnosis in 7 out of 70 
index patients (10%). Three of those 7 patients had a syndromic PAD, suggesting that the 
presence of extra-immunological features facilitates the identification of the underlying 
genetic defect.14 In our cohort, a genetic diagnosis could be given to 3 of the 4 syndromic 
PAD patients (75%): 18q deletion syndrome, RNU4ATAC-associated Roifman syndrome and 
KMT2A-associated Wiedemann-Steiner syndrome. Furthermore, our cohort counted one 
male patient with agammaglobulinemia. Sequencing of the X-linked gene BTK, the most 
obvious candidate gene in that patient, provided a definitive molecular diagnosis.  
Ninety percent of the Ghent PAD cohort (n=63) consisted of patients clinically diagnosed with 
CVID or the related disorders IPH and IgGSD. Within that group, disease-causing variants 
could only be discerned in 3 patients (~ 5%), namely heterozygous variants in GATA2, 
NFKB1, and IKZF1. This was markedly lower than what was reported in literature, where 
disease-causing variants can be identified in up to 15% of patients.6,41 However, in our 
cohort, WES has so far only been performed in a small number of patients and future 
research is likely to recognize disease-causing variants in additional patients. Moreover, 
CVID(-like) patients reported in literature are often preselected based on more severe 
phenotypes, which increases the probability of detecting a monogenic cause.5,6 
The past years, an NGS-driven revolution has taken place in the field of PID that resulted in 
the discovery of numerous novel disease genes and entities.2 Unfortunately, for many 
disease entities, a phenotype-genotype correlation is virtually non-existent.2 This was also 
noted in our cohort: sequencing of selected genes based on patients’ phenotypes had a low 
yield of about 5.7%. In contrast, WES provided a conclusive genetic diagnosis in 15% of 
tested patients. Furthermore, it is clear that non-Mendelian inheritance patterns such as 
variable expressivity and incomplete penetrance are the rule rather than the exception in the 
majority of PIDs. In the Ghent PAD cohort, this was illustrated by the presence of disease-
causing mutations in 3 out of 73 asymptomatic family members (4%), not including 
unaffected carriers of recessive alleles.  
Based on our findings, we concur with the generally accepted notion that, in PID patients, 
targeted testing of small sets of genes is becoming obsolete.2 This is especially true for CVID 
and related disorders, which show considerable phenotypical overlap with many other PID 
entities.5 Hence, WES is currently the most cost-effective approach for diagnostic as well as 
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Common variable immunode!ciency (CVID) is one of the most frequently diagnosed primary immunode!cien-
cies (PIDs), and is de!ned as decreased serum immunoglobulin (Ig) G, decreased IgA and/or IgM, poor antibody 
responses to vaccines, and exclusion of other causes of hypogammaglobulinemia1. Patients commonly experience 
recurrent (sinopulmonary) infections and features of immune dysregulation such as autoimmunity1, 2. About 
25% of CVID patients are diagnosed in childhood3. To rule out transient hypogammaglobulinemia of infancy, in 
which Ig levels spontaneously resolve mostly by the age of two to four years, a de!nite diagnosis of CVID should 
not be given before the age of four years1.
Here, we report novel familial cases of Wiedemann-Steiner syndrome (WSS) and Roifman syndrome (RS) 
that were initially categorized as early-onset CVID. WSS and RS are rare syndromic PIDs, a"ecting the immune 
system as well as other organ systems4–6. Although there is considerable phenotypic heterogeneity in both syn-
dromes, hallmark extra-immunological features are generally evident very early in life7, 8. WSS is typically charac-
terized by hypertrichosis cubiti, growth retardation, developmental delay and facial dysmorphism, and is caused 
by heterozygous mutations in lysine methyltransferase 2 A (KMT2A)7, 9–14. KMT2A (also called mixed-lineage 
leukemia, MLL) encodes a histone methyltransferase involved in regulating chromatin-mediated transcription 
and is a frequent target of chromosomal rearrangements in childhood leukemia9, 15. WSS has only been recently 
associated with primary antibody de!ciency7. RS, on the other hand, is commonly featured by antibody de!-
ciency as well as growth retardation, spondyloepiphyseal dysplasia and retinal dystrophy8, 16. Biallelic mutations 
in RNU4ATAC, a noncoding small nuclear RNA (snRNA) gene, were recently identi!ed as a cause of RS8. U4atac 
snRNA is an important component of the minor spliceosome required for minor intron splicing8.
#is report aspires to increase awareness among immunologists and geneticists that a CVID phenotype can 
be the principal presentation of WSS and RS in early childhood, which is exceptional and has not been previ-
ously reported. #e prior diagnosis of early-onset CVID diverted attention away from the initially less evident 
extra-immunological features, which signi!cantly delayed identi!cation of the underlying syndromic disorders. 
Additionally, in both families we identi!ed mutations that have not been previously associated with disease. We 
aimed to provide insight as to how these mutations are disease-causing. Finally, we expand the immunopheno-
typical spectrum of WSS and RS, which could support future mechanistic research.
Results
ǦǤ #is study reports on two unre-
lated sibling pairs with recurrent respiratory tract infections and antibody de!ciency categorized as CVID in 
early childhood. #e family A monozygotic twin boys (Fig. 1a, II:2 and II:3) were born prematurely at 34 weeks 
Figure 1. Family A with KMT2A-associated Wiedemann-Steiner syndrome (WSS). (a) Pedigree of family A. 
(b) Skipping of KMT2A exon 28. Gel electrophoresis of the KMT2A cDNA region containing exon 28 revealed 
a second shorter transcript in the three a"ected individuals. HC1 and HC2 represent two healthy controls; 
GAPDH was used as reference target. In-frame deletion of exon 28 was con!rmed by cDNA sequencing; c.10755 
and c.10835 indicate the start respectively stop position of exon 28. (c) KMT2A protein domains (adapted from 
ref. 9). KMT2A is cleaved in an N-terminal (KMT2A-N) and C-terminal (KMT2A-C) fragment, which form a 
non-covalently associated complex. Deletion of the amino acids encoded by exon 28 may disrupt the interaction 
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gestational age to non-consanguineous, Belgian parents and are currently 11 years old. One of them (II:3) was 
born with bilateral inguinal hernia and hypospadias, which were attributed to his premature birth. From the !rst 
year of life, the twin boys su"ered from recurrent upper and lower respiratory tract infections, o#en requiring 
antibiotics. At 2 months of age, patient II:3 developed severe pneumonia with respiratory arrest and heart failure. 
$e latter led to the recognition of a patent ductus arteriosus, which was surgically ligated shortly therea#er. $e 
postoperative course was complicated by severe respiratory distress requiring ventilation and systemic corticos-
teroids. Upon immunological evaluation, both patients II:2 and II:3 demonstrated panhypogammaglobulinemia, 
poor antibody responses to Pneumococcal polysaccharide vaccine, increased naive B cells, and very low memory 
B cells (Table 1). Additionally, both patients showed evidence of mild bronchiectasis on high-resolution com-
puted tomography (HRCT) scan at 3.5 years of age.
$e family B brother and sister pair (Fig. 2a, II:1 and II:2) were born to healthy, non-consanguineous, Belgian 
parents and are currently 17 and 14 years of age respectively. $ey had recurrent upper and lower respiratory tract 
infections since the age of 18 months (II:1) and 3 years (II:2). $e girl (II:2) also had recurrent gastroenteritis in 
early childhood and di"use atopic eczema since infancy. Similar to the family A sibling pair, they had panhy-
pogammaglobulinemia and poor global antibody responses to Pneumococcal polysaccharide vaccine (Table 2). 
Serotype-speci!c Pneumococcal antibody responses were not evaluated. In contrast to the family A twins, the 
family B siblings demonstrated severe B cell lymphopenia with normal switched memory B cell percentages and 
increased CD21low B cell levels (Table 2). HRCT scan in patient II:1 at the age of 7.5 years displayed marked bron-
chiectasis, whereas his sister (II:2) only showed discrete bronchiectasis at a similar age.
In both the family A and B sibling pairs, the clinical presentation and laboratory !ndings in the !rst years of 
life were reminiscent of a CVID phenotype. All patients are currently doing well under regular Ig replacement 
therapy, anti&ogistic maintenance treatment with azithromycin and intermittent inhaled corticosteroids and/or 
short-acting beta-agonists therapy.
ǦǤ Although both sibling pairs !rst 
presented with a phenotype resembling CVID, with time they gradually demonstrated additional clinical features 
not typically associated with CVID (Tables 3 and 4). $e family A twin boys developed a third degree atrio-
ventricular block for which a pacemaker was implanted at 5 (II:3) and 6.5 (II:2) years of age respectively. In the 
following years, the boys showed increasing evidence of mild intellectual disability. In retrospect, patient II:3 had 
signs of mild developmental delay during the !rst years of life. Both twins also demonstrated poor weight gain 
and growth retardation, albeit to a limited extent. Around the age of 9 years, dysmorphic facial features became 
more conspicuous (Table 3). Interestingly, the twins’ mother (I:2) had congenital urogenital tract anomalies con-
sisting of a unicornuate uterus and a unique le# ovary, fallopian tube and kidney. Moreover, since childhood, 
she had su"ered from right unilateral sensorineural hearing loss as well as recurrent sinusitis and bronchitis 
frequently requiring antibiotics. At that time, genetic or immunological testing had never been performed in the 
mother as she deemed herself to be in good general health. $e twins’ older brother (II:1) and father (I:1) had an 
uneventful medical history.
Analogously, the boy in family B (II:1) initially displayed subtle syndromic features, such as mild growth 
retardation, that appeared more pronounced over time. At the age of seven years, diverse skeletal abnormalities 
including spondyloepiphyseal dysplasia were detected (Table 4). At the same age, he was also found to have slowly 
progressive retinal dystrophy (Fig. 2b, Panels I-III) with decreased rod function but near-normal cone function 
on full-!eld &ash electroretinography. Antibody de!ciency in combination with skeletal and ophthalmological 
features led to the clinical suspicion of RS in the boy. However, his sister (II:2) had no radiographic sings of spon-
dyloepiphyseal or hip dysplasia nor retinal dystrophy. Moreover, RS was originally presumed to be an X-linked 
recessive condition, although no causal gene had been identi!ed16. When the family B girl (II:2) was about 9 years 
old, Gray et al. reported the !rst female patient with RS, having a skewed X-inactivation and a milder phenotype 
than her a"ected brother17. Subsequently, we hypothesized that patient II:2 might be a manifesting heterozygote 
of RS, which could be compatible with her milder extra-immunological phenotype at that time.
Ǥ In the family A twins, 
conventional G-banding karyotype, &uorescent in situ hybridization for region 22q11.2 and subtelomeric screen-
ing were normal. Furthermore, microarray-based comparative genomic hybridisation analysis in both sibling 
pairs did not demonstrate copy number variations.
ȋȌǤ Since no speci!c genetic syndrome 
was suspected in family A, WES was performed in patient II:2 and both parents. $is revealed a heterozygous 
splice site variant in KMT2A (NM_001197104:c.10835 + 1 G > A), present in the twins (II:2, II:3) as well as in 
the mother (I:2) (Fig. 1a). $e variant is not reported in public or in-house databases. $e KMT2A nucleotide 
substitution is situated in the splice donor site of intron 28. In silico splicing prediction tools suggested complete 
loss of the splice donor site resulting in exon 28 skipping and an in-frame deletion of 81 bp, which was con!rmed 
by analyses on cDNA derived from patients’ PBMCs (Fig. 1b). Mature KMT2A protein is physiologically cleaved 
in an N-terminal (KMT2A-N) and C-terminal (KMT2A-C) fragment, which together form a non-covalently 
associated complex (Fig. 1c)15, 18. Complex formation is necessary for stability and subnuclear localization of the 
protein18. $e amino acids encoded by exon 28 are part of the interaction site between KMT2A-N and KMT2A-C 
(Fig. 1c)15. It has been shown that disrupting the interaction between the two fragments causes degradation of 
the KMT2A-N fragment and loss of protein function18. $e KMT2A-N fragment was only very weakly detecta-
ble by western blot on PBMC lysates, however, and could therefore not be reliably interpreted (data not shown). 
Subsequent investigations in the mother demonstrated mild intellectual disability, undetectable serum IgM, and 
Early-onset primary antibody deficiency resembling common variable immunodeficiency 




4Scientific RepoRtsȁͽǣ 3702 ȁǣͷͶǤͷͶ͹;ȀͺͷͻͿ;ǦͶͷͽǦͶ͸ͺ͹ͺǦͺ
Patient II:2 Patient II:3 Patient I:2
Value Reference range Value Reference range Value Reference range
White blood cells Age: 8 years Age: 8 years Age: 45 years
  Total leukocytes (no./µL) 11930 6000–14000 7340 6000–14000 7210 3650–9300
  Neutrophils (no./µL) 6980 2000–8000 3150 2000–8000 3450 1573–6100
  Lymphocytes (no./µL) 3990 1500–7500 3480 1500–7500 2870 1133–3105
    CD3+ T cells (no./µL) 2630 700–4200 2580 700–4200 2240 700–2100
      CD3+ CD4+ T helper cells (no./µL) 1600 300–2000 1640 300–2000 1120 300–1400
        CD45RA + naive CD4 + T cells (%) 82 46–77† 82 46–77† 44 NA
        CD45RO+ memory CD4+ T cells 
(%) 12 13–30
† 10 13–30† 50 NA
      CD3+ CD8+ T cytotoxic cells (no./
µL) 838 300–1800 800 300–1800 1060 200–1200
        CD45RA+ naive CD8+ T cells (%) 80 63–92† 69 63–92† 26 NA
        CD45RO+ memory CD8+ T cells 
(%) 12 4–21
† 10 4–21† 73 NA
    CD19+ B cells (no./µL) 798 200–1600 592 200–1600 287 100–500
      IgD + CD27- naive B cells (%) 96 47.3–77.0‡ 94 47.3–77.0‡ 88 48.4–79.7‡
      CD24 + + CD38++ transitional B 
cells (%) 19 4.6–8.3
‡ 10 4.6–8.3‡ 14 0.9–5.7‡
      IgD ! CD27+ switched memory B 
cells (%) 1 10.9–30.4
‡ 1 10.9–30.4‡ 6 8.3–27.8‡
      IgD + CD27+ marginal zone B cells 
(%) 2 5.2–20.4
‡ 2 5.2–20.4‡ 3 7.0–23.8‡
      CD21low CD38low B cells (%) 2 2.3–10.0‡ 3 2.3–10.0‡ 2 1.6–10.0‡
    CD3 ! CD56 + CD16+ NK cells 
(no./µL) 479 90–900 244 90–900 344 90–600
  Monocytes (no./µL) 690 700–1500 570 700–1500 780 247–757
  Eosinophils (no./µL) 220 200–500 100 200–500 80 28–273
  Basophils (no./µL) 30 10–100 20 10–100 10 6–50
Immunoglobulins* Age: 7 years Age: 3 years Age: 45 years
    IgG (g/L) 3.6 4.70–10.5 2.8 4.70–9.30 7.6 7.0–16.0
    IgG2 (g/L) 1.13 0.85–4.10 0.54 0.63–3.0 3.03 1.50–6.40
    IgG3 (g/L) 0.265 0.13–1.42 0.176 0.13–1.26 0.307 0.20–1.10
    IgM (g/L) <0.2 0.27–0.63 <0.2 0.27–0.57 <0.18 0.40–2.48
    IgA (g/L) 0.3 0.50–1.41 0.3 0.41–0.91 2.35 0.71–3.65
    IgE (kU/L) <4.4 0–90 <4.4 0–60 NA
Speci!c antibody responses* Age: 7 years Age: 3 years Age: 45 years
    S. pneumoniae polysaccharide IgG 
(Lab U) NA 9 "11: immune NA
    S. pneumoniae polysaccharide IgG: 




2x titer increase for at 




2x titer increase for 
at least 2 out of 3 
serotypes
   Tetanus IgG (IU/mL) 0.01  " 0.01: immune 0.03  " 0.01: immune 0.50  " 0.01: immune
   Rubella IgG (IU/mL) 12 >10: immune 44 >10: immune NA
   Measles IgG (mIU/mL) 350 >300: immune 1200 >300: immune NA
   Mumps IgG (Lab U/mL) 270 >500: immune 540 >500: immune NA
   Varicella Zoster IgG (mIU/mL) 620 >100: immune 1400 >100: immune NA
Lymphocyte proliferation assay Age: 3 years Age: 3 years
   Response to Concanavalin A Normal Compared to control Normal Compared to control NA
   Response to Phytohemagglutinin Normal Compared to control Normal Compared to control NA
   Response to Tetanus toxoid Normal Compared to control Moderately reduced Compared to control NA
Table 1. Routine immunological laboratory results of the family A patients with Wiedemann-Steiner syndrome. 
$e most recent, comprehensive and representative laboratory results are shown for each patient. Patients II:2 
and II:3 were immunized according to the recommended Belgian childhood immunization schedule that, among 
others, included tetanus, measles, mumps, rubella and 7-valent conjugated pneumococcal vaccines. Patient I:2 
had received a tetanus booster vaccine within the last 10 years. A polysaccharide (unconjugated) pneumococcal 
vaccine was given to patients II:2 and I:2 at time of immunological evaluation; patient I:2 had never received 
a pneumococcal vaccine before then. Patients II:2 and II:3 were not vaccinated against varicella zoster virus 
but had chickenpox in early childhood. NA: not available. *Measured when not receiving immunoglobulin 
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reduced switched memory B cells (Table 1). Taken together, the c.10835 + 1 G > A variant in KMT2A indicates a 
molecular diagnosis of WSS in the twin brothers and their mother.
ƤǤ In family B, WES was unable to iden-
tify a potentially disease-causing variant. In 2015, biallelic mutations in RNU4ATAC were identi"ed in patients 
with RS8. Since RNU4ATAC is a noncoding snRNA gene, possible variants would have been missed with WES. 
Indeed, subsequent Sanger sequencing of RNU4ATAC revealed compound heterozygous variants in both siblings 
(c.13 C > T and c.116 A > T) that segregated in the parents (Fig. 2a). #e c.13 C > T variant (rs559979281) had 
been previously reported in RS (Fig. 2c)8. #e c.116 A > T variant has, to our knowledge, not yet been associated 
with human disease. #e public database gnomAD (Genome Aggregation Database) contains two heterozygotes 
for the c.116 A > T variant (allele frequency of 0.00001531) but no homozygotes. Importantly, the c.116 A > T 
variant is located in a highly conserved position involved in splicing activity (Fig. 2c)8. Furthermore, position 116 
is immediately adjacent to the Sm protein-binding site, which is a highly conserved structural element essential 
in splicing activity and previously implicated in RS (Fig. 2c)8. Together, the RNU4ATAC genotype con"rms the 
diagnosis of RS in the family B siblings.
Figure 2. Family B with RNU4ATAC-associated Roifman syndrome (RS). (a) Pedigree of family B. 
(b) Representative retinal images of the RS patients. Panel I, composite retinal image of fundus of le$ 
eye (LE) of patient II:1: note inferior outer retinal atrophy with greyish hue and intraretinal pigment 
migration of the spicular type in inferior retina; mottled aspect of retinal pigment epithelium, more 
pronounced in inferotemporal area. Panel II, blue light auto%uorescence image of LE of patient II:1 showing 
hyperauto%uorescent delineation of inferior atrophic zone, as well as superior to optic disc, illustrating more 
widespread disease than can be seen on white light fundoscopic image only. Panel III, similar image of right eye 
(RE) of patient II:1 as in Panel II. Panel IV, fundus picture of detail of superonasal midperiphery of RE of patient 
II:2. Despite a normal full-"eld %ash electroretinography, recent fundus examination at 14 years of age showed 
a mild mottling of pigment epithelium suggestive of early stage retinal dystrophy. (c) U4atac snRNA showing 
structural elements, conserved positions and location of variants associated with RS (adapted from ref. 8). #e 
here-reported variant that has not been previously associated with RS is shown in red.
Early-onset primary antibody deficiency resembling common variable immunodeficiency 
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Ǥ Because of the prominent immunode!-
ciency in both sibling pairs, we performed "ow cytometric analysis of B and T lymphocyte subsets as previously 
described19. Interestingly, all patients from families A and B had decreased circulating follicular helper T (cT#) 
Patient II:1 Patient II:2
Value Reference range Value Reference range
White blood cells Age: 14 years Age: 11 years
  Total leukocyte count (no./µL) 7720 4500–12000 9800 4500–12000
  Neutrophils (no./µL) 5290 2500–8000 6080 2500–8000
  Lymphocytes (no./µL) 1190 1500–6500 2410 1500–6500
    CD3+ T cells (no./µL) 940 800–3500 1740 800–3500
      CD3 + CD4+ T helper cells (no./µL) 643 400–2100 1080 400–2100
        CD45RA+ naive CD4+ T cells (%) 55 33–66† 68 33–66†
        CD45RO+ memory CD4+ T cells (%) 38 18–38† 27 18–38†
      CD3 + CD8+ T cytotoxic cells (no./µL) 274 200–1200 603 200–1200
        CD45RA+ naive CD8+ T cells (%) 60 61–91† 67 61–91†
        CD45RO+ memory CD8+ T cells (%) 33 4–23† 22 4–23†
    CD19+ B cells (no./µL) 36 200–600 48 200–600
      IgD + CD27- naive B cells (%) 77 51.3–82.5‡ 70 51.3–82.5‡
      CD24 + + CD38++ transitional B cells (%) 15 1.4–13.0‡ 5 1.4–13.0‡
      IgD-CD27+ switched memory B cells (%) 9 8.7–25.6‡ 10 8.7–25.6‡
      IgD + CD27+ marginal zone B cells (%) 4 4.6–18.2‡ 1 4.6–18.2‡
      CD21low CD38low B cells (%) 22 2.7–8.7‡ 21 2.7–8.7‡
    CD3-CD56 + CD16+ NK cells (no./µL) 179 70–1200 554 70–1200
  Monocytes (no./µL) 910 500–1000 960 500–1000
  Eosinophils (no./µL) 290 100–500 230 100–500
  Basophils (no./µL) 20 10–100 90 10–100
Immunoglobulins* Age: 3 years Age: 6 years
   IgG (g/L) 3.8 4.7–9.3 4.4 4.7–10.5
   IgG2 (g/L) 0.53 0.63–3.0 0.49 0.85–4.1
   IgG3 (g/L) 0.021 0.13–1.26 0.242 0.13–1.42
   IgM (g/L) <0.2 0.27–0.57 0.3 0.27–0.63
   IgA (g/L) 0.3 0.41–0.91 <0.3 0.5–1.41
  IgE (kU/L) <4.4 0–60 <4.4 0–90
Isohemagglutinins* Age: 3 years
  ABO blood type O NA
  Anti-A IgM Negative Positive NA
  Anti-B IgM Negative Positive NA
Speci!c antibody responses* Age: 3 years Age: 6 years
  S. pneumoniae polysaccharide IgG (Lab U) <3  ! 11: immune 7  ! 11: immune
  Tetanus IgG (IU/mL) 0.03  ! 0.01: immune 1  ! 0.01: immune
  Rubella IgG (IU/mL) <8 >10: immune NA
  Measles IgG (mIU/mL) <150 >300: immune NA
  Mumps IgG (Lab U/mL) <230 >500: immune NA
  Varicella zoster IgG (mIU/mL) 360 >100: immune 1400 >100: immune
Lymphocyte proliferation assay Age: 9 years Age: 6 years
  Response to Concanavalin A Normal Compared to control Normal
Compared to 
control
  Response to Phytohemagglutinin Normal Compared to control Normal
Compared to 
control
  Response to Tetanus toxoid Normal Compared to control Normal
Compared to 
control
Table 2. Routine immunological laboratory results of the family B patients with Roifman syndrome. %e most 
recent, comprehensive and representative laboratory results are shown for each patient. Both patients were 
immunized according to the recommended Belgian childhood immunization schedule that, among others, 
included tetanus, measles, mumps, rubella and 7-valent conjugated pneumococcal vaccines. A polysaccharide 
(unconjugated) pneumococcal vaccine was given at time of immunological evaluation. %e patients were not 
vaccinated against varicella zoster virus but had chickenpox in early childhood. NA: not available. *Measured 
when not receiving immunoglobulin replacement therapy. †Reference values from Shearer et al.27. ‡Reference 
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cells (Fig. 3a,b). T" cells play an essential role in the formation of antibody-producing plasma cells and mem-
ory B cells20. Furthermore, the two RS patients showed markedly reduced expression levels of B cell activating 
factor-receptor (BAFF-R), a receptor important in peripheral B cell survival (Fig. 3b)21. #e WSS patients had 
normal BAFF-R levels (Fig. 3a). Expression of transmembrane activator and calcium modulator and cyclophilin 





Patient II:2 Patient II:3 Patient I:2
Gender 8 M, 10 F M M F
Age at last examination (years) 1–24 11 11 46
Short stature 18/18 + + +
Craniofacial features
   Microcephaly 2/7 ! ! !
   Mild macrocephaly NA + + !
 Hypertelorism, telecantus 9/17 + + +
   Down-slanted palpebral $ssures 14/16 + + +
   Vertically narrow palpebral $ssures 13/17 + + +
   Strabismus 4/17 ! ! !
   #ick eyebrows 14/17 + + +
   Wide nasal bridge 16/18 + + +
   Broad nasal tip 11/17 + + +
   Long philtrum 2/12 ! ! !
   #in upper lip 6/12 + + +
   Low-set ears 2/12 + + +
   Abnormal dentition, hypodontia 5/9 ! ! !
   High palate 4/8 + + +
   Micrognathia 7/11 + + +
Musculoskeletal features
   Advanced bone age 1/16 NA NA NA
   Small hands and feet 5/17 + + +
   Fleshy hands and feet 3/7 + + +
   Clinodactyly 8/18 ! + +
   Congenital hip dysplasia 2/17 ! ! !
   Muscular hypotonia 9/18 ! ! !
Dermatological features
   #ick hair 14/17 + + +
   Hypertrichosis cubiti 13/18 ! ! !
   Hypertrichosis back and/or lower limbs 16/18 ! ! !
Neurological features
   Developmental or psychomotor delay 18/18 ! + NA
   Intellectual disability 16/17 + + +
   Autism 2/12 ! ! !
   Aggressive behavior 4/13 ! ! !
   Hyperactivity 2/12 ! ! !
   Seizures 1/7 ! ! !
Internal organ anomalies
   Cardiovascular anomalies 3/17 + + !
   Urogenital anomalies 4/17 ! + +
   Intestinal anomalies 4/11 ! ! !
   Feeding di%culties 10/18 + + !
Immunode!ciency features
   Antibody de$ciency 1/1 + + +
   Respiratory tract infections 2/17 + + +
   Urinary tract infections 4/18 ! ! !
   Bronchiectasis NA + + NA
Table 3. Comparison of the family A patients with published cases of KMT2A-associated Wiedemann-Steiner 
syndrome. NA: not available. †Not all clinical features have been ascertained in all previously published patients. 
Adapted from Stellacci et al.7.
Early-onset primary antibody deficiency resembling common variable immunodeficiency 
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For all patients, the alterations in naive and memory lymphocyte subsets (Supplementary Figs 1–4) corresponded 
with those seen in the routine laboratory assessment (Table 1). Other examined B and T cell populations fell 
within the range of the age-matched healthy controls (Supplementary Figs 1–4).

We report two sibling pairs with an early-onset CVID phenotype as primary and cardinal presentation of 
WSS and RS: recurrent sinopulmonary infections, panhypogammaglobulinemia, reduced polysaccharide vac-
cine responses, and aberrant peripheral B cell subsets1. Because extra-immunological features were initially 
subtle and only became conspicuous with age, the establishment of an accurate diagnosis was significantly 
delayed. "erefore, we recommend to proactively evaluate all paediatric patients with a CVID phenotype for 
extra-immunological syndromic features, especially when presenting at an early age. In particular, diagnostic 
workup should include evaluation by a clinical geneticist, in addition to orthopedic, cardiologic, neurologic, 
urogenital and ophthalmologic assessment. To reach a conclusive diagnosis, genetic testing should be performed, 
varying from targeted testing of a speci#c disease gene to WES. Here, the diagnosis of WSS in family A was only 
con#rmed upon WES in a$ected family members7, 9. In family B on the other hand, WES failed to reveal the 
causal genetic defect because this was located in a noncoding gene8. Targeted testing of the known disease gene 
for RS allowed to identify the underlying mutations and to provide a de#nite diagnosis8. Of note, if WES does not 
identify a genetic defect and there is no known disease gene, whole genome sequencing should be undertaken22.
With this study, we extend the phenotypical and mutational spectrum of both KMT2A-associated WSS and 









Gender 5 M, 1 F M F
Age at last examination (years) NA 17 14
Growth retardation
   Prenatal, intra-uterine growth retardation 6/6 NA NA
   Postnatal growth retardation 6/6 + +
Craniofacial features
   Mild microcephaly 5/6 + +
   Long philtrum 6/6 + +
   "in upper lips 6/6 + +
   Narrow, tubular and upturned nose 6/6 + +
Ophthalmological features
   Retinal dystrophy 3/6 + +
Musculoskeletal features
   Epiphyseal dysplasia 6/6 + !
   Vertebral changes 3/6 + !
   Coxa vara NA + !
   Agenesis of anterior cruciate ligaments NA + !
   Agenesis of 12th ribs NA + !
   Short metacarpals 6/6 + !
   5th digit clinodactyly 4/6 ! !
   Brachydactyly 6/6 + !
   Transverse palmar crease 5/6 ! !
   Muscular hypotonia 5/6 ! !
Neurological features
   Intellectual disability, cognitive delay 5/6 ! !
   Sensorineural hearing loss 1/6 ! !
Internal organ anomalies
   Noncompaction of the myocardium 1/6 ! !
   Ventricular septum defect (VSD) 1/6 ! !
   Lung hypoplasia NA ! +
Immunode!ciency and atopic features
   Antibody de#ciency 6/6 + +
   Hepatosplenomegaly 5/6 ! !
   Bronchiectasis NA + +
   Eczema 3/6 ! +
Table 4. Comparison of the family B patients with published cases of RNU4ATAC-associated Roifman 
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Figure 3. cT! cells, BAFF-R expression and TACI expression in WSS and RS patients. (a) Family A patients 
with KMT2A-associated Wiedemann-Steiner syndrome (WSS). "e twins (II:2, II:3) were 8 years old and the 
mother (I:2) was 43 years old at time of analysis. (b) Family B patients with RNU4ATAC-associated Roifman 
syndrome (RS). At time of analysis, the patients (II:1, II:2) were 14 and 11 years old, respectively. Flow 
cytometric immunophenotyping was performed on patients’ PBMCs in comparison with age-matched healthy 
controls (HC). T cells were gated as CD3+ and B cells as CD19+CD20+ in total PBMCs. Circulating follicular 
helper T (cT!) cells were gated as CXCR5+CD45RO+ in CD4+ T cells. BAFF-R and TACI expression were 
measured on B cells. Relative mean #uorescence intensity (MFI) was calculated by dividing the MFI of the 
positive population by the MFI of the Fluorescence Minus One (FMO) population. Graphs of the HC groups 
represent mean ± standard deviation. BAFF-R: B cell activating factor-receptor, cT!: circulating follicular 
helper T, expr: expression, TACI: transmembrane activator and calcium modulator and cyclophilin ligand 
interactor.
Early-onset primary antibody deficiency resembling common variable immunodeficiency 
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causing in-frame deletion of exon 28. !is deletion likely disrupts the stabilizing interaction site between the N- 
and C-terminal KMT2A fragments, resulting in loss of protein function18. So far, we were unable to con"rm this 
on a protein level because the KMT2A-N protein fragment was not reliably detectable by western blot. Further 
studies on protein level are planned in the future. Family A is the "rst published kindred to show autosomal 
dominant transmission of KMT2A-associated WSS in multiple generations, as previously reported cases were 
either sporadic or parents were unavailable7. Remarkably, the characteristic hypertrichosis of elbows, back and/
or lower limbs was absent in the here-reported WSS patients, con"rming previous literature that this feature 
may not be as pathognomonic as initially believed7, 9, 11, 12. Interestingly, KMT2A-associated WSS shows pheno-
typical overlap with Kabuki syndrome type 1 caused by heterozygous mutations in the related gene KMT2D23. 
Over 80% of patients with KMT2D-associated Kabuki syndrome develop defects in terminal B cell di#erentiation 
resulting in antibody de"ciency23. Similarly, the here-described WSS patients demonstrated a block in terminal 
B cell di#erentiation evidenced by a relative increase in transitional and naive B cells and a relative decrease in 
switched memory B cells. Moreover, they had reduced levels of cT$ cells, which play a pivotal role in terminal B 
cell di#erentiation20. Decreased cT$ cells have, to our knowledge, not been previously reported in WSS or Kabuki 
syndrome. It would be interesting to investigate cT$ cells in additional patients with KMT2A-associated WSS and 
KMT2D-associated Kabuki syndrome as this may help elucidate the underlying pathophysiology of the antibody 
de"ciency. In summary, humoral immune de"ciency in patients with WSS reported by us and by Stellacci et al.7, 
and antibody de"ciency in patients with heterozygous mutations in the related KMT2D gene23, strongly suggest a 
previously unknown role for KMT2A in B cell biology that may be related with T helper cell function.
In family B, we identi"ed rare compound heterozygous mutations in the noncoding RNU4ATAC gene, of 
which one mutation (c.116 A > T) had not been associated with RS before8. Although it was not initially apparent, 
with time the boy showed typical features of RS including spondyloepiphyseal dysplasia and retinal dystrophy8. 
Curiously, he also demonstrated bilateral agenesis of the anterior cruciate ligaments and the 12th ribs, which are 
not typically seen in RS8. Spondyloepiphyseal or hip dysplasia have not yet been documented in the girl, currently 
14 years old, although she displays mild growth retardation. Only recently, she was found to have mild fundus 
abnormalities suggestive of early stage retinal dystrophy. Note that retinal dystrophy was already evident in her 
brother at 7 years of age. It would be interesting to investigate why the girl has a milder phenotype than her 
brother. Since U4atac snRNA plays a role in minor intron splicing, it would be valuable to conduct RNA sequenc-
ing analysis in the two siblings and check for possible di#erences in intron retention8. Detailed immunological 
workup in the RS patients revealed markedly decreased BAFF-R expression on B cells. To our knowledge, this 
"nding has not been previously published. As BAFF-R signalling is important for survival of B cells in the periph-
eral blood, this may provide an important clue towards the B cell lymphopenia seen in RS patients21. Moreover, 
analogous to the WSS patients, the RS siblings demonstrated decreased levels of cT$ cells, which may further 
compromise B cell di#erentiation and antibody production20.
In conclusion, we here illustrate that a CVID phenotype can be the initial presentation of WSS and RS in early 
childhood while hallmark extra-immunological characteristics may be less prominent. With this, we highlight 
the importance of pursuing a genetic diagnosis in paediatric patients with an early-onset CVID phenotype, as this 
has important implications in terms of counselling, follow-up and screening for complications associated with 
the speci"c disorder.

Ǥ All experiments and methods were carried out in accordance with relevant guidelines and reg-
ulations. !e research protocol and all experimental protocols were approved by the ethical committee of Ghent 
University Hospital (2012/593). All reported subjects provided written informed consent for participation in the 
study, in accordance with the 1975 Helsinki Declaration.
Ǥ Microarray-based comparative genomic hybridization (array CGH) was performed 
on the a#ected sibling pairs of families A and B using the SurePrint G3 Human CGH Microarray Kit according 
to manufacturer’s instructions (Agilent Technologies). Results were analyzed with arrayCGHbase24. Karyotype 
analysis was performed on the family A twins using the conventional G-banding technique. To screen the fam-
ily A twins for submicroscopic subtelomeric rearrangements, multiplex ligation-dependent probe ampli"cation 
(MLPA) analysis was performed using SALSA P070 and SALSA P036C probe mixes according to manufacturer’s 
instructions (MRC-Holland). To examine the family A twins for 22q11.2 deletion, %uorescence in situ hybridiza-
tion (FISH) analysis was performed using the DiGeorge Region Probe Set – LSI TUPLE 1 SpectrumOrange/LSI 
ARSA SpectrumGreen according to manufacturer’s instructions (Vyvis).
Ǥ Genomic DNA was isolated from whole blood leukocytes using the Puregene DNA isolation kit 
(Qiagen) according to manufacturer’s instructions. Whole exome enrichment was performed with the 
SureSelectXT Human All Exon V5 + UTRs kit (Agilent Technologies). Paired-end massively parallel sequencing 
(100 cycles) was performed on a NextSeq 500 (Illumina). Read mapping against the human genome reference 
sequence (NCBI, GRCh37), and post-mapping duplicate read removal, quality-based variant calling and coverage 
analysis were performed with CLC Genomics Workbench v6.0.4 (CLC bio). Sequencing coverage is summarized 
in Supplementary Table S1. Called variants with coverage !3 were annotated with Alamut Batch (Interactive 
Bioso'ware). Only variants with population frequencies less than 10% were considered, according to public data-
bases NCBI dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/), NHLBI Exome Sequencing Project (http://evs.
gs.washington.edu/EVS/), ExAC Browser (http://exac.broadinstitute.org/), and 1000 Genomes Project Browser 
(http://browser.1000genomes.org/). Variants were further prioritized based on allele frequency, functional pre-
diction scores, nucleotide conservation scores and biological relevance25. Both Mendelian and non-Mendelian 
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mutation interpretation so!ware v2.7 rev. 1 (Interactive Bioso!ware), Ingenuity Variant Analysis (QIAGEN, 
2015 Release Spring), CADD scores v1.3 (http://cadd.gs.washington.edu/home), genome Aggregation Database 
(gnomAD) Browser (http://gnomad.broadinstitute.org), literature search, segregation analysis in available fam-
ily members, and frequency in an in-house database containing variants of more than 1000 exomes at time of 
analysis.
Ǥ DNA templates (GRCh37/hg19) of KMT2A (NM_001197104) 
and RNU4ATAC (NR_023343) were obtained from UCSC Genome Browser (https://genome.ucsc.
edu). Primers for amplification and sequencing were designed with Primer3Plus26. For KMT2A exon 28 
and adjacent intron-exon borders (family A): forward primer 5!-CAACCCACAAGGGTGTCTTC-3! 
and reverse primer 5!-GCCCGGCTAATTCTTTTTGT-3!. For the unique exon and intron-exon bor-
ders of RNU4ATAC (family B): forward primer 5!-TGGAGGCTGGAGGTAAGCTA-3! and reverse primer 
5!-TGAGGTGCAAAGACCTACTGAA-3!. Genomic DNA was amplified by PCR using the specific prim-
ers and KAPA2G Robust Hotstart Ready Mix (KAPA Biosystems). PCR products were enzymatically puri"ed 
with Exonuclease I and Antartic phosphatase (both New England BioLabs Inc.). Puri"ed PCR products were 
sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) on a 3730xl DNA 
Analyzer (Applied Biosystems). Sequence reads were analyzed with SeqScape v2.5 (#ermoFisher Scienti"c).
ǡƤ͸;͸Ǥ Total RNA 
was isolated from total PBMCs of all family A members and two control subjects by use of the RNeasy Plus Mini 
Kit (Qiagen) and reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad), according to manufactur-
er’s instructions. #e cDNA template (GRCh37/hg19) of KMT2A (NM_001197104) was obtained from UCSC 
Genome Browser (https://genome.ucsc.edu). Primers for ampli"cation and sequencing of exon 28 and adjacent 
coding regions were designed with Primer3Plus26: forward primer 5!-AACCCAAACCAAAAACCAAAC-3! and 
reverse primer 5!-CATCAGTGGGGAGCTGAAAT-3!. GAPDH was used as a reference target: forward primer 
5!-CAGCCTCAAGATCATCAGCA-3! and reverse primer 5!-TGTGGTCATGAGTCCTTCCA-3!. PCR ampli"-
cation was performed by use of GoTaq Hot Start Colorless Master Mix (Promega). PCR products were analyzed 
on a 2% agarose gel in 1x TBE bu$er (Quality Biological Inc). SYBR Safe (Invitrogen) signals were captured with 
a Gel Doc EZ Imager system (Bio-Rad). In addition, puri"ed PCR products were Sanger sequenced using the 
BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) on a 3130xL Genetic Analyzer (Applied 
Biosystems). Sequence reads were analyzed with SeqMan (DNAStar).
	Ǥ Immunophenotyping was performed on PBMCs of patients and 
age-matched healthy controls. PBMCs were isolated from EDTA whole blood by Ficoll-Paque density gradient 
centrifugation and cryopreserved at "150 °C. #awed PBMCs were stained with "xable viability dye 506 (eBio-
science) and %uorescently labeled monoclonal antibodies under saturation conditions as previously described19. 
Cells were acquired on an LSR Fortessa %ow cytometer (BD Biosciences). Data were analyzed with FlowJo version 
X (Tree Star Inc.).
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% of regions 
≥ 5 x 
% of regions 
≥ 10 x 
% of regions 
≥ 20 x 
% of regions 
≥ 40 x 
A I:1  74.8 x 98.79% 97.75% 93.52% 75.81% 
A I:2  67.9 x 98.59% 97.39% 92.48% 71.62% 
A II:3  67.6 x 98.69% 97.47% 92.42% 71.62% 
B I:1 61.5 x 96.12% 93.80% 86.31% 63.60% 
B I:2 73.7 x 95.82% 93.82% 88.28% 71.08% 
B II:1 76.7 x 98.90% 97.85% 93.28% 75.34% 
B II:2 65.9 x 95.94% 93.75% 87.09% 67.07% 
 
Read depth was calculated for all regions enriched by the SureSelectXT Human All Exon V5+UTRs kit 
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Supplementary Figure 1. Flow cytometric phenotyping of the family A patients: B cell subsets. 
Flow cytometric immunophenotyping was performed on PBMCs of the 3 patients with KMT2A-
associated Wiedemann-Steiner syndrome (WSS) in comparison with age-matched healthy controls 
(HC). At time of analysis, the twins and the mother were 8 and 43 years old, respectively. For details 
on gating, see reference 19. Relative mean fluorescence intensity (rMFI) was calculated by dividing 
the MFI of the positive population by the MFI of the Fluorescence Minus One (FMO) population. 
Graphs of HC group represent mean ± standard deviation. MZ: marginal zone, sw (mem): switched 












































































































































































































































































































































































Supplementary Figure 2. Flow cytometric phenotyping of the family A patients: T cell subsets. 
Flow cytometric immunophenotyping was performed on PBMCs of the 3 patients with KMT2A-
associated Wiedemann-Steiner syndrome (WSS) in comparison with age-matched healthy controls 
(HC). At time of analysis, the twins and the mother were 8 and 43 years old, respectively. For details 
on gating, see reference 19. Relative mean fluorescence intensity (rMFI) was calculated by dividing 
the MFI of the positive population by the MFI of the Fluorescence Minus One (FMO) population. 
Graphs of HC group represent mean ± standard deviation. cTfh: circulating follicular helper T, DN: 
double negative, expr: expression, NKT: natural killer T, RTE: recent thymic emigrants, TCM: central 
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Supplementary Figure 3. Flow cytometric phenotyping of the family B patients: B cell subsets. 
Flow cytometric immunophenotyping was performed on PBMCs of the 2 patients with RNU4ATAC-
associated Roifman syndrome (RS) in comparison with age-matched healthy controls (HC). At time of 
analysis, the patients (II:1, II:2) were 14 and 11 years old, respectively. For details on gating, see 
reference 19. Relative mean fluorescence intensity (rMFI) was calculated by dividing the MFI of the 
positive population by the MFI of the Fluorescence Minus One (FMO) population. Graphs of HC group 





































































































































































































































































Supplementary Figure 4. Flow cytometric phenotyping of the family B patients: T cell subsets. 
Flow cytometric immunophenotyping was performed on PBMCs of the 2 patients with RNU4ATAC-
associated Roifman syndrome (RS) in comparison with age-matched healthy controls (HC). At time of 
analysis, the patients (II:1, II:2) were 14 and 11 years old, respectively. For details on gating, see 
reference 19. Relative mean fluorescence intensity (rMFI) was calculated by dividing the MFI of the 
positive population by the MFI of the Fluorescence Minus One (FMO) population. Graphs of HC group 
represent mean ± standard deviation. cTfh: circulating follicular helper T, DN: double negative, expr: 
expression, NKT: natural killer T, RTE: recent thymic emigrants, TCM: central memory T, TEM: 




















































































































































































































































































































A novel IKAROS haploinsufficiency kindred  
 with unexpectedly late and variable  
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We report on the first truncating IKZF1 mutation associated with IKAROS haploinsufficiency 
and illustrate an unexpectedly late and variable block in central and peripheral B cell 








To the Editor:  
IKAROS, encoded by IKAROS family zinc finger protein 1 (IKZF1), is a hematopoietic zinc 
finger transcription factor essential in human hematopoiesis and B cell development.1 
Somatic changes in IKZF1 have been associated with B cell leukemia.1 Germline IKZF1 
mutations have been recently identified as a cause of common variable immunodeficiency 
and dysgammaglobulinemia through IKAROS haploinsufficiency.2,3 They are autosomal 
dominantly inherited or appear de novo.2-4 Eleven out of 42 germline IKZF1 mutation carriers 
were clinically asymptomatic at time of publication, suggesting incomplete penetrance.2-4 
However, as age of onset ranged from infancy to the sixth decade, younger asymptomatic 
subjects may still develop disease later in life.2,3 Symptomatic individuals mainly presented 
bacterial infections, especially of the respiratory tract.2,3 In addition, some patients suffered 
from antibody-mediated autoimmune manifestations or B cell acute lymphoblastic 
leukemia.2,3 Affected subjects typically showed a (progressive) decrease of peripheral B cell 
numbers accompanied by a (progressive) reduction in at least one major immunoglobulin (Ig) 
isotype.2,3 Total T cells were not decreased but patients often displayed quantitative changes 
in various T cell subsets.2,3 Here, we report an autosomal dominant kindred with a novel 
truncating mutation in IKZF1, and describe new insights in B cell maturation in two 
symptomatic and one asymptomatic family members. 
The parents (I:1, I:2) were healthy, non-consanguineous, and from Dutch-Italian origin 
(Figure 1A). Sibling II:3, currently 17 years old, was diagnosed with monocyclic systemic-
onset juvenile idiopathic arthritis at the age of six, and reactive arthritis at nine years of age. 
Testing for autoantibodies was negative. Her younger sister (II:4, currently 12.5 years old) 
had multiple episodes of reactive arthritis between the ages of three and five. In addition, 
both patients suffered from recurrent bacterial sinopulmonary infections. Patient II:4 was 
recently diagnosed with juvenile myasthenia gravis confirmed by positive acetylcholine 
receptor auto-antibodies. The immunological workup of patients II:3 and II:4 is provided in 
Table E1 and Figure E1 in this article’s Online Repository. In summary, patient II:3, first 
examined at the age of nine years, had absent serum IgA and IgM and severe B 
lymphopenia (Figure 2A). Patient II:4, first evaluated at 4.5 years of age, showed absent IgA 
but normal IgM. Her B cell counts were initially in the lower normal range but progressively 
decreased over time (Figure 2A). Both patients had poor polysaccharide vaccination 
responses. Total IgG and IgG subclass levels have so far remained normal. There were no 
important abnormalities in peripheral T cell subsets. The youngest sibling (II:5) is currently 8 





Figure 1. Molecular and functional characterization. (A) Pedigree. Square, circle and diamond 
shapes indicate male, female and sex unknown, respectively. Diagonal lines indicate deceased 
siblings. Corresponding electropherograms are shown on the right. Lab abn.: laboratory abnormalities. 
(B) Schematic structure of IKAROS isoform 1 (IKZF1 transcript NM_006060). Grey boxes represent 
exons. Zinc fingers (ZF) 1 to 4 constitute the DNA binding domain, ZF5 and ZF6 the protein 
dimerization domain. Previously published mutations are depicted in black; one family had a large 
chromosomal deletion (7p12.3-p12.1) encompassing the IKZF1 gene. The here-reported novel 
mutation is indicated in red. (C) IKZF1 mRNA expression was determined with real-time quantitative 
PCR by means of two amplicons located upstream and downstream of the mutation site, respectively. 
The cDNA start and end position of each amplicon is given between brackets (IKZF1 transcript 
NM_006060). The two studied patients (II:3, II:4) had similar IKZF1 mRNA levels compared to healthy 
controls (HC) indicating that the mutant transcript escapes nonsense-mediated mRNA decay. The 
graph represents mean ± SD of one experiment. ns: not significant. (D) IKAROS protein expression in 
mutant (M/WT) and wild type (WT/WT) family members and three healthy controls (HC) analyzed in 
CD3+ T cells by use of flow cytometry. Histograms are depicted on the left. The graph on the right 
displays mean ± SD of the corresponding mean fluorescence intensity (MFI) values. Data shown are 
representative of two replicate experiments. FMO: fluorescence minus one. 
 
Whole exome sequencing revealed a heterozygous frameshift mutation in IKZF1 
(NM_006060: c.136delA, p.S46Afs*14) in the two affected siblings (II:3, II:4) and 
asymptomatic mother (I:2) (Figure 1A). The mutation is not reported in public or in-house 
databases. The frameshift introduces a premature stopcodon before the first zinc finger motif 
in all IKZF1 transcripts (Figure 1B). Although nonsense-mediated mRNA decay (NMD) was 
predicted in silico, mutant transcripts were detected at cDNA level (Figure E2 in this article’s 
Online Repository) and patients showed normal levels of IKZF1 cDNA (Figure 1C), 




suggesting mutant transcripts escape NMD. Nonetheless, IKAROS protein expression levels 
were, on average, 40% lower in all three mutant subjects compared to the wild type family 
members and healthy controls (Figure 1D). The latter suggests that the mutant transcript 
encodes an unstable truncated protein that is rapidly degraded.5 Alternatively, the truncated 
protein may not be recognized by the antibody, however, epitope details are lacking. Either 
way, our findings indicate a molecular diagnosis of IKAROS haploinsufficiency in patients II:3 
and II:4 and their asymptomatic mother (I:2). Because the mutation was also present in the 
clinically asymptomatic 43-year-old subject I:2, we performed in-depth immunological testing, 
which revealed mildly reduced serum IgM as well as marginally inadequate antibody 
responses to a polysaccharide pneumococcal vaccine (Table E1 in this article’s Online 
Repository).  
Since germline IKAROS haploinsufficiency is a newly identified primary immunodeficiency 
(PID) and data on asymptomatic mutation carriers is scarce, we evaluated the peripheral and 
central B cell compartment both in the affected siblings and in their asymptomatic mother. In 
patient II:3, the few circulating B cells consisted for 50% of transitional B cells (Figure 2B). 
Total naive B cell levels, encompassing transitional B cells, were also increased at the 
expense of switched memory and marginal zone B cells (Figure 2B). In patient II:4, normal 
numbers of peripheral B cell subsets revealed an arrest at a later stage in development. 
Particularly, transitional B cell levels were normal, whereas total naive B cells were relatively 
increased and memory-type B cell percentages were decreased (Figure 2B). This points 
towards a block after the naive mature B cell stage. Analogous to previously reported 
asymptomatic IKZF1 mutation carriers2,3, the asymptomatic mother (I:2) exhibited peripheral 
B cell frequencies and subsets within normal ranges for age, although memory-type B cells 
were at the lower end and naive B cells at the upper end. This remained stable over a period 
of about two years (Figure 2B). 
Bone marrow aspirates from patient II:3 and asymptomatic mother (I:2) revealed normal 
frequencies of hematopoietic stem cells (HSC). Multipotent progenitors (MPP) were reduced, 
while common lymphoid progenitors (CLP) were moderately expanded (Figure 2C and 
Figure E3 in this article’s Online Repository) and total B-lineage cells were profoundly 
decreased in both patients (Figure 2C and Figure 2D, upper panel). Symptomatic patient II:3 
exhibited additionally a partial block from pro- to pre-B cells (Figure 2D, middle panel) and an 
almost complete block from immature/transitional to mature B cells (Figure 2D, lower panel). 
In the asymptomatic mother I:2 on the other hand, the reduced B-lineage cells demonstrated 
a normal maturation profile and were sufficient to sustain normal peripheral B cell numbers. 





Figure 2. B cell phenotype. (A) Peripheral blood total B cell counts. Measurements shown are from 
the first to the last immunological laboratory evaluation performed in our hospital. Grey shading 
represents the age-based reference range. (B) Peripheral blood B cell subsets. The top row depicts 
total B cells gated as CD19+CD20+ in alive peripheral blood mononuclear cells. In the second and third 
rows, B cell subsets were gated on total CD19+CD20+ B cells as indicated. Note that the samples 
shown here were taken at different time points than those in Table E1 of this article’s Online 
Repository. (C) Overview of different precursor stages of B cell development in bone marrow, shown 
as proportion of total Lin-CD45+, CD45+ or CD19+CD5- cells as indicated. (D) Bone marrow B cell 
subsets. The top row depicts total B-lineage cells gated as CD19+CD5- in CD45+ cells. In the second 
and third rows, B-lineage subsets were gated within this CD19+CD5- population. The middle graphs 
allow discrimination of pro-B cells (CD34+CD19+) from more mature B-lineage cells (CD34-CD19+). 
The lower graphs show the development from pro- and pre-B cells (pro-/pre-B; CD10+CD20-) over 
immature and transitional B cells (immature/trans B; CD10+CD20+) to mature naive B cells (mature B, 
CD10-CD20+). Abbreviations: No.: number, y: years, HC: healthy control, MZB: marginal zone B cells, 
NB: naive B cells, SMB: switched memory B cells, Trans B: transitional B cells, HSC: hematopoietic 
stem cells, MPP: multipotent progenitors, CLP: common lymphoid progenitors, imm: immature B. 
 
The multi-level central B cell developmental block observed in this IKZF1 family appears later 
than observed in previously published IKAROS haploinsufficient cases.2,3 First, early 
hematopoiesis in I:2 and II:3 showed a partial arrest at the MPP and the B-lineage stages, 
whereas two patients reported by Hoshino et al. exhibited blockages at the earlier HSC and 
CLP stages in addition to the B-lineage block.3 Second, within B-lineage cells, symptomatic 
patient II:3 exhibited arrests at the pre-B and mature B cell stages, whereas the Hoshino 
patients showed normal composition of the B-lineage and two patients described by Kuehn 





































































































































































































































genotype of our patients remains to be established, since all four previously reported patients 
harbored missense mutations in the second zinc finger motif of IKZF1, whereas our patients 
have a loss of IKAROS protein due to a frameshift mutation. 
To our knowledge, there have been no previous reports on central B cell development in 
asymptomatic IKZF1 mutation carriers. In subject I:2, the absence of clinical involvement was 
reflected in a quasi-normal peripheral B cell development. However, considering the 
important reduction in central B-lineage cells and the recently documented specific antibody 
deficiency, the B cell compartment is clearly affected and she might still become 
symptomatic at a later age.2 Interestingly, a Kaplan-Meier curve for onset of symptoms 
generated based on 45 reported symptomatic and asymptomatic cases, suggests that all 
germline IKZF1 mutation carriers may eventually go on to develop symptoms (see Figure E4 
in this article’s Online Repository). Although Kaplan-Meier estimates at the utmost ends of a 
time interval need to be interpreted with caution, from a clinical perspective this warrants 
longitudinal follow-up of asymptomatic subjects. Peripheral B cell numbers seem to be a 
suitable marker for monitoring disease progression, whereas serum IgG levels have been 
shown to remain normal for years following the development of B cell lymphopenia.2 
IKAROS haploinsufficiency shares important genetic aspects with other recently identified 
PIDs of haploinsufficiency. Notable are NF-κB1, CTLA-4 and GATA2 haploinsufficiencies, 
disorders that also affect the B cell compartment and are characterized by incomplete 
penetrance as well as variable expressivity and a highly variable age of onset in manifesting 
individuals.6,7 The molecular basis of incomplete penetrance and variable expressivity is 
poorly understood.6 Murine models have implicated an important role for IKAROS at nearly 
every step of B cell development and function.8,9 Besides the more obvious defects in 
hematopoietic progenitor cell development, impaired IKAROS function during recombination 
of Ig gene segments and peripheral B cell responses may provide a link with the antibody-
mediated autoimmune diseases seen in patient II:4 and previously reported cases and with 
the specific polysaccharide antibody deficiency detected in the asymptomatic mother (I:2), 
respectively.2,3 Furthermore, the largely different B cell profile in the here-reported mutant 
subjects despite similarly low IKAROS protein levels, may suggest the presence of 
compensatory mechanisms at multiple levels capable of (partially) surmounting the IKAROS 
defect.8,9 The actions of modifier genes, epigenetic changes and/or environmental exposures 
may affect these compensatory mechanisms in different ways, which may, in part, explain 
the phenotypic heterogeneity in IKAROS-haploinsufficient patients.8,9 Disease-influencing 
mechanisms in IKZF1-associated immunodeficiency await further study.  
In conclusion, we report on the first truncating IKZF1 mutation associated with IKAROS 
haploinsufficiency and illustrate an unexpectedly late and variable block in central and 
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peripheral B cell development in two patients and their asymptomatic mother. Given the 
observed immunological abnormalities we recommend close follow up of asymptomatic 
IKZF1 mutation carriers.  
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Supplementary Information  
 
SUPPLEMENTARY CLINICAL INFORMATION 
The first two pregnancies in the index family were complicated by premature labor of 
unknown etiology at 25 weeks (II:1) and 15 weeks (II:2) gestational age, respectively. Both 
children were not viable. The three remaining sisters (II:3, II:4, II:5) were born around 35 




All reported subjects provided written informed consent for participation in the study, in 
accordance with the 1975 Helsinki Declaration. The research protocol was approved by the 
ethical committee of Ghent University Hospital (2012/593). 
 
Whole exome sequencing (WES) 
WES was performed in the two affected siblings (II:3, II:4) and both parents (I:1, I:2). 
Genomic DNA was isolated from whole blood leukocytes using the Puregene DNA isolation 
kit (QIAGEN) according to manufacturer’s instructions. Whole exome enrichment was 
performed with the SureSelectXT Human All Exon V6 kit (Agilent Technologies). Paired-end 
massively parallel sequencing (100 cycles) was performed on a NextSeq 500 (Illumina). 
Read mapping against the human genome reference sequence (NCBI, GRCh37), and post-
mapping duplicate read removal, quality-based variant calling and coverage analysis were 
performed with CLC Genomics Workbench v6.0.4 (CLC bio). More than 98% of enriched 
regions had a read depth of at least 20x. Called variants with coverage ≥ 3 were annotated 
with Alamut Batch (Interactive Biosoftware). Only variants with population frequencies less 
than 10% were considered, according to public databases NCBI dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/), NHLBI Exome Sequencing Project - Exome 
Variant Server (http://evs.gs.washington.edu/EVS/), ExAC Browser 
(http://exac.broadinstitute.org/), and 1000 Genomes Project Browser 
(http://browser.1000genomes.org/). Variants were further prioritized based on allele 
frequency, functional prediction scores, nucleotide conservation scores and biological 
relevance.E1 Both Mendelian and non-Mendelian inheritance patterns were taken into 
account. Afterwards, variants of interest were evaluated using Alamut Visual mutation 
interpretation software v2.7 rev. 1 (Interactive Biosoftware), Ingenuity Variant Analysis 
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(QIAGEN, 2015 Release Spring), CADD scores v1.3 (http://cadd.gs.washington.edu/home), 
genome Aggregation Database (gnomAD) Browser (http://gnomad.broadinstitute.org), 
literature search, segregation analysis in available family members, and frequency in an in-
house database containing variants of more than 1000 exomes at time of analysis. 
 
Sanger sequencing of genomic DNA 
The DNA template (GRCh37/hg19) of IKZF1 (NM_006060) was obtained from UCSC 
Genome Browser (https://genome.ucsc.edu). Primers for amplification and sequencing of 
exon 3 and adjacent intron-exon boundaries were designed with Primer3Plus 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/)E2: forward primer 5’-
CTCATGCCACCCTCTCAAG-3’ and reverse primer 5’-GAGTGTCCATCCTCCCACAC-3’. 
Genomic DNA was amplified by PCR using the specific primers and KAPA2G Robust 
Hotstart Ready Mix (KAPA Biosystems). PCR products were enzymatically purified with 
Exonuclease I and Antarctic phosphatase (both New England BioLabs Inc.). Purified PCR 
products were sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied 
Biosystems) on a 3730xl DNA Analyzer (Applied Biosystems). Sequence reads were 
analyzed with SeqScape v2.5 (ThermoFisher Scientific). 
 
Sanger sequencing of complementary DNA (cDNA) 
Total RNA was isolated from peripheral blood mononuclear cells (PBMCs) of all available 
family members (I:1, I:2, II:3, II:4, II:5) and two healthy controls by use of the RNeasy Plus 
Mini Kit (QIAGEN) and reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad), 
according to manufacturer’s instructions. The cDNA template (GRCh37/hg19) of IKZF1 
(NM_006060) was obtained from Ensembl Genome Browser 
(http://www.ensembl.org/index.html). Primers for amplification and sequencing of exon 3 and 
adjacent coding regions were designed with Primer3Plus (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi/)E2: forward primer 5’-ATGGATGCTGATGAGGGTCAAG-3’ 
and reverse primer 5’-CGGAATGCAGCTTGATGTGCAGGAGC-3’. PCR amplification was 
performed by use of GoTaq Hot Start Colorless Master Mix (Promega). Purified PCR 
products were Sanger sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit 
(Applied Biosystems) on a 3130xL Genetic Analyzer (Applied Biosystems). Sequence reads 
were analyzed with SeqMan (DNAStar). 
 
IKZF1 gene expression 
Total RNA was isolated from PBMCs of two mutant family members (II:3, II:4) and three 
healthy controls by use of the RNeasy Plus Mini Kit (QIAGEN) and converted to cDNA using 




the Transcriptor High Fidelity cDNA Synthesis Kit (Roche), according to manufacturer’s 
instructions. Two amplicons of IKZF1 were investigated: amplicon 1 located upstream of the 
mutation at genomic position Chr7:50358652-50367269, and amplicon 2 located 
downstream of the mutation at genomic position Chr7:50469628-50469734 (GRCh37/hg19). 
These amplicons were chosen to target as many IKZF1 transcripts as possible. Primers were 
designed using PrimerXL and IDT primerquest (available upon request). GPI and PSMB2 
were used as reference genes. Gene expression was analyzed by real-time quantitative PCR 
using LightCycler 480 SYBR Green I Master reagent and a LightCycler 96 Instrument (both 
Roche) according to manufacturer’s instructions. All reactions were performed in triplicate. 
The relative quantification of gene expression was calculated with the comparative Ct 
method. 
 
Flow cytometric analysis of peripheral blood B and T cell subsets  
Peripheral blood B and T cell subsets were evaluated in the IKZF1 mutation carriers (I:2, II:3, 
II:4) and age-matched healthy controls as previously described.E3 In brief, cryopreserved 
PBMCs were stained with fixable viability dye 506 (eBioscience) and fluorescently labeled 
monoclonal antibodies under saturation conditions. Following antibodies (clones) were used: 
CD8 (RPA-T8), CD16 (3G8), CD19 (HIB19), CD20 (2H7), CD21 (B-LY4), CD27 (M-T271), 
CXCR5 (RF8B2), IgD (IA6-2), γδTCR (11F2) (all BD Biosciences); CD3 (SK7), CD4 (SK3), 
CD24 (ML5), CD25 (BC96), CD45RO (UCHL1), CCR7 (G043H7) (all Biolegend); CD4 (RPA-
T4), CD38 (HIT2), CD56 (TULY56), Foxp3 (PCH101) (all eBioscience). Cells were acquired 
on an LSR Fortessa flow cytometer (BD Biosciences). Data were analyzed with FlowJo 
version X (Tree Star Inc.). 
 
IKAROS intracellular staining  
Cryopreserved PBMCs were first stained with fluorescently labeled anti-CD3 (clone UCHT1) 
and anti-CD19 (clone SJ25C1) (both BD Biosciences). Afterwards, cells were fixed and 
permeabilized using FoxP3 staining kit (eBioscience) following manufacturer’s instructions, 
and incubated with fluorescently labeled anti-IKAROS (clone R32-1149, BD Biosciences).E4 
Cells were acquired on a FACSCanto II flow cytometer (BD Biosciences). Data were 




Flow cytometric analysis of bone marrow aspirates 
Bone marrow aspirates from the hipbone were obtained from subjects I:2 and II:3, with 
informed consent and the ethical approval of Newcastle and North Tyneside Research Ethics 
Committee.  
Analysis of hematopoietic stem and lineage progenitor cells was based on Doulatov et al.E5 
The following antibodies (clones) were used: CD3 (SK7-Leu9), CD19 (HIB19), CD20 (L27), 
CD56 (NCAM16.2), CD38 (HB7), CD45RA (HI100), CD90 (G20-127), CD10 (HI10A) (all BD 
Biosciences), and CD34 (581) (Biolegend). Cells were acquired on an LSR Fortessa X-20 
flow cytometer (BD Biosciences), with dead cell exclusion by DAPI (Sysmex).  
For analysis of B-lineage cells, cryopreserved bone marrow samples were stained as 
previously described.E6 The following antibodies (clones) were used: CD5 (L17F12), CD10 
(HI10a), CD19 (SJ25C1), CD20 (2H7), CD45 (2D1), CD34 (8G12) (all BD Biosciences). 
Samples were acquired on a FACSCanto II flow cytometer (BD Biosciences).  
All data were analyzed with FlowJo version X (Tree Star Inc.). 
 
Statistical analysis 
IKZF1 gene expression and IKAROS expression levels were compared using the Mann-
Whitney U test, with GraphPad Prism Software v7. A two-sided p value ≤ 0.05 was 
considered statistically significant. 
 
  






Table E1. Routine immunological laboratory evaluation.  
 Patient II:3 Patient II:4 Patient I:2 
 Value Reference range Value Reference range Value Reference range 
White blood cells Age: 13 years Age: 11 years Age: 42 years 
  Total leukocytes (no./µL) 6820 4500-12000 5050 4500-12000 11320 3650-9300 
  Neutrophils (no./µL) 3580 2500-8000                      2240 2500-8000                      7850 1573-6100 
  Lymphocytes (no./µL) 1690 1500-6500 2030 1500-6500 2350 1133-3105 
    CD3+ T cells (no./µL) 1370 800-3500 1520 800-3500 1930 700-2100 
       CD3+CD4+ T helper cells (no./µL) 659 400-2100 771 400-2100 1030 300-1400 
            CD45RA+ naive CD4+ T cells (%) 32 33-66 † 52 46-77 † 24 NA 
            CD45RO+ memory CD4+ T cells (%) 60 18-38 † 34 13-30 † 72 NA 
       CD3+CD8+ T cytotoxic cells (no./µL) 575 200-1200 508 200-1200 729 200-1200 
            CD45RA+ naive CD8+ T cells (%) 63 61-91 † 80 63-92† 47 NA 
            CD45RO+ memory CD8+ T cells (%) 32 4-23 † 16 4-21 † 53 NA 
       Ratio CD4/CD8 1.15 0.9-3.4 1.52 0.9-3.4 1.42 1.0-3.6 
    CD19+ B cells (no./µL) 17 200-600 122 200-600 141 100-500 
       IgD+CD27- naive B cells (%) 93 51.3-82.5 ‡ 90 51.3-82.5 ‡ 77 48.4-79.7 ‡ 
       CD24++CD38++ transitional B cells (%) 50 1.4-13.0 ‡ 3 1.4-13.0 ‡ 1 0.9-5.7 ‡ 
       IgD-CD27+ switched memory B cells (%) 1.5 8.7-25.6 ‡ 3 8.7-25.6 ‡ 10 8.3-27.8 ‡ 
       IgD+CD27+ marginal zone B cells (%) 2 4.6-18.2 ‡ 2 4.6-18.2 ‡ 9 7.0-23.8 ‡ 
       CD21low CD38low B cells (%) 3 2.7-8.7 ‡ 3 2.7-8.7 ‡ 3 1.6-10.0 ‡ 
    CD3-CD56+CD16+ NK cells (no./µL) 304 70-1200 386 70-1200 259 90-600 
  Monocytes (no./µL) 730 500-1000 650 500-1000 820 247-757 
  Eosinophils (no./µL) 300 100-500 20 100-500 240 28-273 
  Basophils (no./µL) 30 10-100 80 10-100 30 6-50 
Immunoglobulins * Age: 9 years Age: 11 years Age: 42 years 
  IgG (g/L) 7.0 4.70-11.9 12.7 4.70-11.9 10.7 7.0-16.0 
  IgG2 (g/L) 1.3 0.98-4.8 3.69 0.98-4.8 2.09 1.50-6.40 
  IgG3 (g/L) 0.668 0.15-1.49 0.309               0.15-1.49 0.617 0.20-1.10 
  IgM (g/L) Undetectable 0.27-0.74 0.4 0.27-0.74 0.35 0.40-2.48 
  IgA (g/L) Undetectable 0.50-1.66 Undetectable 0.50-1.66 0.98 0.71-3.65 
  IgE (kU/L) < 4.4 0-90 44.2 0-90 < 4.4 0-100 
Specific antibody responses * Age: 9 years Ages: 5 and 7 years Age: 42 years 
  S. pneumoniae polysaccharide IgG (Lab U) < 3 ≥ 11: immune 3 ≥ 11: immune NA  
  S. pneumoniae polysaccharide IgG :  
  specific IgG response to 3 serotypes  
  (8, 9N, 15B)      




increase for at 







increase for at 
least 2 out of 3 
serotypes $ 
  Tetanus IgG (IU/mL) 1.0 ≥ 0.01: immune 0.3 ≥ 0.01: immune 0.01 ≥ 0.01: immune 
  Rubella IgG (IU/mL) 18 > 10: immune 68 > 10: immune NA  
  Measles IgG (mIU/mL) 610 > 300: immune 1000 > 300: immune NA  
  Mumps IgG (Lab U/mL) 1800 > 500: immune < 230 > 500: immune NA  
  Varicella Zoster IgG (mIU/mL) 580 > 100: immune 1900 > 100: immune NA  
Lymphocyte proliferation assay Age: 9 years  Age: 5 years    
  Response to Concanavalin A Normal  Compared to 
control 
Normal Compared to 
control 
NA  
  Response to Phytohemagglutinin Normal  Compared to 
control 
Normal  Compared to 
control 
NA  









The most recent, comprehensive and representative laboratory results are shown for each patient, with patient age at time of analysis mentioned. Patients II:3 and II:4 were 
immunized according to the recommended childhood immunization schedule that, among others, included tetanus, measles, mumps, rubella and 7-valent conjugated 
pneumococcal vaccines. Patient I:2 had received a tetanus booster vaccine within the last 10 years. A polysaccharide (unconjugated) pneumococcal vaccine was given to 
all three patients at time of immunological evaluation; patient I:2 had never received a pneumococcal vaccine before then. Patients II:3 and II:4 were not vaccinated against 
varicella zoster virus but had chickenpox in early childhood. NA: not available. *Measured before start of immunoglobulin replacement therapy. †Reference values from 









Figure E1. Peripheral blood T cell subsets. Flow cytometric immunophenotyping of T cell subsets 
was performed on patients’ peripheral blood mononuclear cells (PBMCs) in comparison with age-
matched healthy controls (HC). At time of analysis, patients I:2, II:3, and II:4 were 40, 14, and 9.5 
years old, respectively. Patient II:3 is indicated as purple triangle, patient II:4 as blue star. Total T cells 
were gated as CD3+ in alive PBMCs. αβ T cells were gated as γδTCR- in total T cells. CD4+ and CD8+ 
T cells were gated in αβ T cells. In CD4+ and CD8+ T cells, naive cells were gated as CD45RO-
CCR7+, central memory cells (TCM) as CD45RO+CCR7+, effector memory cells (TEM) as 
CD45RO+CCR7-, and terminally differentiated cells (TEMRA) as CD45RO-CCR7-. Regulatory T (Treg) 
cells were gated as CD25+Foxp3+ and circulating follicular helper T (cTfh) cells as CXCR5+CD45RO+ 
in CD4+ T cells. Double negative (DN) T cells were gated as CD4-CD8- in αβ T cells. Natural killer 








































































































































































































































































































Figure E2. IKZF1 cDNA sequencing. Representative IKZF1 cDNA sequences of a mutant (M/WT) 
and wild type (WT/WT) family member. cDNA was derived from total peripheral blood mononuclear 
cells. The position of the nucleotide deletion (c.136) is shown on top. The M/WT individual has both a 
mutant and a wild type cDNA sequence, suggesting that the mutant transcript escapes nonsense-






Figure E3. Flow cytometric analysis of hematopoietic stem and early lineage progenitor cells in 
the bone marrow. The gating strategy was based on Hoshino et al.E10 Percentages represent 
percentage of parent population, indicated on top of each plot. CLP: common lymphoid progenitor, 
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Figure E4. Kaplan-Meier curve on symptom-free survival in germline IKZF1 mutation carriers. 
The curve was generated based on the presence and the age of onset of clinical symptoms in the 42 
previously published cases and the 3 here-reported cases with germline heterozygous IKZF1 
mutations.E4,E10,E11 Manifesting subjects first presented with symptoms up to the age of 57 years. 
Asymptomatic cases were 50 years or younger at time of publication (i.e. censored subjects, indicated 
on the curve as black tick marks). The Kaplan-Meier symptom-free survival curve estimates that all 
IKZF1 mutation carriers will have developed symptoms by 57 years of age. 
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In two Belgian siblings with a CVID-like phenotype born to non-consanguineous parents, we 
used whole exome sequencing to identify novel compound heterozygous missense variants 
in General Transcription Factor IIIA (GTF3A), segregating with disease and predicted to be 
pathogenic. The consequences of GTF3A mutations in humans or mice are unknown, and a 
specific role of GTF3A in the immune system has so far not been described. Transcription 
factor IIIA (TFIIIA), encoded by GTF3A, plays an indispensable role in transcription 
regulation of 5S ribosomal RNA (rRNA) encoding genes. 5S rRNA is a component of 
ribosomes, responsible for protein synthesis. TFIIIA depletion in human cell lines reduces 5S 
rRNA production and impairs ribosome biogenesis. Ribosomopathies, diseases caused by 
inborn defects in ribosome biogenesis, give rise to cell- and tissue-specific deficits and have 
been associated with immunological abnormalities reminiscent of CVID. In the here-reported 
patients, 5S rRNA expression was significantly reduced compared to the unaffected mother 
and healthy controls. Furthermore, both patients had impaired B cell and (albeit less-
pronounced) T cell proliferation, which is compelling because 5S rRNA and ribosome 
biogenesis have important functions in cell cycle regulation and B and T cell proliferation 
defects have been previously documented in ribosomopathies. Altogether, we hypothesize 
that biallelic loss-of-function GTF3A mutations may cause a novel ribosomopathy associated 
with CVID-like primary immunodeficiency disease. Future studies are planned to investigate 
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INTRODUCTION 
Common variable immunodeficiency (CVID) is one of the most frequently diagnosed primary 
immunodeficiencies (PIDs) defined as a marked decrease in serum IgG, decreased IgM 
and/or IgA, impaired production of specific antibodies after immunization, and exclusion of 
defined causes of hypogammaglobulinemia.1,2 CVID encompasses a phenotypically and 
genetically heterogeneous group of patients characterized by an increased susceptibility to 
(sinopulmonary) infections and features of immune dysregulation such as autoimmunity and 
lymphoproliferative disease.1 Furthermore, there are a vast number of patients with a clinical 
and laboratory phenotype reminiscent of CVID but not fulfilling all above-mentioned 
diagnostic criteria.1 In the past years, next-generation sequencing (NGS) technologies have 
facilitated the discovery of novel disease genes in patients diagnosed with CVID or CVID-like 
disease.3 These genetic discoveries have not only advanced our understanding of disease 
pathogenesis, but also uncovered genes with a previously unknown function in immunity 
(e.g. LRBA).3 
Here, we report a brother and sister pair presenting with a CVID-like phenotype in early 
childhood, in whom we identified novel compound heterozygous variants in General 
Transcription Factor IIIA (GTF3A) as possible underlying genetic cause. To our knowledge, 
GTF3A has not yet been associated with human disease. GTF3A encodes transcription 
factor IIIA (TFIIIA), which is a ubiquitously expressed Cys2His2 zinc finger protein.4 The 365 
amino acid sequence of human TFIIIA contains nine Cys2His2 zinc finger motifs and a non-
finger C-terminal tail.5 TFIIIA has been extensively studied for its role in transcription 
regulation of 5S ribosomal DNA (rDNA) genes, encoding 5S ribosomal RNA (rRNA).6,7 5S 
rRNA is a component of the 60S large ribosomal subunit.8 The human genome contains 
multiple 5S rDNA gene copies organized in clusters of tandem repeats.9 Binding of TFIIIA to 
the internal promoter region in the 5S rDNA genes initiates recruitment of TFIIIC, TFIIIB and 
RNA polymerase III (Pol III), forming a transcription complex by which the 5S rDNA genes 
are ultimately transcribed by Pol III.7 In addition, TFIIIA acts as a chaperone by binding and 
stabilizing 5S rRNA as well as other (unspecified) transcripts.10 Binding between 5S rRNA 
and TFIIIA, in turn, represses further transcription of the 5S rDNA genes.11 Furthermore, Pol 
III is also known for transcribing other small noncoding RNA genes involved in translation, 
such as RNase P, 7SK RNA and all transfer RNA (tRNA)-coding genes.7 Transcription 
initiation of these genes occurs independently of TFIIIA.7,8  
The function of GTF3A and its product TFIIIA have been mainly studied in model organisms 
such as Xenopus laevis (frog), Arabidopsis thaliana (plant) and Saccharomyces cerevisiae 
(yeast). 11-16 Thus far, a specific role of TFIIIA in the immune response is unknown and no 
mouse models have been reported. Silencing of GTF3A in human cell lines suppressed the 
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production of nascent 5S rRNA and impaired ribosome biogenesis.8 Defects in ribosome 
biogenesis form a class of diseases known as ribosomopathies, of which Diamond-Blackfan 
anemia and Shwachman-Diamond syndrome are typical examples.17 Ribosomes consist of 
ribosomal proteins and rRNA that are widely or even ubiquitously expressed in human 
tissues. Given the universal requirement of ribosomes for protein synthesis, it was long 
assumed that defective ribosome biogenesis would be incompatible with life.18 Strikingly, with 
the identification of genetic defects in ribosomal components, it became clear that 
ribosomopathies were not lethal but were in fact associated with unique tissue-specific 
phenotypes.17 Current knowledge on disease mechanisms in ribosomopathies is limited.18 
The most puzzling question in ribosomopathy-related research is how the disruption of 
ubiquitously expressed genes involved in fundamental processes can lead to cell- and 
tissue-specific deficits.18 One proposed explanation is the existence of cell- and tissue-
specific specialized ribosomes that recognize specific mRNAs.18 Others speculate that there 
may be spatiotemporal differences in ribosome biogenesis meaning that the required 
threshold levels of activity may be different in one tissue versus another at different times.17 
Common features among ribosomopathies are bone marrow failure and congenital (mainly 
skeletal) abnormalities.17 Considerable phenotypical variability is, however, seen in all 
ribosomopathies; e.g. about half of patients with Diamond-Blackfan anemia only present with 
anemia without dysmorphic features.17 Some, but not all, ribosomopathies increase patients’ 
susceptibility to solid tumors or hematological malignancies.19 Interestingly, several 
ribosomopathies have been associated with immunological defects, including reduced 
numbers and function of both T cells and B cells.20 Even more, in 2011, Khan et al stated 
that ribosomopathies would be able to explain some patients presenting with a CVID 
phenotype.20  
We hypothesize that the here-reported compound heterozygous GTF3A variants cause loss 
of TFIIIA function, impairing 5S rRNA generation and subsequent ribosome biogenesis, and 
resulting in a novel ribosomopathy characterized by a CVID-like primary immunodeficiency 
disease. We present preliminary data from the initial validation studies and discuss plans for 
future research. 
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All reported subjects provided written informed consent for participation in the study, in 
accordance with the 1975 Helsinki Declaration. The research protocol was approved by the 
ethical committee of Ghent University Hospital (2012/593). 
 
Microarray-based comparative genomic hybridization (array CGH) 
Array CGH was performed in both affected siblings (II:1, II:3) using the SurePrint G3 Human 
CGH Microarray Kit with an average genome-wide resolution of 100 kb, according to 
manufacturer's instructions (Agilent Technologies). Results were analyzed using 
arrayCGHbase.21 
 
Whole exome sequencing (WES) 
WES was performed in the two affected siblings (II:1, II:3) and both parents (I:1, I:2). 
Genomic DNA was isolated from whole blood leukocytes using the Puregene DNA isolation 
kit (QIAGEN) according to manufacturer’s instructions. Whole exome enrichment was 
performed with the SureSelectXT Human All Exon V5+UTRs kit (Agilent Technologies). 
Paired-end massively parallel sequencing (100 cycles) was performed on a NextSeq 500 
(Illumina). Read mapping against the human genome reference sequence (NCBI, GRCh37), 
and post-mapping duplicate read removal, quality-based variant calling and coverage 
analysis were performed with CLC Genomics Workbench v6.0.4 (CLC bio). Sequencing 
coverage is summarized in Table 1. Called variants with coverage ≥ 3 were annotated with 
Alamut Batch (Interactive Biosoftware). Only variants with population frequencies less than 
10% were considered, according to public databases NCBI dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/), NHLBI Exome Sequencing Project (ESP) 
Exome Variant Server (http://evs.gs.washington.edu/EVS/), 1000 Genomes Project Browser 
(http://browser.1000genomes.org/), and ExAC Browser (http://exac.broadinstitute.org/). 
Variants were further prioritized based on allele frequency, functional prediction scores, 
nucleotide conservation scores and biological relevance.22 Both Mendelian and non-
Mendelian inheritance patterns were taken into account. Afterwards, variants of interest were 
evaluated using Alamut Visual mutation interpretation software v2.7 rev. 1 (Interactive 
Biosoftware), Ingenuity Variant Analysis (QIAGEN, 2015 Release Spring), CADD scores v1.3 
(http://cadd.gs.washington.edu/home), genome Aggregation Database (gnomAD) Browser 
(http://gnomad.broadinstitute.org), literature search, segregation analysis in available family 
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members, and frequency in an in-house database containing variants of more than 1000 
exomes at time of analysis. 
 
Table 1. WES coverage.  
Subject 
Read depth 
Average       
read depth 
% of regions 
≥ 5 x 
% of regions 
≥ 10 x 
% of regions 
≥ 20 x 
% of regions 
≥ 40 x 
I:1  69.6 x 99.43% 98.12% 92.74% 72.38% 
I:2  98.3 x 99.83% 99.67% 98.78% 90.94% 
II:1 57.8 x 98.98% 97.41% 89.34% 61.83% 
II:3 57.5 x 99.11% 97.35% 88.50% 62.68% 
 
Read depth was calculated for all regions enriched by the SureSelectXT Human All Exon V5+UTRs kit 
(Agilent Technologies, CA, USA), using CLC Genomics Workbench v6.0.4 (CLC bio, MA, USA). 
 
Sanger sequencing of GTF3A 
The DNA template (GRCh37/hg19) of GTF3A (NM_002097) was obtained from UCSC 
Genome Browser (https://genome.ucsc.edu). Primers for amplification and sequencing of 
exons 6 and 7 and adjacent intron-exon borders were designed with Primer3Plus 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/)23: exon 6 forward primer 
5’-TCCTTAAAGGGAGGCACCTT-3’ and reverse primer 5’-GGGGTGGCTCAGAGACCT-3’; 
exon 7 forward primer 5’-CAGGTTTCAGGCACTGAATGT-3’ and reverse primer 5’-
AGCAGGTGAAAAGAATTCCAAA-3’. PCR was performed on an MJ Research PTC-200 
Thermal Cycler (MJ Research Inc.). Genomic DNA was amplified using KAPA2G Robust 
Hotstart Ready Mix (KAPA Biosystems). PCR products were enzymatically purified with 
Exonuclease I and Antarctic phosphatase (both New England BioLabs Inc.). Purified PCR 
products were sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied 
Biosystems) on a 3730xl DNA Analyzer (Applied Biosystems). Sequence reads were 
analyzed with SeqScape v2.5 (ThermoFisher Scientific).   
 
Protein modeling of TFIIIA 
The 3D protein structure of the target sequence, wild type human TFIIIA (UniProtKB ID 
Q92664), was predicted by I-TASSER24 using homology-based modeling based on the 
template structure, Xenopus laevis TFIIIA bound to DNA (PDB ID 1TF6)(target-template 
sequence identity = 53.8%). The 3D homology model was superimposed onto the template 
to determine the approximate locations of the TFIIIA mutation sites (Cys195 and Cys219) 
using UCSF Chimera (v1.11.2).25 
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Immunophenotypic analysis of peripheral blood mononuclear cells (PBMCs) 
Immunophenotyping of PBMC subsets was performed in the patients (II:1, II:3), their 
unaffected parents (I:1, I:2), and age-matched healthy controls as previously described.26 In 
brief, PBMCs were isolated from EDTA whole blood by Ficoll-Paque density gradient 
centrifugation and cryopreserved at -150°C. Thawed PBMCs were stained with fixable 
viability dye 506 (eBioscience) and fluorescently labeled monoclonal antibodies under 
saturation conditions: T cells (CD3, CD4, CD8, CD25, CD31, CD40, CD45RO, CD127, 
γδTCR, FOXP3, HLA-DR, CCR7, CXCR5, ICOS, CD69), B cells (CD19, CD20, CD21, CD24, 
CD27, CD38, CD138, IgD, IgM, IgA, IgG, TACI, BAFF-R, HLA-DR, CCR7, CXCR5), NK cells 
(CD16, CD56, TCR Vα24-Jα18 iNKT), monocytes (CD14, CD16), dendritic cells (CD11c, 
CD123). To analyze ICOS and CD69 upregulation on T cells, PBMCs were stimulated with 
1% PHA (Life Technologies) for 72 hours at a density of 1.25 x 106 PBMCs/mL in 
supplemented RPMI medium (Gibco). Cells were acquired on an LSR Fortessa flow 
cytometer (BD Biosciences). Data were analyzed with FlowJo version X (Tree Star Inc.). 
 
T and B cell proliferation, activation and differentiation 
Thawed PBMCs were incubated with CellTrace Violet proliferation dye (1µM; CellTrace 
Violet Cell Proliferation Kit, Invitrogen) for 20 minutes at 37°C. Afterwards, cells were 
centrifuged and washed twice with RPMI/10% fetal bovine serum (FBS) medium (Gibco). For 
T cell proliferation and activation, 1 x 105 PBMCs were seeded in a 96-well plate in 
RPMI/10% FBS and stimulated for 4 days with anti-CD3/CD28 (Dynabeads Human T-
Activator, ThermoFisher Scientific) or phytohemagglutinin (PHA; 1 m/mL, Sigma-Aldrich), as 
indicated in the figures. Unstimulated PBMCs were used as negative control. After 4 days, 
cells were stained with fluorescently labeled CD4, CD8 and CD25 (all BD Biosciences). 
Proliferation of CD4+ and CD8+ T cells was assessed by CellTrace Violet dye dilution. T cell 
activation was evaluated by upregulation of CD25 expression. For B cell proliferation, 
activation and differentiation, 4 x 105 PBMCs were seeded in a 96-well plate in RPMI/10% 
FBS and stimulated for 4 days with different combinations of F(ab’)2 anti-IgM (10 ng/mL, 
Jackson ImmunoResearch Laboratory), CD40L (200 ng/mL, Enzo Life Sciences), IL-21 (100 
ng/mL, Cell Signaling), and CpG ODN2006 (2.5 µM, InvivoGen), as indicated in the figures. 
PBMCs only treated with F(ab’)2 anti-IgM were used as negative control. After 4 days, cells 
were stained with fluorescently labeled CD19, CD25, CD27, CD38 (all BD Biosciences) and 
CD3 (Invitrogen). Proliferation of CD19+ B cells was assessed by CellTrace Violet dye 
dilution. B cell activation was evaluated by upregulation of CD25 expression. B cell 
differentiation into CD38highCD27high plasmablasts was determined.  
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To further assess B cell activation, 1.5 x 105 thawed PBMCs were cultured separately in a 
96-well plate in RPMI/10% FBS in the presence of F(ab’)2 anti-IgM (10 ng/mL, Jackson 
ImmunoResearch Laboratory) and soluble CD40 ligand (CD40L; 500 ng/mL, PeproTech). 
After 4 days, cells were stained with fluorescently labeled CD19, CD25, CD95 (all BD 
Biosciences), CD80 (eBioscience) and CD3 (Invitrogen). B cell activation was evaluated by 
upregulation of CD25, CD95 and CD80 expression. PBMCs only stimulated with F(ab’)2 anti-
IgM were used as negative control. 
Cells were acquired on a FACSCanto II flow cytometer (BD Biosciences). Data were 
analyzed with FlowJo version X (Tree Star Inc.). Fold change in mean fluorescence intensity 
(MFI) was calculated by dividing the MFI of stimulated cells by the MFI of the corresponding 
negative control. Proliferation indices were computed as the sum of cells in all generations, 
including the parental generation, divided by the computed number of original parent cells 
theoretically present at the start of the experiment, whereby the number of parent cells in 
each nth division was calculated as: (No. of cells in the nth division)/(2n).27 
 
Cytokine secretion 
Thawed PBMCs were seeded in a 96-well plate (1 x 105/well) in RPMI/10% FBS and 
stimulated with anti-CD3/CD28 (Dynabeads Human T-Activator, ThermoFisher Scientific) for 
24 hours, or lipopolysaccharide (LPS; 100 ng/mL, PeproTech) for 24 hours, or F(ab’)2 anti-
IgM (10 ng/mL, Jackson ImmunoResearch Laboratory) and CD40L (500 ng/mL, PeproTech) 
for 4 days, as indicated in the figures. Cell-free supernatants were harvested and stored at -
80°C. Cytokines (as indicated in the figures) were measured simultaneously with Fluorokine 
MAP Human Base Kit A (R&D Systems) using the Luminex 200 System (Luminex 
Corporation). 
 
BTK and PLCγ2 phosphorylation 
Thawed PBMCs were seeded in a 96-well plate (1 x 105/well) in RPMI/10% FBS and stained 
with fluorescently labeled CD19 (BD Biosciences). Cells were then stimulated with F(ab’)2 
anti-IgM (10 ng/mL, Jackson ImmunoResearch Laboratory) for 10 minutes. Unstimulated 
PBMCs were used as negative control. To terminate the stimulation response, cells were 
fixated in BD Cytofix/Cytoperm Buffer (BD Biosciences) for 30 minutes at 4°C in the dark. 
After washing, intracellular staining was performed with fluorescently labeled pBTK/ITK and 
pPLCγ2 (both BD Biosciences) in BD Perm/Wash Buffer (BD Biosciences). Cells were 
incubated for 1 hour at 4°C in the dark, washed three times with BD Perm/Wash Buffer, and 
acquired on a FACSCanto II flow cytometer (BD Biosciences). Data were analyzed with 
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FlowJo version X (Tree Star Inc.). Fold change in MFI was calculated by dividing the MFI of 
stimulated cells by the MFI of unstimulated cells. 
 
STAT1 and STAT5 phosphorylation 
Thawed PBMCs were cultured in a 96-well plate (2 x 105/well) in RPMI/10% FBS in the 
presence of IL-7, IFNα or IFNγ (all 10 ng/mL, PeproTech), and fluorescently labeled CD4 
(BD Biosciences) for 20 min. Unstimulated PBMCs were used as negative control. To 
terminate the stimulation response, cells were fixated in BD Cytofix/Cytoperm Buffer (BD 
Biosciences) for 30 minutes at 4°C in the dark. After washing, intracellular staining was 
performed with fluorescently labeled pSTAT1 and pSTAT5 (both BD Biosciences) in BD 
Perm/Wash Buffer (BD Biosciences). Cells were incubated for 1 hour at 4°C in the dark, 
washed three times with BD Perm/Wash Buffer, and acquired on a FACSCanto II flow 
cytometer (BD Biosciences). Data were analyzed with FlowJo version X (Tree Star Inc.). 
 
Western blot 
Thawed PBMCs (0.5-1.0 x 106) were lysed in 0.5% Triton X-100, 0.5% NP-40, 50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 2 mM ethylenediaminetetraacetic acid, protease inhibitor cocktail 
(EMD Millipore or Sigma-Aldrich) and phosphatase inhibitor cocktail (ThermoFisher Scientific 
or Sigma-Aldrich). For western blot analysis of T cell receptor signaling, thawed PBMCs were 
stimulated with anti-CD3/CD28 (Dynabeads Human T-Activator, ThermoFisher Scientific) in 
RPMI/10% FBS for 30 minutes prior to lysis. Lysate protein was quantitated using Pierce 
BCA Protein Assay Kit (ThermoFisher Scientific). Samples of equal protein concentration 
were prepared. Approximately 20 µg total protein was separated by 4-12% gradient gels and 
transferred onto nitrocellulose membranes. Membranes were blocked with 5% non-fat dry 
milk in Tris-buffered saline (TBS) with 0.05% Tween-20 (TBST) for 1 hour at 21°C. Next, 
membranes were incubated with primary antibody for 2 hours at 21°C. After washing with 
TBST for 30 minutes at 21°C, membranes were incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibody (Jackson ImmunoResearch Laboratory) for an 
additional hour at 21°C. Membranes were again washed with TBST for 30 minutes at 21°C. 
HRP substrate (ThermoFisher Scientific) was added to the membranes, which were then 
subjected to chemiluminscent imaging. For re-probing, membranes were first incubated with 
stripping buffer (ThermoFisher Scientific) for 15 minutes at 21°C, and then blocked and 
incubated with primary and secondary antibodies as described. The following primary 
antibodies were used: PLCγ1, NFκB p65, p-NFκB p65, IκBα, p-IKKα/β, IKKβ, p-ERK1/2, β-




Wild type (WT) and mutant GTF3A plasmids  
Human GTF3A (NM_002097) cDNA was cloned into CMV driven N-terminal flag-tagged 
expression vector (pFLAG-CMV-2, Sigma-Aldrich). Wild type (WT) GTF3A construct was 
purchased from Dharmacon. The two mutant GTF3A constructs (c.585T>G, p.C195W and 
c.655T>C, p.C219R) were generated via site directed mutagenesis using AccuPrime Pfx 
DNA Polymerase (Invitrogen) followed by Dpn I digestion (BioLabs). The primers used to 
generate the mutant constructs are provided in Table 2. Proper expression of the GTF3A 
plasmids was evaluated in HEK293T cells (Figure 1). 
 
Table 2. Primers for site directed mutagenesis of GTF3A. 
Primer Sequence (5’-3’) 
GTF3A C195W, forward TATGTATGTCAAAAAGGATGGTCCTTTGTGGCAAAAACATG 
GTF3A C195W, reverse CATGTTTTTGCCACAAAGGACCATCCTTTTTGACATACATA 
GTF3A C219R, forward CCCATAAAGAGGAAATACTACGTGAAGTATGCCGGAAAACA 
GTF3A C219R, reverse TGTTTTCCGGCATACTTCACGTAGTATTTCCTCTTTATGGG 
 
Nucleotide changes compared to the wild type sequence are marked in bold. 
  
 
Figure 1. Expression of GTF3A plasmids in HEK293T cells. The western blot membrane was 
probed with anti-flag antibody. Empty flag-tagged vector was used as negative control. TFIIIA protein 
size is approximately 35 kDa. WT: wild type. 
 
NFκB luciferase reporter assay 
HEK293T cells were seeded in a 24-well plate (4 x 104/well) in DMEM/10% FBS (Gibco) and 
transfected with WT, one mutant or both mutant GTF3A plasmids along with an NFκB firefly 
luciferase reporter gene plasmid using Effectene Transfection Reagent (QIAGEN) according 
to manufacturer’s instructions. Each condition was performed in duplicate. Twenty-four hours 
after transfection, cells were stimulated with TNFα (100 ng/mL, R&D Systems) for 6 hours at 
37°C. Next, cells were lysed in 0.5% Triton X-100, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 
mM ethylenediaminetetraacetic acid, and aprotinin protease inhibitor (MP Biomedicals). 
Luciferase activity was measured using the Luciferase Assay System kit (Promega) on a 
Synergy 4 Multi-Mode Microplate Reader (BioTek). To verify equal seeding and transfection 
efficiency, an aliquot of the lysates was prepared for western blot using NuPAGE LDS 
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Sample Buffer and NuPAGE Sample Reducing Agent (Invitrogen). Western blot for β-actin 
and Flag was performed as described above. 
For each independent experiment, data were normalized by dividing the luciferase signal of 
the sample by the luciferase signal of unstimulated cells transfected with empty flag-tagged 
vector (negative control). 
 
Small interfering RNA (siRNA) transfection 
siRNA-universal negative control and siRNA-GTF3A were purchased from Sigma-Aldrich. 
Freshly isolated PBMCs from healthy donors were plated in a 24-well plate (5 x 106/well) in 
RPMI/10% FBS and transfected with 300 nM siRNA using Amaxa electroporation (Lonza) 
according to manufacturer’s instructions. To evaluate transfection efficiency, a separate 
aliquot of PBMCs was transfected with pmaxGFP provided in the Lonza transfection kit. The 
next day, transfected cells were washed with fresh RPMI/10% FBS, and cell viability and 
GFP expression were determined on a FACSCanto II flow cytometer (BD Biosciences). To 
evaluate B cell proliferation, a first aliquot (1/3) of each sample was incubated the next day 
with CellTrace Violet proliferation dye as described above, and cultured with F(ab’)2 anti-IgM 
(10 ng/mL, Jackson ImmunoResearch Laboratory) and CD40L (200 ng/mL, Enzo Life 
Sciences) for an additional period of 4-5 days. Proliferation of CD19+ B cells was assessed 
by dye dilution as described above. A second aliquot (1/3) of each sample was cultured the 
next day with anti-IgM and CD40L as described above (without prior labeling with 
proliferation dye), to determine gene expression at the time of B cell proliferation 
assessment. A third aliquot (1/3) of each sample was used to determine gene expression at 
48 hours after transfection. In some experiments, an additional aliquot of cells was used to 
evaluate T cell proliferation by means of CellTrace Violet dye dilution at day 4-5 after 




Total RNA was extracted from unstimulated total PBMCs or siRNA-transfected PBMCs by 
means of the RNeasy Plus Mini Kit (QIAGEN) according to manufacturer’s instructions. Total 
RNA (100 ng - 1 µg) was reverse transcribed to cDNA using the iScript cDNA synthesis kit 
(Bio-Rad) according to manufacturer’s instructions. Gene expression was analyzed by 
quantitative PCR (qPCR) using SYBR Green reagent (Applied Biosystems) and 
StepOnePlus Real-Time PCR System (Applied Biosystems) according to manufacturer’s 
instructions. Expression of the following target genes was investigated: GTF3A, 5S rRNA, 
leucyl-tRNA (tRNALeu), and tyrosyl-tRNA (tRNATyr). GAPDH was used as reference gene. 
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Primers for 5S rRNA28, GAPDH28, tRNALeu29 and tRNATyr29 were obtained from previous 
publications (Table 3). Primers for GTF3A were designed in-house with Primer3Plus23 as 
described above (Table 3). All reactions were performed in triplicate for 40-45 cycles at Tm 
60-65°C. The relative quantification of gene expression was calculated with the comparative 
Ct method (ΔΔCt method). For each sample, the difference in threshold cycle (Ct) between 
the target and reference gene was determined as followed: ΔCt = (Ct of target gene) - (Ct of 
GAPDH). Next, data were normalized relative to a chosen control sample. For unstimulated 
total PBMCs: ΔΔCt = (ΔCt of each sample) - (ΔCt of one healthy control among 2 or 3 
healthy controls). For siRNA-transfected PBMCs: ΔΔCt = (ΔCt of each sample) - (ΔCt of the 
respective donor’s control siRNA sample). The fold change in expression of the target gene 
was calculated as 2^(-ΔΔCt).  
 
Table 3. Primers for qPCR. 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) Primer design  
GTF3A GGAGAAAAGCCGTTTGTTTG TGGGTGATGCAAAGTGTTTC In-house 
5S rRNA TACGGCCATACCACCCTGAA GCGGTCTCCCATCCAAGTAC Pagano et al.28 
leu-tRNA ATGGCCGAGTGGTCTAAGG ACCAGAAGACCCGAACACAG Birch et al.29 
tyr-tRNA CCTTCGATAGCTCAGCTGGT CGACCTAAGGATGTCCACAAAT Birch et al.29 
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC Pagano et al.28 
 
Statistical analysis 
When indicated, statistical analysis was performed with GraphPad Prism Software v6. A two-
sided p value < 0.05 was considered statistically significant. 
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We studied a sister and brother pair from a Belgian, non-consanguineous family (Figure 2A, 
II:1 and II:3 respectively) who presented with recurrent infections in early childhood. The 
sister (II:1), currently 28 years old, has been suffering from recurrent upper and lower 
respiratory tract infections often needing antibiotics since the age of 2 months. She had two 
severe pneumonias, at 4 and 5 years of age, of which one was complicated with sepsis. At 5 
years, she had acute Campylobacter gastroenteritis. At 6 years, she was hospitalized for 
acute Salmonella gastroenteritis. Around 10 years of age, she suffered from a persistent 
intestinal Giardia lamblia infection, requiring repeated courses of metronidazole. 
Immunological lab assessment revealed decreased IgM, normal IgA, normal total IgG and 
subclasses, and absent global antibody responses to polysaccharide pneumococcal vaccine 
(Table 4). B and T lymphocyte counts were normal (Figure 3). In accordance with the 
consensus ESID/PAGID diagnostic criteria at that time, she was diagnosed with possible 
CVID.30 During her teenage years, she was doing clinically well with few infections. Since 
young adulthood, however, she has developed additional symptoms of recurrent lower 
urinary tract infections, recurrent diarrhea, and fatigue. She started with immunoglobulin 
replacement therapy at 18 years of age, albeit with variable compliance. At 24 years, she 
presented with bilateral blue toe syndrome. Biopsy was suggestive of thrombotic 
vasculopathy. Diagnostic workup for thrombotic disorders including autoimmune vasculitis 
was, however, negative. At 26 years of age, she gave birth to healthy twin girls. The 
pregnancy was complicated by preeclampsia at 38 weeks gestational age, requiring an 
urgent caesarian section. Furthermore, she developed group A Streptococcus postpartum 
endometritis, responding well to oral antibiotic treatment. Recent immunological lab 
evaluations suggested a progressive decrease in total B cells (Figure 3). Peripheral B cell 
subsets, first evaluated at 24 years, showed an abnormal distribution with elevated 
transitional B cells and high-normal switched memory B cells (Table 4). Total IgG levels have 
so far remained within normal ranges, meaning that patient II:1 does not fulfill the current 
consensus diagnostic criteria for CVID.1 
The younger brother (II:3), currently 18 years of age, had a more severe clinical course. 
Similar to his sister, patient II:3 has been suffering from recurrent (mainly upper) respiratory 
tract infections since infancy, often requiring antibiotics. At the age of 7 months, he 
developed chronic secretory diarrhea with malabsorption. At that time serum IgG, IgA and 
IgM were decreased, at least partially due to enteric protein loss, and monthly intravenous 





Figure 2. Pedigree and GTF3A variants. (A) Pedigree of the core family and corresponding 
electropherograms. Squares, circles, and diagonal lines indicate males, females and deceased 
subjects, respectively. (B) Predicted 3D model of human wild type TFIIIA zinc finger 6 (purple) and 7 
(yellow) bound to DNA (blue). The mutation sites at two different conserved cysteines (C195 & C219) 
are highlighted in red. As these conserved residues act within a Cys2His2 zinc finger motif to 
coordinate zinc ions (Zn2+) that stabilize the fold, this model suggests that both mutations would 
destabilize the structure, thereby disrupting DNA binding. For clarity, only one conserved cysteine 
(stick) and histidine (pentagon) is shown for zinc finger 6. 
 
 
Figure 3. Evolution of peripheral blood lymphocyte counts in the patients. The most 
comprehensive and representative laboratory evaluations performed in our center are shown. Grey 
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Table 4. Routine immunological lab assessment. 
 Patient II:1  Patient II:3  
 Value Reference range Value Reference range 
White blood cells Age: 27 years Age: 17 years 
  Total leukocytes (no./µL) 4860 3650-9300 5610 4500-12000 
  Neutrophils (no./µL) 2600 1573-6100 3350 2500-8000 
  Lymphocytes (no./µL) 1480 1133-3105 1230 1500-6500 
    CD3+ T cells (no./µL) 1290 700-2100 886 700-2100 
       CD3+CD4+ T helper cells (no./µL) 636 300-1400 492 300-1400 
            CD45RA+ naive CD4+ T cells (%) 21 33-66 † 26 33-66 † 
            CD45RO+ memory CD4+ T cells (%) 75 18-38 † 72 18-38 † 
       CD3+CD8+ T cytotoxic cells (no./µL) 607 200-1200 283 200-1200 
            CD45RA+ naive CD8+ T cells (%) 47 61-91 † 63 61-91 † 
            CD45RO+ memory CD8+ T cells (%) 51 4-23 † 35 4-23 † 
       Ratio CD4/CD8 1.05 1.0-3.6 1.74 1.0-3.6 
    CD19+ B cells (no./µL) 89 100-500 160 100-500 
       IgD+CD27- naive B cells (%) 63  48.4-79.7 ‡ 96 48.4-79.7 ‡ 
       CD24++CD38++ transitional B cells (%) 27  0.9-5.7 ‡ 23 0.9-5.7 ‡ 
       IgD-CD27+ switched memory B cells (%) 28  8.3-27.8 ‡ 0.5 8.3-27.8 ‡ 
       IgD+CD27+ marginal zone B cells (%) 4  7.0-23.8 ‡ 1 7.0-23.8 ‡ 
       CD21low CD38low B cells (%) 6  1.6-10.0 ‡ 4 1.6-10.0 ‡ 
    CD3-CD56+CD16+ NK cells (no./µL) 104 90-600 172 90-600 
  Monocytes (no./µL) 420 247-757 900 500-1000 
  Eosinophils (no./µL) 320 28-273 110 100-500 
  Basophils (no./µL) 40 6-50 10 10-100 
Immunoglobulins * Age: 17 years Age: 13 years 
  IgG (g/L) 11.4 7.0-16.0 5.7 7.0-16.0 
  IgG2 (g/L) 1.57 1.06-6.1 1.94 1.06-6.1 
  IgG3 (g/L) 1.450 0.18-1.63 0.293 0.18-1.63 
  IgM (g/L) 0.2 0.40-2.48 Undetectable 0.34-2.14 
  IgA (g/L) 2.9 0.71-3.65 1.4 0.83-4.07   
  IgE (kU/L) < 4.4 0-100 < 4.4 0-200 
Specific antibody responses * Age: 17 years Age: 10 years 
  S. pneumoniae polysaccharide IgG (Lab U) Undetectable ≥ 11: immune 4 ≥ 11: immune 
  Tetanus IgG (IU/mL) 0.2 ≥ 0.01: immune 0.2 ≥ 0.01: immune 
  Rubella IgG (IU/mL) < 8 > 14: immune NA  
  Measles IgG (mIU/mL) 1400 > 300: immune NA  
  Mumps IgG (Lab U/mL) 380 > 500: immune NA  
  Varicella Zoster IgG (mIU/mL) 410 > 100: immune NA  
Lymphocyte proliferation assay Age: 23 years Age: 13 years 
  Response to Concanavalin A Normal  Compared to 
control 
Normal Compared to 
control 
  Response to Phytohemagglutinin Normal  Compared to 
control 
Normal  Compared to 
control 
  Response to Tetanus toxoid Normal  Compared to 
control 
Normal Compared to 
control 
  Response to Candida Normal  Compared to 
control 
Normal Compared to 
control 
 
The most recent, comprehensive and representative laboratory results are shown, with patient age at time of analysis 
mentioned. Aberrant values are indicated in bold. Both patients were immunized according to the recommended Belgian 
childhood immunization schedule that, among others, included tetanus, measles, mumps, and rubella vaccines. A 
polysaccharide (unconjugated) pneumococcal vaccine was given to both patients at time of immunological evaluation. The 
patients were not vaccinated against varicella zoster virus but had chickenpox in early childhood. *Measured when not receiving 






Despite elaborate diagnostic workup, the cause of the chronic enteropathy in patient II:3 
could not be found. Severe failure to thrive (below the 1st percentile for height and weight) 
and poor intake eventually resulted in the need for total parental nutrition (TPN) from the age 
of 2 to 5 years. In that period, he also had total lymphopenia (Figure 3) and reduced T cell 
proliferative responses to stimulation with mitogens (PHA, Concanavalin A). At 9 months of 
age, he was hospitalized for herpes simplex encephalitis (positive herpes simplex virus type 
1 (HSV-1) PCR testing on cerebrospinal fluid), which responded well to intravenous 
treatment with acyclovir. In his 3rd and 4th year of life, he had recurrent episodes of 
autoimmune anemia and two episodes of central venous catheter-related sepsis with 
enterococci and coagulase-negative staphylococci. After the age of 5 years, his clinical and 
laboratory phenotype remarkably ameliorated, with resolution of the chronic enteropathy, 
catch-up growth and cessation of TPN as well as a gradual increase of T cell numbers 
(Figure 3), normalization of mitogen-induced T cell proliferation, and normalization of serum 
IgA. Up to this day, however, he has mild total lymphopenia and absent serum IgM (Figure 3, 
Table 4). Similar to his sister (II:1), global antibody response to polysaccharide 
pneumococcal vaccine was impaired, total B cell numbers fluctuated around the lower limit of 
normal and transitional B cell levels were increased (Table 4, Figure 3). However, patient II:3 
had very low switched memory B cells, which is the opposite of what was observed in his 
sister (II:1) (Table 4). When he was 9 years old, immunoglobulin therapy was interrupted for 
several months revealing decreased serum levels of total IgG. Analogously, in early 
adolescence, total IgG levels were reduced during a period of poor therapy compliance 
(Table 4). Together, this supported the diagnosis of CVID in patient II:3.30 Today, he is doing 
clinically well under regular immunoglobulin replacement therapy and has reached his 
predicted height (12th percentile). Repeated imaging in patients II:1 and II:3 has, so far, not 
shown signs of lymphoproliferation, granulomata or bronchiectasis. 
The father (I:1) was diagnosed with distal esophageal adenocarcinoma at the age of 45 
years, secondary to chronic gastroesophageal reflux disease complicated by barrett's 
esophagus. He had two recurrences and deceased at 50 years of age. There were no clinical 
or laboratory signs of immunodeficiency in his past medical history. The mother (I:2) and 
third sibling (II:2) are in good health and basic immunological lab phenotyping was normal. 
 
The affected siblings were compound heterozygous for novel GTF3A variants 
predicted to disrupt zinc finger formation and nucleic acid binding  
To determine the underlying genetic defect, WES was performed in the two affected siblings 
(II:1, II:3) and both parents (I:1, I:2). Prior to WES, large pathogenic copy number variations 
(> 100 kb) were ruled out in both patients by routine array CGH. WES did not reveal good 
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candidate variants in known PID genes or other genes known to be involved in 
immunological responses. Interestingly, both affected siblings were compound heterozygous 
for two missense variants in GTF3A (NM_002097: c.585T>G, p.C195W and c.655T>C, 
p.C219R) predicted to be pathogenic and segregating with disease (Figure 2A, Table 5). 
Furthermore, both GTF3A variants were absent from public databases (dbSNP, ESP, GoNL, 
1000 Genomes, ExAC, gnomAD) and from an in-house database containing variants from 
more than 1000 exomes at time of analysis. The GTF3A variants p.C195W and p.C219R 
were located in Cys2His2 zinc finger motifs 6 and 7, respectively (Figure 2B). Previous 
biochemical experiments demonstrated that zinc fingers 6 and 7 are involved in binding the 
5S rDNA promoter region and the 5S rRNA transcript.10 For both GTF3A variants, one of the 
two highly conserved, negatively charged, cysteine residues essential for zinc finger 
formation was replaced by a bulky, non-negatively charged, amino acid (Figure 2B). These 
amino acid substitutions were, therefore, likely to disrupt zinc ion binding, destabilizing the 
3D zinc finger structure necessary for nucleic acid binding (Figure 2B). Notwithstanding that 
GTF3A is ubiquitously expressed in human tissues, publically available mRNA expression 
datasets showed that it is highly expressed in all lymphocytes and highest in B cells 
(http://biogps.org/). Altogether, this made GTF3A a strong candidate gene for the 
immunodeficiency phenotype observed in the here-presented patients.  
 
Table 5. In silico pathogenicity predictions of the GTF3A variants. 
 c.585T>G, p.C195W c.655T>C, p.C219R 
Conservation nucleotide Weak   High   
Conservation amino acid High, up to Fruitfly  
(considering 14 species)  
High, up to Fruitfly  
(considering 14 species)  
Grantham distance 215  180  
Align GVGD C15  C0  
SIFT Deleterious Deleterious  
PolyPhen-2 Probably Damaging Probably Damaging 
CADD phred score (MSC: 4.921) 27.2 27.8 
 
 
By Alamut Visual software, nucleotide conservation is determined based on phastCons and phyloP scores,33,34 
and amino acid conservation through orthologue alignments and information on protein domains. Grantham 
distance reflects the differences in physicochemical properties between amino acids. Grantham scores range 
from 5 to 215; higher scores are considered more deleterious with values ≥ 150 considered radical.35 Align-
GVGD combines the biophysical characteristics of amino acids and protein multiple sequence alignments to 
predict pathogenicity of missense variants. Align-GVGD predictions are shown as classes (C0 to C65) with class 
≥ C45 considered to interfere with function.36 SIFT (Sorting Intolerant From Tolerant) predicts the possible impact 
of amino acid substitutions based on sequence homology and the physical properties of amino acids.37 
PolyPhen-2 (Polymorphism Phenotyping v2) predicts the possible impact of missense variants on the stability 
and function of human proteins using structural and comparative evolutionary considerations.38 CADD (Combined 
Annotation Dependent Depletion) scores the deleteriousness of single nucleotide variants as well as 
insertion/deletion variants in the human genome.39 CADD phred scores ≥ 20 predict that a variant is among the 
1% most deleterious of all possible substitutions. MSC (Mutation Significance Cutoff) is a quantitative approach 




TFIIIA expression is normal whereas 5S rRNA expression is reduced in the patients 
TFIIIA protein expression was comparable between the two affected siblings, unaffected 
sister, mother and healthy controls (Figure 4A). In contrast, transcript expression levels of 5S 
rRNA, the main target of TFIIIA, were significantly lower in the patients compared to the 
mother and healthy controls (Figure 4B). tRNALeu and tRNATyr, two TFIIIA-independent 
genes, were similarly expressed in all studied subjects (Figure 4B). These expression data 
support the hypothesis of loss of TFIIIA function in the patients, while TFIIIA-independent Pol 
III transcriptional activity appears to be intact. 
 
 
Figure 4. Expression of TFIIIA, 5S rRNA, tRNALeu and tRNATyr. (A) TFIIIA protein expression 
evaluated by western blot. β-tubulin was used as loading control. (B) Transcript expression levels of 
the TFIIIA-dependent gene 5S rRNA and the TFIIIA-independent genes tRNALeu and tRNATyr, 
determined by qPCR. Data represent mean ± SEM of two replicate experiments (2-3 HC per 
experiment). The three groups were compared by use of one-way ANOVA. If this indicated significant 
differences, 2-by-2 comparisons were done with the unpaired Student’s t test. ns: not significant. All 
analyses were performed on unstimulated total PBMCs of the affected siblings (II:1, II:3), the 
unaffected mother (I:2) and healthy controls (HC). Since material of the unaffected sister (II:2) was 
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Patients’ B cells demonstrated intact surface IgM expression, normal activation and 
cytokine secretion, but altered differentiation in vitro  
A possible role of TFIIIA in the immune system is thus far unknown. To assess which 
pathways might be affected by mutant TFIIIA, we performed detailed immunophenotypic 
analysis of PBMCs (as previously described26) and general immuno-functional screening of B 
cells, T cells and TLR signaling. 
 
Despite the fact that serum IgM is reduced to undetectable in the patients, surface IgM 
expression on B cells was comparable to that of healthy controls (Figure 5A). Moreover, 
upon stimulation of patients’ PBMCs with anti-IgM, phosphorylation of the immediately 
downstream effector proteins BTK and PLCγ2 was normal (Figure 5B). Hence, surface IgM 
in the patients was not only present but also capable of signal transduction. 
To evaluate the overall B cell activation response, patients’ PBMCs were treated with 
different B cell stimuli for 4 days. After anti-IgM/CD40L stimulation, upregulation of the B cell 
activation markers CD80, CD25 and CD95 was normal in the patients compared to the 
mother and healthy controls (Figure 5C). Similar results were observed after IgM-
independent stimulation with IL-21/CD40L or CpG/CD40L (data not shown). Note that anti-
IgM will mainly activate naive B cells and IgM+ memory B cells, whereas IgM-independent 
stimuli will mostly trigger memory B cells.41,42 In correspondence with the adequate B cell 
activation responses, patients’ B cells secreted normal amounts of cytokines upon 
stimulation with anti-IgM/CD40L for 4 days (Figure 5D). 
In vitro differentiation of B cells into CD38highCD27high plasmablasts was examined by 
stimulating patients’ PBMCs with IL-21/CD40L or CpG/CD40L for 4 days (Figure 5E).43 
Stimulation with anti-IgM/CD40L was used as negative control (Figure 5E, top graphs).44 In 
patient II:3, plasmablast formation was reduced after IL-21/CD40L and virtually absent after 
CpG/CD40L stimulation (Figure 5E). In patient II:1, however, plasmablast generation was 
normal after CpG/CD40L and markedly elevated after IL-21/CD40L compared to healthy 
controls (Figure 5E). These findings corresponded with the patients’ in vivo levels of switched 









Figure 5. IgM surface expression, and B cell activation, cytokine secretion and differentiation. 
(A) IgM surface expression on resting CD19+ B cells of the patients (II:1, II:3) compared to an adult 
healthy control (HC). (B) Total PBMCs were stimulated with anti-IgM for 10 min. BTK and PLCγ2 
phosphorylation, evaluated in CD19+ B cells, was similar in the patients compared to the mother (I:2) 
and HC (unpaired Student’s t test). Graphs show mean ± SD. ns: not significant, MFI: mean 
fluorescence intensity. (C) Total PBMCs were stimulated with anti-IgM and CD40L for 4 days. 
Upregulation of the activation markers CD80, CD25 and CD95 was determined on CD19+ B cells. 
Graphs show mean ± SD. MFI: mean fluorescence intensity. (D) Total PBMCs were stimulated with 
anti-IgM and CD40L for 4 days, and cytokine secretion was measured in harvested supernatant of the 
patients, mother and 3 HC. Graphs show mean ± SD. (E) Total PBMCs were stimulated as indicated. 
After 4 days (4d), in vitro differentiation of B cells into CD27highCD38high plasmablasts was evaluated. 
Representative data of two (A), three (B, C) or one (D, E) replicate experiment(s) are displayed. HC: 
healthy control. 
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B cell proliferation responses were impaired in both patients 
B cell proliferation upon in vitro stimulation was significantly reduced in the patients 
compared to the unaffected mother and healthy control subjects (Figure 6). This was seen 
for all tested combinations of B cell stimuli. In patient II:1, percentages of divided B cells in 
the IL-21 condition were normal, but there was still a large undivided peak (i.e. utmost right 
peak on graph) that was not seen in the healthy controls nor the mother (Figure 6A). In 
accordance, proliferation indices (representing the number of divisions a cell has undergone) 
were significantly lower in the patients compared to the mother and healthy controls for all 
tested conditions (Figure 6B). The B cell proliferation defect seemed to be most pronounced 
in the patients’ naive B cell compartment (Figure 6C). Particularly after stimulation with IL-21, 
the patients’ naive B cells showed a large undivided peak while naive B cells of the mother 





Figure 6. Impaired B cell proliferation. Total PBMCs were stimulated as indicated for 4 
days (4d). Data in all panels are derived from the same samples and are representative for 
three replicate experiments. (A) Proliferation of total CD19+ B cells measured as the 
percentage of divided cells based on dilution of the CellTrace Violet proliferation dye. 
Histograms depict stimulated cells (red shaded) versus anti-IgM only treated cells (grey 
shaded, negative control). (B) Proliferation (Prolif.) indices of the same conditions presented 
in panel (A). Graphs show mean ± SD. Statistical significance was determined using the 
unpaired Student’s t test. (C) Proliferation of naive (CD27-) and memory (CD27+) B cells, 
derived from the same samples presented in panel (A). Total B cells only treated with anti-
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T cell receptor induced proliferation is impaired while overall signaling appears 
unaltered  
Detailed immunophenotyping of peripheral T cell subsets did not reveal any abnormalities in 
the patients compared to age-matched healthy controls (data not shown).  
Upon stimulation with anti-CD3/anti-CD28 Dynabeads, the T cell proliferation histograms 
showed a large undivided peak in the patients that was absent in the mother and healthy 
controls (Figure 7A, top). Indeed, the corresponding proliferation indices were significantly 
reduced in the patients (Figure 7B, top). However, T cell proliferation after stimulation with 
the mitogen PHA was normal in both patients (Figure 7A-B, bottom). Proliferation differences 
between naive and memory T cells were not yet evaluated. 
Analogous to the normal activation and cytokine production by patients’ B cells, upregulation 
of the T cell activation marker CD25 at day 4 as well as T cell cytokine secretion at 24 hours 
after stimulation was similar in the patients, mother and healthy controls (Figure 7C-D).  
To evaluate downstream T cell receptor signaling, western blot was performed for the 
proximal effector molecule PLCγ1, several key components of the NFκB pathway, and ERK 
as overall measure of the MAPK signaling pathway (Figure 7E). Both total levels and 
phosphorylation of the investigated proteins were comparable between patients, their mother 
and healthy controls (Figure 7E).  
Finally, STAT1 and STAT5 phosphorylation in CD4+ T cells upon cytokine stimulation were 





Figure 7. T cell proliferation, activation, cytokine secretion and signaling. (A) Total PBMCs were stimulated 
as indicated for 4 days (4d). Proliferation of CD4+ and CD8+ T cells was measured as the percentage of divided 
cells based on dilution of the CellTrace Violet proliferation dye. Histograms depict stimulated (red shaded) versus 
unstimulated cells (grey shaded). PHA: phytohaemagglutinin. (B) Proliferation (Prolif.) indices of the same 
conditions presented in panel (A). Graphs show mean ± SD. Statistical significance was determined using the 
unpaired Student’s t test. ns: not significant. (C) Upregulation of the activation marker CD25 on CD4+ T cells after 
4 days (4d) of stimulation with anti-CD3/CD28 Dynabeads. Graph shows mean ± SD. MFI: mean fluorescence 
intensity. (D) Total PBMCs were stimulated as indicated, and cytokine secretion was measured in the patients, 
mother and 3 HC. Graphs show mean ± SD. (E) Total PBMCs were stimulated with anti-CD3/CD28 Dynabeads 
for 30 min (+) or left untreated (-). T cell receptor signaling molecules were evaluated by western blot. (F) STAT1 
and STAT5 phosphorylation in CD4+ T cells after cytokine stimulation of total PBMCs. Histograms depict 
unstimulated cells (grey shaded), stimulated cells (red shaded), and IgG isotype control (black line). 







































  -      +      -      +       -      +      -      +      -      +      -       + 




Total PBMCs + anti-CD3/CD28 Dynabeads (30 min) 
B 





CD4+ T CD4+ T 
CD4+ T CD4+ T 
C 














































Total PBMCs + anti-CD3/CD28 Dynabeads (24h) D 








































































p = 0.0141 
















































Compound heterozygous GTF3A mutations cause a novel ribosomopathy characterized by 
CVID-like primary immunodeficiency disease 
 209 
Limited screening of the innate immune system in the patients was normal 
As part of the first-step general functional screening pipeline, limited testing of the innate 
immune system was performed. The patients did not show alterations in peripheral NK cell, 
monocyte or dendritic cell subsets (data not shown). Furthermore, cytokine secretion after 
stimulation with the TLR4-agonist LPS was comparable to that of healthy controls (Figure 8). 
Analogous to the normal STAT1 phosphorylation in CD4+ T cells (Figure 7F), IFNγ-induced 
STAT1 phosphorylation in monocytes was also normal (data not shown). 
 
 
Figure 8. LPS-induced cytokine secretion. Total PBMCs of the patients, mother and 3 healthy 
controls (HC) were stimulated with the TLR4-agonist LPS for 24 hours (24h). Cytokine secretion was 
measured in harvested supernatant. Graphs show mean ± SD. Data is representative of three 
replicate experiments. 
 
Mutant TFIIIA did not affect NFκB signaling activity in HEK293T cells 
It was recently described that canonical NFκB signaling is broadly impaired among CVID 
patients with reduced switched memory B cells, independent of the clinical phenotype or 
genetic defect.45 In the here-reported patients, patient II:3 had very low switched memory B 
cells whereas patient II:1 had high switched memory B cells. To determine the specific effect 
of the mutant GTF3A alleles on NFκB signaling, independent of the patients’ genetic 
background, an NFκB luciferase reporter assay was performed (Figure 9). HEK293T cells 
were transfected with WT, one mutant or both mutant GTF3A plasmids, along with a 
luciferase reporter gene construct for NFκB. Luciferase signal was measured after 6 hours 
stimulation with TNFα. NFκB signaling activity induced by the TFIIIA mutants, either 
separately or combined, was comparable to that of WT TFIIIA (Figure 9). These findings are 






















































Figure 9. NFκB luciferase reporter assay. HEK293T cells were transfected with GTF3A wild type 
(WT) or mutant (single or combined) plasmids along with the NFκB reporter construct. Transfection 
with empty vector was used as control and for normalization. Twenty-four hours after transfection, 
cells were stimulated with TNFα for an additional 6 hours (6h) or left untreated. Reporter luciferase 
activity was subsequently measured. There were no significant differences in luciferase activity 
between cells transfected with empty vector, WT GTF3A, single mutant GTF3A or combined mutant 
GTF3A (one-way ANOVA). Data represent mean ± SEM of five independent experiments. 
 
Normal intracellular localization of mutant TFIIIA 
We found that 5S rRNA expression was significantly reduced in patients’ PBMCs (Figure 4), 
suggestive of reduced transcriptional activity of TFIIIA. Therefore, the effect of the GTF3A 
variants on nuclear translocation of the protein was investigated. NIH-3T3 cells were 
transfected with WT, single mutant or combined mutant GTF3A vectors and TFIIIA was 
detected by fluorescently labeled antibody. Fluorescence microscopy showed no difference 
in intracellular localization patterns between WT and mutants, implicating that the two GTF3A 
missense variants did not disrupt nuclear translocation of TFIIIA (data not shown). 
 
Transient TFIIIA depletion mildly reduced 5S rRNA expression and B cell proliferation 
To examine whether a reduction of TFIIIA function was responsible for the diminished 5S 
rRNA expression in the patients, we knocked down GTF3A in healthy donor PBMCs by use 
of siRNA. Transfection efficiency was rather low (~25%) but consistent between 
experiments. qPCR at 48 hours posttransfection showed a mild decrease in 5S rRNA 
expression in TFIIIA-depleted cells, but this did not reach statistical significance (p = 0.058) 
(Figure 10A). Expression of the control targets tRNALeu and tRNATyr at 48 hours 
posttransfection was very variable across experiments, but was on average unchanged 
(Figure 10A). Although transient GTF3A knockdown with siRNA is expected to wear off after 
a few days, in 4 out of 6 experiments GTF3A expression was still silenced at day 5 to 6 
posttransfection. At that time, 5S rRNA expression was found to be significantly reduced in 
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observable effect on B and T cell proliferation, transfected cells were dyed with CellTrace 
Violet and stimulated with anti-IgM/CD40L or anti-CD3/CD28 Dynabeads, respectively, for 4 
to 5 days starting 24 hours posttransfection. B cell proliferation of TFIIIA-depleted cells was 
mildly reduced compared to that of cells transfected with control siRNA, although this did not 
reach statistical significance (p = 0.0536) (Figure 10C). In contrast, proliferation of CD4+ and 
CD8+ T cells was not altered in TFIIIA-depleted cells (data not shown).  
 
 
Figure 10. Transient GTF3A knockdown in healthy donor PBMCs. Cells were transfected with 
siRNA-universal negative control (siControl) or siRNA-GTF3A (siGTF3A).  (A) Relative gene 
expression at 48 hours posttransfection, evaluated with qPCR. (B) Relative gene expression at 5-6 
days posttransfection, evaluated with qPCR. (C) To examine B cell proliferation, cells were stained 
with CellTrace Violet proliferation dye and stimulated with anti-IgM/CD40L for 4 to 5 days starting 24 
hours posttransfection. A representative histogram is depicted on the right. Data from six (A) or four 
(B, C) independent experiments are shown. All graphs represent mean ± SEM. Statistical significance 



































































































































































We identified novel compound heterozygous variants in GTF3A, encoding the transcription 
factor TFIIIA,4 in a Belgian brother and sister pair presenting with a CVID-like phenotype. 
Thus far, GTF3A has not been associated with human disease and a possible role of TFIIIA 
in the immune system remains enigmatic. Computational predictions as well preliminary 
functional studies have provided evidence that the here-reported GTF3A variants could be 
disease-causing through loss of TFIIIA function. In particular, the variants were located in 
highly conserved cysteine residues of zinc finger motifs 6 and 7, respectively, and were 
predicted to destabilize the corresponding 3D zinc finger structures and subsequent nucleic 
acid binding. TFIIIA protein expression in the patients was similar to that in the unaffected 
family members and healthy controls. Expression of 5S rRNA, the best-established TFIIIA 
target gene,6,7 was significantly reduced in the patients compared to the heterozygous 
mother and healthy controls, whereas expression of TFIIIA-independent tRNA-coding genes 
appeared to be unaltered. 
Based on the normal TFIIIA expression, the reduced but not completely absent 5S rRNA 
expression, and the fact that each variant only disrupts one of nine consecutive zinc fingers 
of TFIIIA, we hypothesize that the patients have two partial loss-of-function GTF3A alleles 
resulting in two aberrant TFIIIA proteins that each lost part of their nucleic acid binding 
capacity. Since 5S rRNA is important in ribosome biogenesis,6-8 the two hypomorphic GTF3A 
alleles may result in a novel ribosomopathy associated with primary antibody failure.17,20 
 
Both siblings, currently 28 (II:1) and 18 (II:3) years old, had recurrent (mainly respiratory 
tract) infections since early childhood, reduced to absent serum IgM, impaired antibody 
responses to polysaccharide pneumococcal vaccine, and low-normal total B cells. The boy 
(II:3) also demonstrated decreased levels of total IgG and mild lymphopenia. Consistent with 
the laboratory phenotype, patient II:3 had a more severe clinical course than his older sister. 
In early childhood, the boy suffered from chronic idiopathic enteropathy resulting in severe 
failure to thrive and need for TPN for several years. During that time he showed evidence of 
a combined immunodeficiency with T cell lymphopenia and panhypogammaglobulinemia. 
However, once the gastrointestinal symptoms resolved, his immunological lab phenotype 
ameliorated into a CVID-like picture. This suggests that the more severe immunosuppression 
in the first years of life might have been secondary to the enteropathy and/or the underlying 
cause of the enteropathy. We presume that the chronic intestinal inflammation in patient II:3 
was most likely triggered by an infectious agent. In support of this, there have been sporadic 
reports on immunodeficient patients with persistent enteric (viral) infections that subsequently 
developed inflammatory enteropathy.46 Furthermore, viral infections are notorious for 
Compound heterozygous GTF3A mutations cause a novel ribosomopathy characterized by 
CVID-like primary immunodeficiency disease 
 213 
inducing transient T cell lymphopenia47, although the prolonged course and the residual 
persistent mild lymphopenia seen in patient II:3 were probably associated with his primary 
immunodeficiency.  
 
Preliminary functional studies on patients’ PBMCs uncovered an important B cell proliferation 
defect, irrespective of stimulation through the B cell receptor or through cytokine receptors. 
Remarkably, total B cell proliferation percentages were normal in patient II:1 after stimulation 
with IL-21, although there was still a large peak of undivided cells. It was previously shown 
that memory B cells possess an intrinsic advantage over naive B cells in terms of 
proliferation and differentiation after in vitro stimulation.48 Indeed, subsequent investigations 
revealed that especially the naive B cells in both patients proliferated very poorly while 
memory B cell proliferation was close to normal upon IL-21 stimulation. Since patient II:1 had 
> 25% memory B cells and patient II:3 had < 1%, this probably explains why total B cell 
proliferation percentages after stimulation with IL-21 were markedly higher in patient II:1 than 
in patient II:3. Still, it is unclear why the patients’ (memory) B cells proliferated more after IL-
21/CD40L stimulation than after anti-IgM/CD40L or CpG/CD40L stimulations.  
Besides impaired B cell proliferation, less-pronounced defects in T cell proliferation were 
detected. Remarkably, T cell proliferation was significantly reduced after anti-CD3/CD28 but 
not after PHA stimulation. Anti-CD3/CD28 specifically triggers the T cell receptor whereas 
PHA engages surface glycoproteins in an aspecific manner.49 As such, PHA stimulates IL-6 
production by monocytes, which, in turn, enhances T cell proliferation.50 It is possible that, in 
contrast to the B cell situation, adding cytokines to anti-CD3/CD28 could overcome the T cell 
proliferation defect. The latter needs to be further explored. Moreover, differences between 
naive and memory T cell proliferation will also be investigated in the near future.  
In contrast to the defects in B and T cell proliferation, both patients showed normal 
upregulation of B and T cell surface activation markers, normal B and T cell cytokine 
production, normal proximal B and T cell receptor signaling, normal T cell receptor-induced 
NFκB and ERK signaling, normal cytokine-induced STAT1 and STAT5 phosphorylation in T 
cells, and normal LPS-induced cytokine production. Furthermore, the GTF3A variants did not 
affect NFκB reporter luciferase activity in HEK293T cells. Altogether, these data suggested 
that, despite the proliferation defect, overall activation and signaling machineries in the 
patients’ immune cells appeared to be intact. In fact, since proliferation responses were 
impaired upon stimulation through the B cell receptor, B cell cytokine receptors, as well as 




OUTSTANDING QUESTIONS AND STRATEGIES TO ADDRESS THEM 
5S rRNA (the main target of TFIIIA) is a component of the 60S large subunit of ribosomes.8 
Ribosome synthesis and 60S subunit maturation have been previously studied in yeast 
models for Diamond-Blackfan anemia and Shwachman-Diamond syndrome, two well-known 
ribosomopathies.51 To examine the effect of the GTF3A variants on 60S subunit synthesis, 
we will first perform polysome profiling in patient cells, which visualizes the presence of the 
different ribosome subunits in the form of a peak diagram.51 Since 5S rRNA expression was 
found to be decreased in the patients, we expect a similar reduction in 60S subunit 
synthesis. Afterwards, a direct link between TFIIIA and reduced 60S synthesis could be 
further investigated using a relevant cellular model (see below, CRISPR/Cas9 genome 
editing technique). 
 
The lymphocyte proliferation defect observed in the GTF3A-mutant patients was particularly 
interesting because ribosome biogenesis and 5S rRNA play key roles in the regulation of cell 
cycle progression.8,17,18,52 When ribosome biogenesis is impaired, 5S rRNA is redirected from 
assembly into nascent 60S ribosomes and becomes an essential element in the signaling 
cascade inducing p53-dependent cell cycle arrest.8,52 In the absence of 5S rRNA, p53-
independent cell cycle arrest can be induced.8,52 Moreover, defects in cell cycle progression 
as well as variable B and T cell proliferation defects have been previously documented in 
several ribosomopathies.17,20 The role of TFIIIA and 5S rRNA in lymphocyte cell cycle is 
unknown. We, therefore, plan to do flow cytometric cell cycle analysis on patients’ PBMCs 
using a DNA-binding dye and counterstaining for (naive and memory) B and T cell markers. 
PBMCs will be stimulated with anti-IgM/CD40L or anti-CD3/anti-CD28 to stimulate B or T cell 
proliferation, respectively. Furthermore, defects in SBDS, the underlying cause of 
Shwachman-Diamond syndrome, have been implicated to destabilize the mitotic spindle (a 
microtubule-based structure that separates chromosomes during mitosis) in human 
hematopoietic progenitor cells and lymphoblasts.53,54 Hence, we will investigate if TFIIIA 
colocalizes with the mitotic spindle in healthy donor cells (e.g. PHA lymphoblasts, skin 
fibroblasts) by use of immunofluorescence.53,54 If so, the effect of the mutant TFIIIA proteins 
on mitotic spindle formation and cell division will be further explored.54   
The rate of cell growth and cell proliferation is largely determined by the rate of protein 
synthesis by ribosomes.8 Most species, including humans, have multiple gene copies of 5S 
rDNA.9 Studies in Escherichia coli (E. coli) have shown that multiple 5S rDNA gene copies 
were not necessary for survival but allowed the bacteria to rapidly upregulate 5S rRNA 
increasing their growth potential.55 In particular, deletion of 75% of the 5S rDNA gene copies 
in an E. coli strain was not lethal to the bacteria but markedly reduced growth (proliferation) 
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rates.55 In human cancer cell lines, siRNA-mediated GTF3A knockdown did not reduce total 
5S rRNA expression levels up to 72 hours posttransfection.8,56 Correspondingly, a decrease 
in cell proliferation only became visible after 72 to 96 hours posttransfection.56 Analogously, 
in our experiments, transient GTF3A knockdown in healthy donor PBMCs did not significantly 
reduce 5S rRNA expression after 48 hours, but did after 5 to 6 days posttransfection. Still, 
after 5-6 days, proliferation of TFIIIA-depleted B cells was not significantly reduced although 
it showed a decreasing trend. T cell proliferation was normal in TFIIIA-depleted cells. A 
reason as to why we were unable to detect a proliferation defect after siRNA-mediated 
knockdown of GTF3A, may be because PBMCs have a lower, less demanding, proliferation 
rate compared to human cancer cell lines and E. coli bacteria.55-57 Indeed, lower resource 
needs in PBMCs could make it more difficult to pick up a proliferation defect in a transient 
transfection setting, particularly because 5S rRNA is not yet sufficiently depleted in the first 
48-72 hours posttransfection. In the future, we wish to generate a mutant GTF3A knock-in 
model in primary healthy control B and T cells using the CRISPR/Cas9 genome editing 
technology.58,59 This technology allows stable DNA sequence alterations in eukaryotic cells, 
generating a more suitable cellular system to investigate the effect of mutant TFIIIA on both 
B and T cell proliferation and ribosome synthesis (see above) independent of the 
patients’ genetic background.  
 
Next to variable B and T cell proliferation defects, several ribosomopathies have been 
associated with various degrees of B cell and/or T cell lymphopenia, reduced serum IgM, 
IgA, IgG and/or IgG subclasses, and/or impaired specific antibody responses to 
immunization.20 Furthermore, there have been reports on patients with well-established 
ribosomopathies that were diagnosed with CVID.20 Importantly, the immunodeficiency 
phenotype of the here-reported patients bears striking similarities with the immunological 
abnormalities seen in ribosomopathies.20 Patient II:1 had reduced IgM, whereas patient II:3 
had absent IgM and reduced IgG serum levels. In addition, both patients had very poor 
antibody responses to polysaccharide pneumococcal vaccines. IgM deficiency with normal 
levels of IgA, IgG and IgG subclasses, as seen in the oldest sibling II:1, is rare and poorly 
understood.60,61 Similar as in the here-presented patients, the majority of cases with IgM 
deficiency have intact surface IgM expression on B cells.60,61 Furthermore, impaired 
polysaccharide antibody responses are often encountered in patients with IgM deficiency.60 
Total B cell numbers fluctuated around the lower limit of normal in both patients. Peculiarly, 
patient II:3 had < 1% switched memory B cells whereas sibling II:1 had very high (> 25%) 
switched memory B cells. This difference in B cell differentiation was also observed in vitro, 
where patient II:3 had reduced and patient II:1 had normal to elevated plasmablast formation. 
The dissimilarity in B cell differentiation between the two siblings is not easily explained. 
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Overall, patient II:3 had a more severe clinical and laboratory phenotype than his sister (II:1). 
Over the past years, it has become clear that most PID- or ribosomopathy-related genes, 
including recessive ones, are associated with considerable phenotypical variability even 
within the same family.3,17,62 It is possible that the dissimilarity in switched memory B cells in 
particular, and disease severity in general, is part of a phenotypical spectrum. Additionally, it 
cannot be excluded that natural disease progression has been influenced by environmental 
factors such as exposure to infectious pathogens or administration of immunoglobulin 
replacement therapy. Indeed, immunoglobulin therapy has been shown to inhibit B cell 
differentiation in vitro.63 Besides a few temporary interruptions, patient II:3 has been on 
immunoglobulin replacement therapy since he was 7 months of age. In contrast, patient II:1 
started immunoglobulin therapy when she was 18 years old. Unfortunately, studies on long-
term in vivo effects of immunoglobulin replacement therapy on peripheral B cell 
differentiation are lacking.  
To date, the full transcriptome of the transcription factor TFIIIA is unknown. To address the 
abnormalities in antibody production and memory B cell differentiation, we plan to do 
transcriptome analysis using a combination of two techniques: Chromatin Immuno-
Precipitation followed by next-generation sequencing (ChIP-seq) and RNA-sequencing 
(RNA-seq). ChIP-seq will reveal the DNA binding sites of TFIIIA and whether these are 
affected by the GTF3A variants, while RNA-seq will show possible consequences on gene 
expression. Since the patients’ defects appear to be quite cell type specific, ChIP-seq and 
RNA-seq will be performed on purified B cells of the patients (II:1, II:3) in comparison to 
healthy controls as well as to the heterozygous mother (I:2) and WT/WT sister (II:2) as 
controls for genetic background. ChIP-seq and RNA-seq data can then be integrated to 
evaluate the consequences of the GTF3A variants on transcription regulation. We believe 
that transcriptional profiling may provide additional clues towards the patients’ phenotypes. 
 
CONCLUSION 
We have identified compound heterozygous GTF3A variants as potential cause of a novel 
ribosomopathy featured by a CVID-like phenotype; thereby revealing a previously unknown 
role of TFIIIA in lymphocyte proliferation and B cell biology. Future studies are planned to 
investigate the causal relationship between the GTF3A genotype and the clinical phenotype 
via relevant cellular models. 
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8 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
Common variable immunodeficiency (CVID) is one of the most frequently diagnosed primary 
immunodeficiencies (PIDs) with an estimated prevalence between 1/100,000 and 1/10,000.1,2 
This means that in Belgium, with a population of about 11.5 million, between 115 and 1150 
individuals suffer from CVID. Although CVID is a rare disease, it carries a high burden to 
patients and their families as well as to healthcare providers and society. Recurrent and/or 
severe infections are a major cause of morbidity in CVID patients, and disease-related 
complications can lead to an 11-fold increase of mortality.3,4 Furthermore, healthcare 
providers are faced with a high number of medical encounters while universal guidelines on 
follow-up and treatment of disease-related complications are lacking.5 Finally, frequent 
healthcare visits, repeated hospitalizations and, especially, life-long treatment with expensive 
immunoglobulin preparations put pressure on society’s healthcare budgets.6  
It has become apparent that CVID is an umbrella diagnosis covering a clinically, 
immunologically and genetically heterogeneous group of disorders.7,8 To date, the 
pathogenesis of CVID remains largely enigmatic and a monogenic defect has only been 
identified in 2-10% of patients.7,8 In addition, patients with primary antibody deficiencies 
(PADs) resembling CVID but not reaching the somewhat arbitrary diagnostic cutoffs of 
reduced serum immunoglobulin (Ig) levels, have been less well studied.9,10  
In this thesis, we aimed to utilize detailed immunophenotypical characterization to facilitate 
the identification of (novel) molecular genetic defects in a cohort of patients diagnosed with 
CVID or related PADs mainly including idiopathic primary hypogammaglobulinemia (IPH) and 
IgG subclass deficiency (IgGSD). 
 
Summarizing discussion on the main findings of this thesis 
In chapter 3, detailed immunological characterization of peripheral blood mononuclear cells 
(PBMCs) in patients with CVID, IPH and IgGSD demonstrated that some 
immunophenotypical alterations were shared between all PADs whereas others were only 
associated with CVID. Unexpectedly, asymptomatic first-degree family members of patients 
(AFM) had lower mean levels of serum IgG and IgM than healthy controls and showed 
similar, albeit less pronounced, abnormalities in peripheral B and T cell subsets than PAD 
patients. Hence, by simultaneously investigating a broad range of parameters in three groups 
of PAD patients and their AFM, we were able to show for the first time in a larger cohort that 
peripheral immunophenotypical abnormalities of PADs form a spectrum ranging from AFM 
over IgGSD and IPH patients to CVID patients, being most notable in naive and memory B 
and T cell subsets. Moreover, unsupervised computational clustering techniques were 
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unable to discriminate subgroups of subjects, further underlining the heterogeneous and 
overlapping nature of CVID and related PADs. Together, our findings support recent notions 
that the majority of CVID(-like) patients have a complex rather than a monogenic etiology, 
whereby an accumulation of multiple genetic, epigenetic and/or environmental factors 
contributes to the final phenotype.8,11,12 
As outlined in chapter 4, we so far identified a causative monogenic defect in seven out of 
70 index patients (10%) from our PAD cohort. In five of those patients, hallmark 
immunological abnormalities (BTK, GATA2) or the presence of extra-immunological features 
(18q deletion, RNU4ATAC, KMT2A) provided additional clues towards the identification of 
the underlying genetic defect. These “clues” were sometimes not yet apparent at time of 
inclusion in the study, however. The mutations in the other two patients were detected by an 
exploratory approach, either via targeted resequencing (NFKB1) or whole exome sequencing 
(WES) (IKZF1). In our cohort, WES had a considerably higher detection rate (15%) than 
targeted sequencing of known disease genes (5.7%). Moreover, WES also revealed three 
novel candidate disease genes, for which functional validation is currently ongoing or 
planned in the near future. We therefore concur with the literature that WES and WGS, which 
was not performed in this study, are currently the preferred approach for genetic testing in 
patients with CVID and related PADs.13,14 When drawing up the balance sheet of genetic 
testing in our PAD cohort, three compelling observations were made. First, in two of the 7 
solved index cases, the causal mutation was located in non-coding regions: in an intronic 
region of a protein-coding gene (GATA2) and in a non-coding RNA gene (RNU4ATAC), 
respectively. Although GATA2 and RNU4ATAC are not regarded as CVID-associated genes, 
this observation suggests that non-coding variation may be able to explain a subgroup of 
patients diagnosed with CVID or related PAD disorders. The role of non-coding variation in 
these conditions is, however, an underexplored but emerging field given the implementation 
of WGS in the near future. Second, phenotype-based targeted sequencing of candidate 
genes had a yield of about 5.7% in our cohort, which is markedly lower than what is expected 
in Mendelian diseases.15 This reflects the lack of a phenotype-genotype correlation for 
many CVID- and in extension PID-associated genes.16 Third, disease-causing mutations 
were also found in 4% of asymptomatic family members of index patients, not including 
unaffected carriers of recessive alleles. These last two observations support the idea that 
CVID and related PADs are mostly non-Mendelian phenotypes influenced by the actions 
of modifier genes, epigenetic changes and/or environmental factors.8,17  
In the following chapters of this thesis, we focused on three families with novel or rare 
variants in known disease genes that expanded phenotypical spectra and one family with a 
novel candidate disease gene. The two sibling pairs with KMT2A-associated Wiedemann-
Steiner syndrome (WSS)18 and RNU4ATAC-associated Roifman syndrome (RS)19, 
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respectively, described in chapter 5, stress the importance of a thorough genetic 
assessment in patients presenting with a CVID-reminiscent phenotype at a very young age, 
including proactive evaluation for extra-immunological syndromic features. In addition, we 
found reduced levels of circulating follicular helper T (cTfh) cells in all WSS and RS patients, 
and decreased BAFF-R expression on B cells in the RS patients. These immunological 
abnormalities had not been previously reported and were in line with the impaired B cell 
differentiation and/or decreased total B cell numbers, respectively, seen in the patients. It will 
be of interest to investigate these parameters in additional patients with WSS and RS as they 
may help elucidate the underlying pathophysiology of primary antibody failure in these 
syndromic disorders. 
In chapter 6, we examined the first truncating IKZF1 mutation associated with IKAROS 
haploinsufficiency in two symptomatic sisters and their asymptomatic mother.20-22 The 
premature stop codon near the N-terminal end was particularly interesting because IKZF1 is 
believed to be under strong purifying selection, meaning that deleterious alleles are usually 
purged from the population.22 In accordance, only one premature stop codon in IKZF1 
(variant 7: 50468298 AG/A), located near the C-terminal end, was found in more than 
126,000 exomes and 15,000 genomes included in gnomAD Browser, currently the largest 
public database (http://gnomad.broadinstitute.org). However, the variable expressivity and 
incomplete penetrance seen in previously published patients with germline IKAROS 
haploinsufficiency indicate that additional disease-influencing mechanisms are at play.22 The 
three IKZF1 mutation carriers of the here-examined kindred showed similarly low IKAROS 
protein expression levels but a remarkable variation in clinical involvement and B cell 
maturation defects. They demonstrated a variable, multi-level central B cell developmental 
block situated at a later stage than the block observed in four previously reported 
symptomatic subjects. Since these previous cases all harbored missense mutations in the 
same protein domain, a possible genotype-phenotype correlation should be further 
explored.21,22 Interestingly, the reduced central B-lineage cells in the asymptomatic mother 
were, so far, able to sustain normal peripheral B cell development and numbers.21,22  
Finally, in chapter 7, we investigated novel compound heterozygous variants in GTF3A, 
encoding transcription factor IIIA (TFIIIA),23 identified in a Belgian brother and sister pair with 
a CVID-like phenotype. GTF3A has not been previously implicated in disease and a possible 
role of TFIIIA in the immune system is unclear. Notwithstanding, in silico pathogenicity 
prediction tools and protein modeling as well as preliminary functional validation studies have 
provided evidence that the GTF3A variants could be disease-causing through loss of TFIIIA 
function. Since TFIIIA regulates 5S rRNA transcription important for ribosome biogenesis24-26, 
we hypothesize that biallelic loss-of-function GTF3A mutations cause a novel ribosomopathy 
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featured by CVID-like antibody failure.27,28 Future studies are planned to investigate a direct 
causal relationship between the GTF3A genotype and the phenotype in these patients. 
 
The utility of extensive immunophenotyping to guide genetic testing and WES data 
mining 
The identification of genetic defects in patients diagnosed with CVID has proven to be 
arduous.13 Thus far, monogenic defects have been predominantly identified in patients with 
an early disease onset, disease-related complications such as autoimmunity or 
lymphoproliferation, a positive family history, and/or consanguineous parents.8,13 As 
mentioned above, the main objective of this thesis was to utilize extensive peripheral blood 
immunophenotyping to facilitate the discovery of genetic defects in our PAD cohort. This 
objective was built on the fact that the peripheral blood compartment is far more easily 
accessible than lymphoid organs, increasing the likelihood of participation in the study, and 
that white blood cell constituents mirror (ab)normal immunological processes in the body. 
Detailed immunophenotyping of PBMCs could, therefore, indicate which immunological 
pathways might be affected. However, we found that the latter was only partly true. In 
general, a first “basic” immunophenotypical evaluation of the patients was performed in a 
routine clinical setting, including total B, total/CD4+/CD8+ T, and total NK lymphocyte counts, 
naive and memory T cell subsets, and naive, transitional, marginal zone-like, switched 
memory and CD21low B cell subsets. Upon inclusion in the study, more extensive 
immunophenotyping (as explained in chapter 3) was performed in research setting. Based 
on our experience from this project, we conclude that more extensive immunophenotyping 
did not have an added value to routine lymphocyte phenotyping for the first phases of genetic 
testing. In other words, “basic” immunophenotypical information was necessary and sufficient 
for an initial genetic assessment. An important footnote is that numerous study participants 
had not undergone a routine immunophenotypical evaluation since this is not required for a 
diagnosis of CVID or related PADs and is of limited prognostic value.7,29 From this 
experience we learn that future genetic studies in PAD patients would not only benefit from a 
complete clinical workup, but also from complete lymphocyte phenotyping in routine setting. 
In rare cases, (immuno)phenotypical information can directly point to one or a few specific 
genotypes. For example, in our patient cohort, the combination of clinical features with 
routine immunophenotyping eventually led to the identification of mutations in BTK, GATA2, 
and RNU4ATAC through targeted sequencing. Furthermore, to analyze WES data, the 
investigator must know what he is looking for, at least to certain extent, to be able to filter on 
biologically relevant variants. More specialized immunological investigations can afterwards 
be performed in function of genetic variants of interest. Overall, genetic studies in 
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heterogeneous disorders like CVID and related PADs ask for an interactive collaboration 
between clinicians, routine laboratory immunologists and geneticists, and researchers.14  
 
The importance of a genetic diagnosis 
Like for all monogenic disorders, identifying a monogenic subtype of CVID supports the 
clinical diagnosis, genetic counseling of the index case and his/her family and reproductive 
options. Establishing a genetic diagnosis can also entail important implications in terms of 
patient management. When the gene has already been described in other patients, knowing 
the genetic defect helps to assess the prognosis of the patient and to guide follow-up with 
screening for specific complications.8,14  
Immunoglobulin replacement therapy, the current cornerstone of treatment, significantly 
decreases the infection frequency but has little effect on disease-related non-infectious 
complications.7 Therefore, other treatment modalities are being explored. In some 
monogenic subtypes (e.g. LRBA, PIK3CD), hematopoietic stem cell transplantation (HSCT) 
is now considered an acceptable treatment option.30,31 In clinical practice, the decision to 
perform high-risk HSCT in PID patients with a severe clinical course often hinges on the 
identification of the underlying genetic defect, underlining the importance of an early genetic 
diagnosis. Furthermore, the identification of monogenic defects has offered the opportunity to 
develop targeted drug therapies.32 As mentioned in the introduction of this thesis (section 
1.7), a few targeted immunomodulatory drugs have already been reported to be of potential 
use: the CTLA-4 mimetic abatacept in LRBA and CTLA-4 deficiencies, and mTOR inhibitors 
in patients with activated phosphatidyl-inositol-3-kinase (PI3K) p110δ syndrome (APDS).33-35 
Two clinical trials of PI3K p110δ-specific inhibitors in patients with APDS have been recently 
announced.36 Note that targeted drug therapies are also being explored in many other PID 
disorders.32 Another major opportunity of a molecular diagnosis is gene-based therapy. Gene 
therapy relying on viral vectors to transfer a functional copy of the mutated gene to 
autologous HSCs has shown great promise in selected PID disorders.38 The newer SIN-
gammaretroviral and lentiviral vector platforms are more effective and markedly safer than 
the first generation of gammaretroviral vectors. In recent years, several gene-editing 
technologies have been developed such as zinc finger nucleases (ZNF), transcription 
activator-like effector nucleases (TALEN) and clustered regularly interspaced short 
palindromic repeats/CRISPR-associated gene 9 (CRISPR/Cas9).38 In contrast to vector-
based gene addition platforms, gene-editing approaches can precisely target and repair a 
mutated genetic sequence, or can precisely target an insertion region within the genome 
enabling the use of natural regulatory elements and decreasing the risk of insertional 
mutagenesis. The application of gene-editing strategies in PIDs is currently being 
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investigated.38 Although gene-based therapies for PIDs are still mostly experimental, in 2016 
the European Commission approved a viral vector gene therapy for adenosine deaminase 
deficient severe combined immunodeficiency (ADA-SCID) called Strimvelis.39 It is both the 
first gammaretrovirus-based and the first ex vivo gene therapy to be granted marketing 
authorization. This approval is based on a clinical trial in 18 children that has shown a 100% 
survival rate with substantial immunological improvement and no leukemic events up to 13 
years after treatment.39 In the future, gene-based therapy may become a valid treatment 
option for all monogenic PIDs in which case a genetic diagnosis will become indispensible.  
Finally, the identification of monogenic defects in CVID, and PIDs in general, has important 
implications for the field of basic immunology as it expands our understanding on basic 
cellular pathways and mechanisms of host defense.40 Unraveling fundamental immunological 
mechanisms in humans has also revealed striking differences with animal models, indicating 
the importance of human studies and PIDs as “experiments of nature”.40 Novel insights in 
basic immunology can, in turn, be translated back into clinical immunology to continue 
optimization of patient care.40  
 
Future directions in investigating the molecular basis of CVID 
Studies on the molecular basis of CVID have mainly focused on identifying monogenic 
defects. Still, a few genome-wide and epigenetic studies have addressed the hypothesis of a 
complex polygenic or multifactorial molecular basis of CVID. As discussed in the introduction 
of this thesis (section 1.6.3.3), two GWAS of CVID cohorts have reported several significantly 
associated loci.41,42 In the first GWAS, the authors used the SNP dataset to build an 
algorithmic model for predicting the risk of developing CVID.41 Although the internal 
validation test was successful and identified CVID patients with 98,7% accuracy, the 
prediction model has, to our knowledge, not been used in other study cohorts.41 In addition, 
the first GWAS reported a significantly higher burden of CNVs in CVID patients compared to 
controls.41 So far, CNVs have not been systematically examined in CVID patients. A recent 
report on 278 PID index patients has detected several PID-causing CNVs of which some 
were intragenic CNVs smaller than 30 kb that would have been missed with the genome-
wide array CGH used here (resolution ~100 kb).14 The second GWAS found that CVID 
shares genetic susceptibility loci with complex autoimmune diseases such as the locus 
containing the CLEC16A gene.42 A common genetic basis could be one of the keys to further 
unravel the co-occurrence of immunodeficiency and autoimmunity seen in many CVID 
patients.17 van Schouwenburg et al. performed WGS and RNA sequencing in sporadic CVID 
cases.11 Despite the relatively small sample size (n=32), the lack of functional validation 
analyses and absence of replication in other cohorts, this first WGS-based study in a CVID 
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cohort has generated interesting hypotheses that should be further explored.11 The authors 
found that all patients showed evidence of a mutational burden in shared genes and 
pathways implicated in B cell biology.11 Future pathway and network analyses in larger CVID 
cohorts would be of interest to determine the collective contribution of genetic variants that 
individually do not suffice to cause disease.17 Furthermore, the combination of WGS and 
RNA sequencing in three sporadic CVID cases has provided proof-of-concept that non-
coding variation and differential gene expression could play a role in the pathogenesis of 
CVID.11 DNA methylation is one of the mechanisms of epigenetic regulation of gene 
expression.43 Differences in DNA methylation and subsequent gene expression have 
recently been identified in B cells derived from monozygotic twins discordant for CVID.12 
Thus, epigenetic mechanisms may also be involved in the etiology of CVID.12 Epigenetic 
processes are, in turn, influenced by environmental factors such as smoking, diet and 
perhaps even infectious agents.43 Indeed, similar to other complex diseases, the risk of 
developing CVID may be modified by an interplay between internal genetic components and 
environmental influences.17  
In summary, genomics (including analysis of structural variations such as CNVs, non-coding 
variation, and pathway and network analyses of possible disease-modifying variants), 
epigenomics, transcriptomics, and proteomics will form the garrison for future studies on the 
molecular basis of CVID. Although much of the generated data will be challenging to 
interpret, it could offer important insights in the underlying disease-mechanisms of CVID at 
different molecular levels.17 Moreover, the integration of multi-level molecular data could 
significantly enhance our understanding on the etiology of CVID.17 In addition, multi-level 
molecular data could offer new opportunities for distinguishing subgroups of CVID patients 
and establishing reliable biomarkers to predict the risk of developing disease-related 
complications.17 
 
Has the term “CVID” become obsolete? 
The diagnosis of CVID is an umbrella for a wide range of distinct disorders. Hence, one 
might ask if the term “CVID” has become obsolete in the era of advanced genomic and 
molecular technologies. In my view, the answer to this question is “no, not at all”. A first 
argument is, of course, the fact that currently identified monogenic defects only encompass 
2-10% of patients diagnosed with CVID. Secondly, since genetic testing is not yet readily 
available in the consultation room, but, in contrast, can still take a lengthy period of time, it is 
essential to have a clinical diagnosis. A clinical diagnosis is not only the starting point for 
patient management decisions, but is also important for administrative purposes such as 
reimbursement requests for immunoglobulin replacement therapy, claims for higher child 
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benefits, and patient registration. Lastly, if CVID indeed has a multifactorial basis in the 
majority of patients, this term will probably remain to exist to cover that group of patients 
while those with a monogenic defect will be removed from under the umbrella.  
Instead of questioning the continued existence of the term “CVID”, I believe that a change in 
mentality on how and when to use this term is more at hand. In particular, we should 
increase awareness among healthcare providers and scientists that a diagnosis of CVID is 
not the end point of the diagnostic process, and that continuous re-evaluation and, if 
possible, molecular (genetic) testing should be pursued. For now, a definitive molecular 
diagnosis will not be reached in many CVID patients, but with the current evolution in 
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Common variable immunodeficiency (CVID) is one of the most prevalent primary 
immunodeficiencies (PIDs) estimated to affect 1/100,000 to 1/10,000 people worldwide. 
CVID is a collective term for a clinically, immunologically and genetically heterogeneous 
group of disorders characterized by markedly reduced serum immunoglobulin levels, 
inadequate antibody responses to vaccinations, recurrent infections, and complications due 
to immune dysregulation (e.g. autoimmunity, malignancy). The molecular pathogenesis of 
CVID remains largely unknown. Up to date, a monogenic cause is only found in 2-10% of 
patients. Accumulating data suggest that most CVID patients have a multifactorial etiology, 
meaning that multiple genetic, epigenetic and/or environmental factors determine the final 
phenotype. In extension, primary antibody deficiencies (PADs) showing phenotypical overlap 
with CVID but with a less severely impaired antibody production may be part of the same 
multifactorial disease spectrum. The general aim of this thesis was to unravel the underlying 
monogenic defects in patients with CVID and related PADs followed in our center by using 
an integrative immunological and genetic approach.  
 
We started by investigating the peripheral blood immunological phenotype of 77 patients with 
CVID and two milder PAD disorders named idiopathic primary hypogammaglobulinemia 
(IPH) and IgG subclass deficiency (IgGSD), as well as 47 asymptomatic first-degree family 
members of patients (AFM) and 101 age-matched healthy controls (HC) (chapter 3). 
Interestingly, some immunophenotypical alterations were shared between all three patient 
groups whereas others were only associated with CVID. Unexpectedly, AFM showed similar, 
albeit intermediate, abnormalities in peripheral B and T cell subsets compared to PAD 
patients. Moreover, unsupervised computational clustering techniques were unable to 
discriminate subgroups of subjects in our cohort. Together, we demonstrated for the first time 
in a relatively large cohort that peripheral immunophenotypical abnormalities in PADs form a 
spectrum ranging from AFM over milder disorders like IgGSD and IPH to the most severe 
disorder CVID. Our findings add to the growing body of literature on the complex etiological 
basis of CVID and related PADs. 
 
Chapter 4 describes the genetic analyses performed in our PAD cohort using microarray-
based comparative genomic hybridization, Sanger sequencing, targeted next-generation 
sequencing (NGS), whole exome sequencing (WES), and homozygosity mapping. So far, a 
disease-causing genetic defect was identified in 7 out of 70 index patients (10%) from our 
cohort: three patients with a syndromic form of PAD (caused by a 18q deletion, KMT2A or 
RNU4ATAC mutations respectively), one patient with agammaglobulinemia (caused by a 
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BTK mutation), and three patients with a prior diagnosis of IPH or CVID (caused by GATA2, 
NFKB1, or IKZF1 mutations respectively). In five of the seven solved cases, hallmark (extra-) 
immunological features ultimately provided essential clues. Remarkably, targeted 
sequencing of known disease genes had a yield of only 5.7% (4/70). WES revealed novel 
mutations in known disease genes in two out of 13 tested index patients (15%), known 
disease-modifying variants in four patients (31%), and novel candidate disease genes in 
three cases (23%). Genetic analyses in this cohort are still ongoing. 
 
In chapter 5, we studied a family with a novel heterozygous mutation in KMT2A causing 
Wiedemann-Steiner syndrome (WSS), and a second family with rare compound 
heterozygous mutations in the non-coding RNA gene RNU4ATAC causing Roifman 
syndrome (RS). In both families, the sibling pairs exceptionally presented with a CVID 
phenotype in early childhood while extra-immunological features were not apparent at that 
time, significantly delaying the establishment of an accurate diagnosis. This underlines the 
importance of pursuing a genetic diagnosis in patients with an early-onset CVID phenotype. 
In addition, we found previously unreported abnormalities in circulating follicular helper T 
(cTfh) cells in WSS and RS, and in B cell BAFF-R expression in RS, suggestive for novel 
pathophysiogical insights in these syndromic disorders. 
 
We next examined two patients and their mother who harbored a novel heterozygous 
mutation in IKZF1 leading to IKAROS haploinsufficiency (chapter 6). All three subjects had a 
variable, multi-level central B cell developmental block which was situated more downstream 
compared to the arrest observed in previously published symptomatic cases. Although the 
mother had reduced bone marrow B-lineage cells, peripheral blood B cell subsets were 
within normal ranges and clinical symptoms were absent. With this study, we provided novel 
insights in central B cell development in both symptomatic and asymptomatic IKZF1 mutation 
carriers. 
 
Finally, in chapter 7 we identified a novel candidate disease gene, GTF3A. In particular, we 
found novel compound heterozygous variants in GTF3A in a Belgian brother and sister pair 
with a CVID-like phenotype and profound B cell proliferation defects. Preliminary functional 
validation studies have provided evidence for pathogenicity of the GTF3A variants through 
loss-of-function. Since GTF3A has a known role in ribosome biogenesis and some 
ribosomopathies have been previously associated with various lymphocyte abnormalities, we 
hypothesize that biallelic GTF3A mutations cause a novel ribosomopathy characterized by a 
CVID-like phenotype. Future studies are planned to explore a direct causal relationship 




Common variable immunodeficiency (CVID) is één van de meest voorkomende primaire 
immuundeficiënties (PIDs) en treft naar schatting 1/100.000 tot 1/10.000 mensen wereldwijd. 
CVID is een verzamelterm voor een klinisch, immunologisch en genetisch heterogene groep 
van aandoeningen gekenmerkt door sterk verlaagde immuunglobuline serumspiegels, 
onvoldoende vorming van antistoffen na vaccinaties, herhaaldelijke infecties, en complicaties 
ten gevolge van ontregeling van het immuunsysteem (bijv. autoimmuniteit, maligniteit). De 
moleculaire pathogenese van CVID is nog grotendeels onduidelijk. Op dit moment wordt een 
monogenetische oorzaak slechts in 2-10% van de patiënten gevonden. Recente studies 
suggereren dat de meeste CVID patiënten een multifactoriële etiologie vertonen, waarbij 
meerdere genetische, epigenetische en/of omgevingsfactoren het uiteindelijke fenotype 
bepalen. Aansluitend kunnen we stellen dat primaire antilichaamdeficiënties (PADs) die 
fenotypisch gelijken op CVID maar met een minder uitgesproken antilichaamstoornis, 
mogelijk deel uitmaken van hetzelfde multifactoriële ziektespectrum. Het algemene doel van 
deze thesis was om bij patiënten met CVID en gerelateerde PADs, die gevolgd worden in 
ons centrum, het onderliggende monogenetische defect te identificeren aan de hand van een 
geïntegreerde immunologische en genetische aanpak. 
 
In een eerste fase hebben we op perifeer bloed het immunologisch fenotype nagekeken bij 
77 patiënten met CVID en twee mildere PAD aandoeningen, namelijk idiopathische primaire 
hypogammaglobulinemie (IPH) en IgG subklasse deficiëntie (IgGSD), alsook bij 47 
asymptomatische eerstegraadsverwanten van patiënten (AFM) en 101 leeftijdsgematchte 
gezonde controles (HC) (hoofdstuk 3). Bepaalde immunofenotypische veranderingen 
werden gedetecteerd in de drie patiëntengroepen terwijl andere afwijkingen enkel 
geassocieerd waren met CVID. Verrassend stelden we vast dat AFM gelijkaardige, al zij het 
intermediaire, afwijkingen vertoonden in perifere B en T cel subsets in vergelijking met PAD 
patiënten. Daarnaast konden ongecontroleerde computationele clustertechnieken geen 
subgroepen van studiepersonen onderscheiden in onze cohorte. Samenvattend hebben we 
voor het eerst in een relatief grote cohorte aangetoond dat perifere immunofenotypische 
afwijkingen in PADs een spectrum vormen gaande van AFM over mildere aandoeningen 
zoals IgGSD en IPH tot de ernstigste aandoening CVID. Deze bevindingen dragen bij tot 
recente literatuur over de complexe etiologie van CVID en gerelateerde PADs.  
 
Hoofdstuk 4 beschrijft de genetische analyses die uitgevoerd werden op onze PAD cohorte, 
waarbij gebruik gemaakt werd van microrooster-gebaseerde vergelijkende 
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genoomhybridisatie, Sanger sequenering, doelgerichte next-generation sequenering (NGS), 
volledige exoom sequenering (WES), en homozygositeitsmapping. Tot nu toe werd een 
ziekte-veroorzakend genetisch defect geïdentificeerd in 7 van de 70 index patiënten (10%) 
van onze cohorte: drie patiënten met een syndromale vorm van PAD (respectievelijk door 
een 18q deletie, KMT2A of RNU4ATAC mutaties), één patiënt met agammaglobulinemie 
(door een BTK mutatie), en drie patiënten met een voorafgaande diagnose van IPH of CVID 
(door GATA2, NFKB1, of IKZF1 mutaties). In vijf van de zeven genetisch gediagnosticeerde 
patiënten hebben karakteristieke (extra-)immunologische kenmerken uiteindelijk 
doorslaggevende aanwijzingen gegeven. Opvallend was dat doelgerichte sequenering van 
gekende ziektegenen maar een beperkte opbrengst had van 5.7% (4/70). WES onthulde 
nieuwe mutaties in gekende ziektegenen in twee van de 13 geteste index patiënten (15%), 
gekende ziekte-beïnvloedende varianten in vier patiënten (31%), en nieuwe kandidaat 
ziektegenen in drie patiënten (23%). De genetische analyses in deze cohorte zijn nog 
lopend.  
 
In hoofdstuk 5 bestudeerden we een familie met een nieuwe heterozygote mutatie in 
KMT2A die Wiedemann-Steiner syndroom (WSS) veroorzaakt, en een tweede familie met 
zeldzame, samengesteld heterozygote mutaties in het niet-coderende RNA gen RNU4ATAC 
die Roifman syndroom (RS) veroorzaken. In beide families presenteerden de broer/zus duo’s 
zich uitzonderlijk met een CVID fenotype in de vroege kinderjaren terwijl extra-
immunologische kenmerken minder duidelijk waren op dat moment, wat het vinden van de 
juiste diagnose aanzienlijk heeft vertraagd. Dit onderlijnt het belang van het nastreven van 
een genetische diagnose in patiënten met een vroeg CVID fenotype. Daarnaast vonden we 
niet eerder gerapporteerde afwijkingen in circulerende folliculaire T helper (cTfh) cellen in 
WSS en RS, alsook in B cel BAFF-R expressie in RS, die de basis kunnen vormen voor 
nieuwe pathofysiologische inzichten in deze syndromale aandoeningen. 
 
Vervolgens werd in twee patiënten en hun moeder een nieuwe, heterozygote mutatie 
gevonden in IKZF1 dat resulteerde in IKAROS haploinsufficiëntie (hoofdstuk 6). De drie 
studiepersonen hadden allen een variabele, multi-level centrale B cel ontwikkelingsstoornis 
dat bovendien op een later niveau was gesitueerd in vergelijking met het 
ontwikkelingsstoornisniveau voordien gerapporteerd in symptomatische gevallen. Alhoewel 
de moeder een verminderd aantal B cellen vertoonde in het beenmerg, waren haar B cel 
subsets in het perifere bloed normaal en ontwikkelde ze geen klinische klachten. In deze 
studie beschreven we nieuwe inzichten in de centrale B cel ontwikkeling in zowel 
symptomatische als asymptomatische IKZF1 mutatiedragers.  
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Tot slot werd in hoofdstuk 7 een nieuw kandidaat ziektegen, namelijk GTF3A, 
geïdentificeerd. Meer bepaald hebben we nieuwe, samengesteld heterozygote varianten in 
GTF3A gevonden in een Belgische broer en zus met een CVID-achtig fenotype en ernstige B 
cel delingsdefecten. Preliminaire functionele validatiestudies toonden aan dat de GTF3A 
varianten potentieel pathogeen zijn door verlies van functie. Aangezien GTF3A een gekende 
rol speelt in ribosoom biogenese en sommige ribosomopathieën vroeger reeds geassocieerd 
werden met diverse afwijkingen in lymfocyten, veronderstellen we dat biallelische mutaties in 
GTF3A leiden tot een nieuwe ribosomopathie, gekenmerkt door een CVID-achtig fenotype. 
Toekomstige studies zijn gepland om een direct causaal verband tussen het GTF3A 
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Hier is het dan, mijn doctoraatsthesis. De voorbije vier jaar kan ik het best omschrijven met 
de woorden van Walt Disney: “We keep moving forward, opening new doors, and doing new 
things, because we're curious and curiosity keeps leading us down new paths.” 
Wetenschappelijke nieuwsgierigheid was dan wel de onderliggende drijfveer van mijn 
doctoraat, dit werk zou niet tot stand gebracht zijn zonder de bijdrage van talrijke mensen.  
 
In de eerste plaats wil ik mijn drie promotoren bedanken. Jullie hebben me voortreffelijk en 
vol vertrouwen begeleid. Elfride, bedankt om het hoofdpromotorschap op jou te nemen en 
me de mogelijkheid te geven om samen te werken met jouw team binnen het Centrum 
Medische Genetica Gent (CMGG). Ondanks je overvolle agenda vond je toch de tijd om me 
te begeleiden bij het genetische luik van mijn onderzoek. Jouw kalmte, optimisme en 
gedrevenheid werkten steeds bemoedigend. Filomeen, tijdens mijn co-assistentschap 
pediatrie bracht je me in contact met de wondere wereld van PID. Het duurde dan ook niet 
lang voordat ik vroeg of ik zou kunnen doctoreren op dit onderwerp. In de daaropvolgende 
jaren heb je me heel wat kansen geboden, waaronder mijn introductie in de ESID (European 
Society for Immunodeficiencies) gemeenschap en de mogelijkheid om zes maanden 
onderzoek te verrichten aan de prestigieuze National Institutes of Health (NIH) in de VS. 
Verder kon ik steeds op je rekenen om me de klinische knepen van het vak bij te brengen en 
kritisch feedback te geven op mijn onderzoekswerk. Ik bewonder jouw onuitputtelijk 
enthousiasme, jouw toewijding aan je patiënten en jouw doorzettingsvermogen in 
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